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ABSTRACT 
 
Activation of neuronal nitric oxide synthase (nNOS) in dorsal root ganglia 
(DRG) neurons leads to axon retraction dependent on S-nitrosylation of microtubule 
associated protein 1B (MAP1B)1. These findings raised the question whether this 
mechanism is involved in classical axon guidance signaling, for example in response to 
the guidance cues netrin-1 and semaphorin3A. Netrin-1 is expressed at the midline of 
the developing central nervous system and can act as attractive or repulsive cue, 
depending on the environmental context. The absence or presence of laminin in the 
extracellular matrix determines whether netrin-1 triggers attraction or repulsion, 
respectively2. On the other hand, it has been shown that MAP1B is necessary for the 
proper transduction of the attractive netrin-1 signal3 and for axon guidance across the 
midline in the murine forebrain4. Netrin-1 guidance involves calcium influx and could 
lead to nNOS activation. 
In the first part of my PhD thesis, I investigated the role of nNOS, NO and 
MAP1B in netrin-1 guidance. I analyzed growth cone behaviour of wild-type and 
MAP1B-/- DRG neurons on laminin and monitored the morphological changes upon 
netrin-1 treatment and intracellular NO synthesis. The analysis of the response of wild-
type and MAP1B-/- DRG neurons to netrin-1 revealed a significant increase of retracted 
neurons after the incubation with netrin-1 in both cell types suggesting that MAP1B is 
not relevant for repulsive netrin-1 signaling in DRG neurons. Moreover, after netrin-1 
treatment, a striking increase in the production of intracellular NO could be observed in 
wild-type and MAP1B-/- DRG neurons. The highest concentration of NO was seen in 
the collapsed growth cones of retracted axons. This result suggests that the Ca2+ influx 
induced by netrin-1 activates a NOS. With the help of specific NOS inhibitors I could 
show that in wild-type DRG neurons nNOS was activated downstream of netrin-1, 
whereas in MAP1B-/- DRG neurons it was endothelial NOS (eNOS). This difference in 
the downstream target of netrin-1 was due to a greatly reduced expression of nNOS in 
MAP1B-/- DRG neurons. These results demonstrate a novel role for nNOS and NO in 
netrin-1 mediated axon guidance. The production of NO following netrin-1 treatment 
can affect two possible downstream effectors: protein-S-nitrosylation or the cGMP 
pathway. Since my results indicate that S-nitrosylation of MAP1B is probably not 
essential for netrin-1 repulsion, the cGMP pathway was investigated in more detail. For 
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this purpose the specific inhibitors for soluble guanylyl cyclase (sGC), ODQ and 
LY83583 were used. However, the inhibition of sGC did not prevent netrin-1 induced 
retraction. Instead, inhibitions of sGC per se lead to rapid, MAP1B-dependent axon 
retraction and an increase in NO synthesis. This indicates that a negative feedback 
mechanism, which was previously suggested by results obtained in vitro5, is indeed at 
work in DRG neurons. According to this model, NO triggers cGMP synthesis, which in 
turn will activate PKG to phosphorylate and thereby inactivate nNOS. By inhibiting 
sGC, this negative feedback mechanism is shut down and nNOS continues to produce 
NO which will finally lead to MAP1B dependent axon retraction. Consistent with this 
model, I could show that sGC inhibitor induced axon retraction is not observed in 
MAP1B-/- Neurons and can be prevented in wild-type neurons by NPA, which 
mimicked inhibition of nNOS by PKG. 
 In order to analyze whether NO might also play a role in the semaphorin3A 
pathway, I grew explants from hippocampus and DRGs in media supplemented with 
semaphorin3A in the presence of NOS inhibitors. I obtained strong evidence that NO 
production might indeed be involved in repulsive semaphorin3A signaling. 
 In the second part of my PhD thesis I was interested in the role of MAP1B in 
oligodendrocytes. MAP1B expression precedes terminal differentiation of and was 
observed in oligodendrocytes that initiate ensheathment of axons6. NO has been 
postulated to play a role in oligodendrocyte damage and myelin loss in multiple 
sclerosis7. This raised the question whether MAP1B might be a mediator of the highly 
toxic effect of NO to oligodendrocytes. Moreover, it was suggested that MAP1B plays a 
role in the transport of mRNA in DRG neurons. As the transport of mRNAs to the cell 
periphery is essential for the establishment of myelin bearing sheaths during terminal 
oligodendrocyte differentiation, I investigated the role of MAP1B in these cells.  
Surprisingly, in vitro oligodendrocyte differentiation was normal in MAP1B-/- 
cells. Moreover, oligodendrocytes did not show any reaction when treated with NO 
donors at high concentrations suggesting a lower susceptibility to NO than expected. In 
contrast, stimulation of calcium influx in oligodendrocytes triggered a NOS-dependent 
collapse of the cytoskeleton. This collapse could be partially prevented by inhibition of 
nNOS in wild-type and eNOS in MAP1B-/- cells suggesting that in oligodendrocytes, as 
in neurons, lack of MAP1B changes the NOS expression pattern. These results show 
that NOS and NO can indeed be toxic to oligodendrocytes, affecting their cytoskeleton. 
                                                                                                                Zusammenfassung 
ZUSAMMENFASSUNG 
 
Die Aktivierung der neuronalen Stickoxidsynthase (nNOS) in dorsalen 
Wurzelganglion (DRG) Neuronen führt zu Axonretraktion die abhängig von MAP1B 
S-Nitrosylierung ist1. Um zu untersuchen ob dieser Mechanismus auch in klassischen 
Signaltransduktionswegen der Axonführung wichtig ist, erforschte ich die Rolle von 
MAP1B und NO in den Netrin-1- und Semaphorin3A-Signaltransduktionswegen. 
Netrin-1 wird an der Mittellinie des sich entwickelnden zentralen Nervensystems 
exprimiert und kann, je nach extrazellulärer Umgebung, entweder anziehend oder 
abstossend auf Nervenzellen wirken. Zum Beispiel wurde gezeigt, dass die 
Verfügbarkeit von Laminin bestimmt ob Netrin-1 attraktiv oder repulsiv agiert2. 
Ausserdem scheint MAP1B wichtig für die korrekte Interpretierung des attraktiven 
Netrin-1 Signals3 und die Axonführung über die Mittelllinie im Mausvorderhirn4. 
Bindung von Netrin-1 an seinen Rezeptor induziert einen Kalziumeinstrom welcher 
eventuell nNOS aktivieren könnte. 
Im ersten Teil meiner Dissertation erforschte ich die Rolle von nNOS, NO und 
MAP1B in Netrin-1-Axonführung. Ich analysierte das Verhalten von neuronalen 
Wachstumskegeln von Wildtyp und MAP1B-/- DRG Neuronen auf Laminin und die 
morphologischen Veränderungen, sowie die Bildung von intrazellulärem NO nach einer 
Behandlung mit Netrin-1. Die quantitative Analyse zeigte, dass Netrin-1 in Wildtyp 
sowie in MAP1B-/- DRG Neuronen einen signifikanten Anstieg in Axonretraktion 
hervorruft, was wiederum annehmen lässt, dass MAP1B im repulsiven Netrin-1 
Signalweg keine Rolle spielen dürfte. Nach der Behandlung mit Netrin-1 wurde in 
Wildtyp und MAP1B-/- DRG Neuronen ein starker Anstieg in der Produktion von NO 
beobachtet. Die stärkste Konzentration an NO war in kollapierten Wachstumskegeln 
und zurückgezogenen Axonen zu sehen. Das weist darauf hin, dass durch den Netrin-1 
induzierten Kalziumeinstrom eine NOS aktiviert wird. Mithilfe spezifischer NOS-
Inhibitoren konnte ich zeigen, dass in Wildtyp DRG Neuronen nNOS und in MAP1B-/- 
DRG Neuronen endotheliale NOS (eNOS) durch Netrin-1 aktiviert werden. Dieser 
Unterschied kommt daher, dass in MAP1B-/- DRG Neuronen nNOS-Expression stark 
hinunterreguliert ist. Diese Resultate deuten auf eine neue Rolle von nNOS und NO in 
Netrin-1 Axonführung hin. Die NO-Synthese kann zwei Effekte bewirken: zum Ersten 
die S-Nitrosylierung von Protein oder die Aktivierung des sGMP Signalweges. Da 
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meine Resultate zeigen, dass die S-Nitrosylierung von MAP1B nicht essenziell im 
repulsiven Netrin-1 Signalweg ist, untersuchte ich den cGMP Signalweg etwas genauer. 
Dafür verwendete ich spezifische Inhibitoren für soluble Guanylyl Cyclase (sGC), ODQ 
und LY83583. Die Inhibierung von sGC verhinderte nicht die Netrin-1 induzierte 
Axonretraktion. Stattdessen führte die Inhibierung von sGC per se zu einer rapiden, 
MAP1B-abhängigen Axonretraktion. Dieses Resultat weist darauf hin, dass ein 
negativer Feedbackmechanismus, der zuvor beschrieben wurde5, in der Tat in DRG 
Neuronen auftritt. Demnach bewirkt NO die cGMP-Synthese, diese aktiviert PKG 
welche nNOS phosphoryliert und deaktiviert. Durch die Inhibierung der sGC wird 
dieser negative Feedbackmechanismus ausgeschaltet und nNOS bleibt aktiv und 
synthetisiert weiterhin NO, welches letztendlich zu MAP1B-abhängiger Axonretraktion 
führte. Übereinstimmend damit konnte ich zeigen, dass sGC Inhibitor-induzierte 
Axonretraktion nicht in MAP1B-/- Neuronen auftritt und, dass die Retraktion in 
Wildtypneuronen durch NPA verhindert werden kann, welche die Inhibierung von 
nNOS durch PKG nachahmt. 
Um herauszufinden, ob NO Synthese auch im Semaphorin3A Signalweg eine 
Rolle spielt, kultivierte ich Explantate von Hippocampus und DRGs in 
Wachstumsmedium welches Semaphorin3A und/oder NOS Inhibitoren enthielt. Diese 
Experimente gaben einen klaren Hinweis darauf, dass NO in der Tat wichtig für den 
repulsiven Semaphorin3A Mechanismus ist. 
Im zweiten Teil meiner Dissertation interessierte ich mich für die Rolle von 
MAP1B in Oligodendrozyten. MAP1B Expression geht der terminalen Differenzierung 
dieser Zellen voran und wurde in Oligodendrozyten beobachtet, die kurz davor stehen, 
Axone zu myelinisieren6. Es wurde mehrmals postuliert, dass NO in 
Oligodendrozytenschädigungen und in der Demyelinisierung im Laufe von Krankheiten 
wie Multipler Sklerose involviert ist7. Daher stellt sich die Frage, ob MAP1B als 
Mediator der NO-Toxizität in diesen Zellen dienen könnte. Ausserdem wurde gezeigt, 
dass MAP1B für den Transport von mRNA in DRG Neuronen wichtig ist. Da der 
mRNA-Transport zur Zellperipherie essenziell für die Etablierung einer Myelinschicht 
ist, wollte ich die Wichtigkeit von MAP1B in diesen Zellen untersuchen. 
Überraschenderweise differenzierten MAP1B-/- Zellen in vitro normal. 
Oligodendrozyten zeigten auch keine Reaktion auf eine Behandlung mit 
hochkonzentrierten NO-Donoren. Andererseits bewirkte die Stimulierung eines 
Kalziumeinstroms, welcher NOS aktiviert, einen Kollaps des Zytoskeletts. Dieser 
 12
                                                                                                                Zusammenfassung 
 13
Kollaps konnte teilweise durch die Inhibierung von nNOS in Wildtyp und eNOS in 
MAP1B-/- Zellen verhindert werden. Ich nehme daher an, dass in Oligodendrozyten, wie 
in Neuronen, ein Unterschied im NOS Expressionsschema zu finden ist. Ausserdem 
zeigen die Resultate, dass NOS und NO in der Tat toxisch auf Oligodendrozyten wirken 
und das Zytoskelett beeinflussen. 
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INTRODUCTION 
Regulatory elements of the neuronal cytoskeleton 
 
The nervous system is a highly complex network of billions of neurons 
supported by glial cells. Neurons have an elaborate morphology. They possess structural 
and functional polarity with short dendrites conveying information towards the cell 
body and a long axon conveying information away from the cell body. Glial cells 
provide nutrition and form myelin insulating neuronal processes in order to facilitate 
signal transmission. During development of the nervous system, neurons and glial cells 
have to migrate from the place of birth to their final destination. For migration and axon 
guidance, neurons bear at the end of each axon the growth cone, a motile terminal 
structure that explores the environment and translates guidance information into 
movement8. This requires an accurate coordination and regulation of cytoskeletal 
components in response to extracellular guidance cues. Thus, proteins interacting with 
the cytoskeleton, such as microtubule-associated proteins, actin-binding proteins, and 
motor proteins, play important roles in the establishment and maintenance of neuronal 
morphology and functionality. 
 
The cytoskeleton in neuronal cells 
 
As in other motile cells, the cytoskeleton of developing neurons consists of 
microtubules, actin filaments and intermediate filaments, called neurofilaments.  
Microtubules are polar structures composed of tubulin dimers assembled into 
linear arrays forming stable, cross-linked bundles in the axon shaft. Tubulin dimers are 
assembled from one α-tubulin subunit and one β-tubulin subunit9. Microtubules lend 
structural support to the neuronal cytoskeleton and are involved in many cellular 
processes including intracellular transport mechanisms and growth cone steering. In 
axons, all microtubules are oriented with their plus end towards the distal tip of the 
axon, whereas in dendrites they exhibit both orientations. Single microtubules also 
emerge into the growth cone. These filaments display the classic properties of dynamic 
 15
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instability, polymerizing and shrinking as they explore the peripheral region of the 
growth cone10. 
Actin filaments play an essential role in driving motility and guidance of growth 
cones11. They are helical polymers composed of actin monomers, often referred to as 
globular actin. It can exist as ATP-actin and ADP-actin. ATP- and ADP-actin can 
associate and dissociate from both the rapidly growing barbed and the slower growing 
pointed ends in vitro12. G-actin polymerizes into actin filament as ATP-actin and is 
converted to ADP-actin through its intrinsic ATPase activity. Several actin-associated 
proteins have been found to bind preferentially to these different forms of actin13. The 
actin filaments connect to the extracellular substrate via interactions with integral 
membrane proteins such as cadherins, integrins and neural cell adhesion molecules14. 
Neurofilaments are present in the axon and the central domain of the growth 
cone but their function in growth cone motility and axon guidance is unknown15. Since 
my work focuses on the interplay between signaling molecules, microtubules, and actin, 
neurofilaments will not be dealt with. 
 
Microtubule associated proteins 
 
Classical microtubule associated proteins, such as MAP1A, MAP1B, MAP2 and 
tau, were among the first identified microtubule regulators16. MAPs were suggested to 
play a role in the establishment and regulation of neuronal morphology because of their 
specific associations with the three structural compartments of neurons – the axon, the 
soma and the dendrites. MAP2 shows a preferential subcellular expression in dendrites 
and somata but not in axons in vivo. In contrast to MAP2, tau is enriched in the axons. 
The MAP1 family has been found to be prominent in axons as well as in somata and 
dendrites.  
MAP1B and MAP2 are among the most abundant neuronal MAPs but they do 
not show all the same developmental expression pattern. Early MAPs that are expressed 
during fetal and neonatal stages are the 48 kDa isoform of tau, MAP2, MAP2 and 
MAP1B. Later expressed MAPs include the heavier isoforms of tau and MAP1A17. 
MAP2 is present at both early and late stages and has three isoforms, MAP2A, B and 
C18. MAP2-deficient mice develop without any apparent abnormalities suggesting a 
functional redundancy among MAPs.  
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MAP1B and MAP2 have overlapping functions in neuronal migration and 
neurite outgrowth by organizing microtubules in developing neurons. MAP1B-/-MAP2-/- 
double knockout mice die in their perinatal period. They show fiber tract malformations 
and disrupted cortical patterning caused by retarded neuronal migration. Hippocampal 
neurons of these mice reveal inhibition of microtubule bundling and neurite 
elongation19, 20. Similarly, the phenotypes of tau-/-MAP1B-/- double mutants are 
markedly more severy than the single mutants of those proteins. They show hypoplastic 
commissural axon tracts and disorganization of neuronal layering in the brain. 
Moreover, in neurons from double knockout mice inhibited axonal elongation and 
delayed neuronal migration were observed21. 
Although structural differences among the MAPs exist, all of them can interact 
with tubulin, stabilize microtubules and link them with other components of the 
cytoskeleton22. This function is dependent on posttranslational modifications of the 
MAPs. Dependent on the kinase and the phosphorylation site, phosphorylation of 
MAP1B can lead to an increased association with microtubules, whereas 
phosphorylation of MAP2/tau generally results in their dissociation from 
microtubules23. Studies suggest that MAPs can restrict access to the microtubule for 
certain molecular motors. Thus, there is the potential for thight regulation by signaling 
cues relevenant to neuronal development and degeneration. Overexpression of tau can 
inhibit the attachment of both motor proteins kinesin and dynein, MAP4 and MAP2c 
similarly inhibit motor-based transport24. The current view is that MAPs generally 
diminish the frequency by which a motor can interact with the microtubule and thereby 
move along it25. 
Microtubule associated proteins have also been suggested to contribute to the 
regulation of axonal transport of mitochondria. In comparison with wild-type neurons, 
the highest velocities of mitochondrial movement in the anterograde fashion are reached 
in tau-deficient neurons26 whereas the highest rates of mitochondrial retrograde 
movement are attained in MAP1B-deficient neurons. This suggests that MAP1B and tau 
could compete with kinesin and/or dynein motors, respectively, for binding or 
positioning on the microtubule tracks27.  
 
 
 17
                                                                                                                 Introduction 
MAP1B  
 
MAP1B is one of the three members of the structurally related family of MAP1 
proteins comprising MAP1A, MAP1B and MAP1S (Figure 1). MAP1B is translated as 
a polyprotein containing the heavy chain and one of the two light chains, LC1, which is 
cleaved from the C-terminus of the precursor after translation. MAP1A and MAP1S are 
also posttranslationally cleaved into a heavy and a light chain28, 29. Futsch is the 
homologue of MAP1B in flies; it is also cleaved into a heavy chain and a light chain 
after translation30. MAP1A, MAP1B and MAP1S share homology domains (MH1-3); 
futsch bears the homology domains MH1 and MH3. The activity of the light chains is 
inhibited by the heavy chain, whereby the interaction takes place between the MH1 
domain of the heavy chain and the MH3 domain of the LC1 or LC220. LC1 and LC2 are 
able to interact with the heavy chains of either MAP1A or MAP1B31. 
MAP1B is expressed in neuronal and non-neuronal cells in the nervous system. 
MAP1B protein and mRNA for MAP1B are expressed at high levels during 
development and while they are down-regulated at the end of axonogenesis in most 
regions of the CNS they remain at relatively high levels in adult PNS32, including some 
of the developmentally regulated phosphorylated isoforms22. In contrast to MAP1B, 
MAP1A is expressed in mature neurons only. MAP1S is expressed in a wide range of 
tissues and represents a nonneuronal counterpart of this cytolinker family29. Futsch is 
expressed in many neurons in the fly CNS and was also shown to bind microtubules. 
Binding of the MAP1B LC1 to microtubules induces formation of stable but 
flexible microtubules with increased resistance to nocodazole and taxol but it was not 
found to promote microtubule bundling, like MAP2 and tau22. The LC2 of MAP1B 
interacts with PDZ-Rho-GEF, a member of a Rho-GEF subfamily. Mutants of PDZ-
Rho-GEF alter the activation of Rho-GTPases, thus, modulation of the guanine 
nucleotide exchange activity of PDZ-Rho-GEF through interaction with MAP1B LC2 
may coordinate microtubule integrity and the reorganization of actin cytoskeleton33. 
Futsch is required to regulate microtubule architecture, thereby controlling growth cone 
function and synapse formation25. 
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Figure 1: The family of microtubule associated proteins 1 with its members MAP1A, MAP1B, 
MAP1S, and Futsch. 
MAP1A, MAP1B, MAP1S and futsch, the fly homologue of MAP1B, are posttranslationally cleaved into 
a heavy chain and a light chain bearing microtubule and actin binding domains34. The blue boxes indicate 
microtubule binding sites and the green boxes show actin binding sites. The three MAP1s share 3 
homology domains (MH1-3) indicated by the brown boxes. Futsch shares 2 homology domains with the 
MAP1 family. 
 
MAP1B can be phosphorylated at more than 33 serine and threonine sites via 
two modes: mode I sites are generated by the proline-directed serine/threonine kinases 
cdk5 and GSK-3β, and mode II sites are generated by casein kinase II35. GSK-3β is 
expressed in two isoforms: a short form GSK-3β1 and a long form GSK-3β2. GSK-3β1 
is more efficient in phosphorylating MAP1B than GSK-3β2. Despite much work that 
has been performed on different phosphorylation sites of MAP1B, it is difficult to know 
exactly which particular phorphorylation site is examined. Thus the effects of the 
different kinds of MAP1B phosphorylation remain elusive. So far it is known that mode 
I phosphorylated MAP1B concentrates at distal regions of regenerating nerves, whereas 
mode II phosphorylation undergoes an overall decrease in regenerating axons36. In the 
developing nervous system, the expression of GSK-3β phosphorylated MAP1B is 
spatially restricted to growing axons, despite the expression of MAP1B and GSK-3β 
throughout the entire neuron. This suggests a mechanism which is spatially regulating 
the phosphorylation of MAP1B by GSK-3β37. Moreover, mode I phosphorylated 
MAP1B is present only in stable regions of a growth cone and absent from unstable 
regions of a turning growth cone. Additionally, the activator of Cdk5, p35, is also 
restricted to the stable parts of the growth cone. Inhibition of Cdk5 results in loss of 
mode I phosphorylated MAP1B and growth cone collapse, axon retraction and prevents 
axonal outgrowth38. 
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Another function of the phosphorylation of MAP1B is the regulation of the 
interaction between MAP1B and another MAP, the lissencephaly-related protein 1 
(LIS1). This interaction interferes with the association between LIS1 and the 
microtubule dependent molecular motor dynein, thereby regulating the functions 
attributed to the LIS1-dynein complex, including those related to extension of the neural 
processes necessary for neuronal migration39. 
Studies of cultured primary neurons showed that MAP1B is constitutively highly 
expressed in adult dorsal root ganglia (DRG) and is associated with central sprouting 
and peripheral regeneration of these neurons. MAP1B negative neurites grow often in a 
curled manner and exhibit higher terminal and collateral branching40. During 
synaptogenesis in vitro, MAP1B was observed to be translocated to the plasma 
membrane of rat cortical neurons and seems to contribute to the maturation of neurites 
after an initial phase of neurite elongation41. Moreover, it has been reported that a 
significant fraction of MAP1B is expressed as an integral membrane glycoprotein in 
vesicles and the plasma membrane of neurons42. 
Four groups generated mice bearing a mutated product of MAP1B. They showed 
either embryonic lethality43, perinatal lethality when smaller isoforms of the protein 
were overexpressed44, only a weak influence on nervous system development45. The 
complete deletion of the MAP1B gene leads to an agenesis of the corpus callosum. 
Commissural nerve fibers that should cross the midline at the regions of the corpus 
callosum and the hippocampal commissure form thick bundle of fibers that run in the 
longitudinal direction of the brain, the so called Probst bundles. Moreover, axonal 
myelinization defects were observed, resulting in reduced motor nerve conduction 
velocity. The discrepancies concerning the severity of the MAP1B phenotype might be 
due to different strategies for inactivation of the gene and for differences in the genetic 
background of the four MAP1B mutant lines. However, this demonstrates that MAP1B 
is required for correct axon guidance during brain development4.  
A loss of function futsch allele produces defects in axonal and dendritic growth 
in the embryonic nervous system46, 47. Moreover, it was shown to play a critical role in 
the maintenance of the CNS throughout adult life and is involved in progressive 
neurodegeneration48. 
The phenotype of the complete MAP1B knock-out shares similarities with the 
phenotype of mice lacking netrin-1, DCC or Mena. All of them have severe defects in 
generation of the corpus callosum49-51. However, one has to keep in mind that netrin-1, 
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DCC and Mena mutant mice show much stronger phenotypes than MAP1B mutants. 
Callosal axon guidance defects are also observed in mice lacking the cdk5 activator 
p3552 which is implicated in regulation of laminin-induced MAP1B phosphorylation53. 
Thus, MAP1B might also be involved in laminin-mediated cell signaling and regulation 
of actin polymerization in the growth cone involved in corpus callosum formation4, 49. 
 
Regulation of cytoskeletal dynamics in neuritogenesis 
 
In neuritogenesis, behaviors such as advancing, retracting, turning and branching 
are driven by the dynamics and reorganization of the actin and microtubule cytoskeleton 
regulated through signaling pathways downstream of guidance cue receptors located at 
the growth cone54. Enzymes essential for directed motility during neurite extension, 
axon guidance and neuronal migration are the Rho family of GTPases, including Cdc42 
(cell division cycle 42), Rac (Ras-related C3 botulinum toxin substrate) and Rho (Ras 
homologous)55. There are three isoforms of Rho: RhoA, RhoB and RhoC; in neurons 
RhoA is expressed at higher levels than the other isoforms56. In fibroblasts, RhoA, Rac 
and Cdc42 induce the formation of stress fibers, lamellipodia, and filopodia, 
respectively57, 58. There is evidence that Rho is involved in growth cone collapse and 
repulsion whereas Rac and Cdc42 participate in growth cone attraction and advance59. 
The balance of these opposing activities of the different Rho GTPases is crucial for the 
morphology of the neurons60.  
Other important signaling molecules are cAMP/cGMP and calcium. Levels of 
intracellular calcium have a profound influence on growth cone behavior, neurite 
sprouting, elongation and motility of axons and dendrites61,62, either by directly acting 
on cytoskeletal proteins or by activating various calcium-binding proteins63. Small or 
relatively large local Ca2+ elevations trigger growth cone repulsion, whereas a moderate 
local elevations induce growth cone motility and extension64. Recent evidence indicates 
that Ca2+ can regulate Rho GTPases through Ca2+-regulated GTPases-activating 
proteins and Ca2+-regulated guanine nucleotide exchange factors65. 
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Axon retraction 
 
The selective elimination of axons, dendrites and synaptic connections without 
death of the parent neurons is a crucial common theme in many biological processes 
and central to normal neuritogenesis and neural function. The mode of axon elimination 
occurs through one of two distinct phenomena: small-scale eliminiation typically occurs 
by retraction, whereas large-scale elimination appears to occur primarily by 
degeneration. A retracting neuron shows three characteristics: sinusoidal bundles along 
the axon shaft, a collapsed growth cone and a trailing remnant (Figure 2). 
 
 
Figure 2: A retracting axon. 
The figure shows phase contrast picture of a retracting DRG neuron with collapsed growth cone (red 
arrow), sinusoidal bundles (white arrow) and a trailing remnant (green arrow). 
 
Axon retraction entails major rearrangements of both the axonal and growth cone 
cytoskeleton and can be triggered by changes in the activity of microtubule or actin 
motors. For example, inhibition of microtubule motor dynein causes axon retraction in 
the presence of intact microtubules; this effect is reversed by depletion of the actin 
cytoskeleton or inhibition of myosin motors. Thus, myosin-actin and dynein-
microtubule cytoskeletons were proposed to contribute opposing and counter-balanced 
forces regulating axon stability66. Moreover, cytoplasmic dynein and dynactin are 
essential for the transport of microtubules from the centrosome into the axon, thereby 
serving to align them with one another and permit them to invade filopodia67, 68. 
RhoA plays an important role in axon retraction. Its activation results in changes 
in actin dynamics and activation of myosin which further lead for instance to prevention 
of axon initiation in primary neurons69, neurite retraction in cultured neuroblastoma cell 
lines70 and retraction of dendritic processesin maturing neurons in vivo71. Moreover, 
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activation of RhoA is also implicated in mediating the activity of myelin-associated 
inhibitors in blocking axon regeneration72. Given the potential similarities between 
repulsive axon guidance and axon retraction, repulsive guidance molecules such as 
ephrins, slits or semaphorins, all of which signal through RhoA, could also signal axon 
retraction11. Moreover, outgrowth of one axonal process is often accompanied by 
simultaneous retraction of another process belonging to the same axon, suggesting a 
competitive mechanism for differential process outgrowth73. 
 
Axonal transport of mitochondria and peroxisomes 
 
Organelle transport is essential for the axonal development and maintenance. In 
neurons and glia cells, the distances between the sites of organelle biogenesis, function 
and degradation can be vast. Long-range transport along microtubules provides delivery 
of biosynthetic products and organelles produced in the cell body to the neurite74. 
Defects in axonal transport such as transport blockade of nutrients, survival factors, or 
any other proteins lead to neuronal dysfunction and degeneration66 and eventually to 
neurological disorders including Alzheimer’s, Huntington’s, and motor neuron 
diseases75. 
Mitochondria are essential for the function of all aerobic cells; they produce 
ATP, buffer cytosolic calcium and sequester apoptotic factors76. Mitochondria were also 
suggested to play a pivotal role in organizing neuronal polarity, possibly by controlling 
local calcium and/or energy gradients77. Nevertheless, mitochondria are often involved 
in pathologies of the nervous system due to alterations in their migratory behavior or 
localization78. Movement of mitochondria in axons can serve as a general model for 
how organelles generally move. They move along both microtubules and actin 
filaments, they pause and change direction, and their transport is modulated in response 
to physiological signals. Mitochondria can quickly switch between anterograde and 
retrograde movement and shift between moving and stationary states79. Anterograde 
organelle transport implicates motor proteins of the kinesin superfamily and retrograde 
transport involves proteins of the dynein family80. Mitochondria can also move along 
actin filaments in axons implicating myosin motors81. Kinesins, cytoplasmic dynein and 
myosins cooperate to give rise to the complex movement of mitochondria but possible 
control mechanisms remain largely speculative76. 
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For peroxisomes, although the interaction with microtubules has been 
demonstrated82, little is known about the nature of involved proteins. Two types of 
peroxisome movement can be distinguished: a relatively slow, random, vibration-like 
movement displayed by the majority of the peroxisomes, and a saltatory, fast directional 
movement exhibited by only a small fraction of the peroxisomes, possibly being energy 
dependent83. Addition of ATP or motor proteins kinesin and dynein increases the 
binding capacity of peroxisomes to microtubules, while ATP-depletion or microtubule 
associated proteins such as MAP2 and tau decrease it84 and inhibition of cytoplasmic 
dynein based motility inhibits the movement of peroxisomes. Microtubule-destabilizing 
agents disturb proper localization and directional movement of peroxisomes. In 
contrast, microtubule-stabilizing compounds do not exert effects85.  
The lack of MAP1B was shown to influence the motility of mitochondria27, 
whereas the role of MAP1B in peroxisomal movement has never been investigated. 
This subject will be outlined in the second part of this thesis. 
 
Axon guidance 
The growth cone 
 
Growth cones, the highly motile tips of growing axons, are guided through their 
environment in response to multiple sources of spatial information to reach the 
appropriate region in the brain. Besides cell adhesion molecules and the extracellular 
matrix (ECM) molecules, diffusible chemotropic cues direct the traveling growth 
cone86. The two main structures of the growth cone are actin-based fingerlike 
protrusions called filopodia and flattened extensions called lamellipodia (Figure 3). The 
filopodia are thought to be particularly sensitive to extrinsic signals because of their 
small intracellular volume87. The major changes that occur in the cytoskeleton of 
growing neurites are rapid rearrangements of actin filaments in the filopodia and 
lamellipodia of growth cones and polymerization of microtubules61. The shape and the 
size of the growth cone change according to the rate of neurite extension. Large, 
splayed growth cones are typical during prolonged pauses, as the neurite explores the 
local microenvironment, whereas rapidly extending neurites have small and streamlined 
growth cones16. 
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Figure 3: The structure of the growth cone.  
The peripheral (P) domain of a growth cone comprises filopodia, fine extensions of F-actin bundles and 
dynamic microtubules that explore the environment, and lamellipodia, veil-like structures consisting of F-
actin meshwork. The central (C) domain of the growth cone is dominated by stable microtubules86. 
 
In growth cones, microtubules predominate in the central region whereas actin 
filaments prevail in the periphery. However, there are extensive regulatory and 
structural interactions between these two cytoskeletal elements in the growth cone 
transitional domain containing the actin arcs88 required for functions such as cell 
motility and growth cone guidance89. Actin arcs are thought to mediate the microtubule 
alignment from the growth cone to the neurite shaft90. The neurite shaft is generated by 
a process called consolidation, which results from the collapse of the proximal part of 
the growth cone and the suppression of protrusive activity along the neurite8. This 
dynamic interaction is believed to be made possible through shared regulatory proteins 
such as MAP1B, MAP2 and spectraplakins, which can bind to both actin and 
microtubules16.  
Microtubules were found to extend along actin filament bundles that served to 
guide their anterograde and retrograde transport. Although many stable microtubules 
remain in the center of the growth cone, a population of dynamic microtubules can 
actively explore the periphery and penetrate filopodia54. The cytoplasmic motor protein 
dynein transports short microtubules anterogradely along the axon in part by pushing 
against the actin cytoskeleton. These dynein-driven forces overcome myosin-II-driven 
counterforces, oppose the tendency of the axon to retract, and thereby, permit 
microtubules to advance into the peripheral zone of the growth cone91. 
The prevailing view is that axonal growth involves the assembly of new 
cytoskeleton components and axonal retraction involves the disassembly of existing 
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cytoskeletal components92. Guidance cue receptors located at filopodia and lamellipodia 
and their downstream signaling pathways regulate those cytoskeletal dynamics. When 
microtubule dynamics are inhibited by nocodazole or taxol the growth cone is not 
capable to respond in a proper manner to signaling molecules. Otherwise, local 
stabilization of microtubules is an important mechanism to guide a growth cone. 
Microtubule stabilization in one side of the growth cone induces attractive steering in 
this direction. This can be abolished by inhibition of actin polymerization. In contrast, 
local microtubule depolymerization causes growth cones to steer away. Thus, inhibition 
of microtubule dynamics and localized stabilization and de-stabilization of microtubules 
are sufficient to induce attractive and repulsive turning93. 
Another important feature of growth cones is that they contain mRNAs, a 
translation machinery, and a protein degradation machinery. Thus, the protein synthesis 
is not confined to the perikaryon94. Guidance molecules can activate translation 
initiation factors and stimulate a marked rise in protein synthesis within minutes. This 
suggests that they can steer axon growth by triggering rapid local changes in protein 
levels in growth cones95. Local translation and upregulation of expression of specific 
receptors might also be used to completely switch the growth cone’s responsiveness to 
specific cues once it reaches an intermediate target96. The best described intermediate 
target is the central nervous system midline97. First, commissural axons grow toward the 
midline, and after crossing, they are prevented from recrossing and are guided along 
longitudinal tracts even though they were ignoring the same tracts before crossing. This 
involves for instance local upregulation of specific receptors. 
Nevertheless, protein synthesis is not strictly required in the mechanisms for 
growth cone responses to many guidance cues. In the presence of cycloheximide or 
anisomycin, some guidance cues still induce growth cone collapse and loss of actin 
filaments. In contrast, NGF and neurotrophin-3 still induce growth cone protrusion and 
increase filamentous actin while sensory growth cones turn toward the NGF source98.  
In addition, interactions between neurons and ECM components are 
fundamental. The most prominent promoters of neurite growth are the laminins which 
are an important family of ECM glycoproteins99. A typical laminin molecule consists of 
three polypeptide chains linked via disulfide bonds forming the asymmetric cross-
structure100. Laminin is also required for normal CNS myelination although the exact 
mechanisms remain unknown101. Adult mouse DRG neurons have been shown to 
express different receptors for laminins, such as integrin α3, α6, α7 and β1102. As it is 
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the case in many other signaling pathways, laminin mediated growth cone turning 
requires an influx of extracellular Ca2+ 103. 
 
Axon guidance cues 
 
Classically, guidance cues have been divided into attractive and repulsive 
signals. The cues can be substrate bound or cell-membrane bound and act on nearby 
axons97. Alternatively, cues secreted from far away sources diffuse and form gradients, 
this mechanism is called chemotropism104, 105. 
Guidance cues are grouped into four classes, the netrins/Unc6106, the slits107, the 
semaphorins108 and the ephrins109. More recent reports also identified the Wnt family110, 
sonic hedgehog111 and FGFs112 as axon guidance molecules. Slits, semaphorins and 
netrins are widely expressed outside the nervous system and they may also play 
important roles in cancers. They were denoted to act as tumor suppressors and appear to 
control the vascularization of tumors. Moreover, many axon guidance cues regulate cell 
migration and apoptosis in normal and tumorigenic tissues113. How a growth cone 
responses to those cues, being attracted or repelled, depends on the receptors present on 
its surface, on their downstream targets that become activated and on the extracellular 
matrix on which the axon grows. These factors finally lead to the decision whether the 
axon extends along the dorsal-ventral or the anterior-posterior axes or if they cross the 
midline. 
Disturbed responses to axon guidance cues during development can result in 
defects in the formation of commissures. Furthermore, major brain or motor 
dysfunctions might be the consequences114. Growth cone migration in the dorsal-ventral 
region is mainly controlled by netrins with their receptors, Unc-40/DCC/Frazzled and 
Unc-5, and the slits with their receptors, Robo/SAX-3. Axon guidance in the anterior-
posterior axis is mainly controlled by Wnts and their receptors, the Frizzleds. There is 
evidence that the axes of growth cone migration are determined by the manner in which 
netrin, slit and Wnt receptors are localized within the neuron prior to axon outgrowth115. 
Targets for the signaling pathways downstream of guidance receptors are 
molecules such as the actin nucleator Arp2/3, proteins to promote filament elongation, 
adhesion molecules to couple actin filaments to the substrate and motorproteins to 
regulate the transport of actin filaments. Molecules that capture microtubule ends or 
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suppress microtubule instability, such as MAP1B, are also potential targents for 
guidance signals116. 
Guidance cues such as netrins have been shown to induce actin polymerization 
in case of attractive signaling, thereby promoting rapid axon branching. Netrin-1 rapidly 
increases axon branching and growth cone filopodia in cortical neurons with a 
concomitant increase in actin filaments117.  
In contrast, inhibitory guidance cues such as semaphorins collapse growth cones 
by depolymerizing actin filaments118. For instance, semaphorin3A (referred to hereafter 
as Sema3A) induces depolymerization of actin filaments, attenuates microtubule 
dynamics and collapses microtubule arrays. Additionally to its repellent effect, Sema3A 
also inhibits branching of cortical axons without affecting axon length significantly. 
Netrins and semaphorins are especially interesting for this thesis and will be discussed 
in a separate chapter. 
Other repellent factors are the slits. Mice lacking slit1 and slit2 are deficient in 
all three major forebrain commissures119. Slits are large secreted proteins that signal 
through Roundabout (Robo) family receptors and control midline crossing of axons in 
Drosophila120 and in regions of the mammalian CNS121. In Drosophila, slits are 
expressed at the ventral midline, where they act as a short-range repellents to prevent 
ipsilateral axons from crossing the midline and commissural axons from recrossing120. 
Moreover, an intracellular signaling pathway has emerged linking slit2/Robo to actin 
regulation. Slit2 was shown to stimulate the binding of a Rho GTPase activating protein 
with the intracellular domain of Robo, leading to the inactivation of Cdc42122. The 
current working model is that Robo3 interferes with slit-mediated repulsion, thereby 
allowing Robo1/2-expressing axons to reach and cross the midline123. Commissural 
neurons that grow towards the midline are first attracted by netrins but insensitive to 
midline repellents slit and semaphorins. After an axon has been guided successfully to 
the midline, attraction by netrin is turned off and repulsion is turned on. Once midline 
crossing has occurred, the axons are guided along either rostral or caudal on the 
contralateral side in tracts parallel to the midline120. 
There are several theories how an axon loses the responsiveness to a special 
guidance cue once it has reached its destination. It was shown that netrin-1 induces for 
instance the ubiquitination and proteolytic cleavage of DCC in dissociated cortical 
neurons124. Another hypothesis is that there is one hierarchical silencing mechanism, 
which involves the suppression of the attractive effect of netrin by the repulsive 
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guidance cue slit. Slit activates Robo which silences the attractive effect of netrin-1 
through direct binding of its cytoplasmic domain to the cytoplasmic domain of DCC125. 
Mutations in robo lead to a phenotype, in which too many axons cross the midline126, 
perhaps because recrossing is not impeded. In addition, slit was identified as a factor 
that stimulates sensory axon branching and elongation. Thus, slits, like netrins, are 
multifunctional127.  
Another family of guidance cues are the Wnts. Wnts are well-studied 
morphogens involved in asymmetric cell divisions in many organisms. They were also 
found to play a role in neurite outgrowth, midline crossing and anterior-posterior 
guidance110. 
Matrix and membrane bound molecules also directly instruct neuronal growth 
and migration. The classical members of this family include EphB2, its ligand EphrinB2 
and heparin sulfate glycosaminoglycans128. The ephrins are membrane-bound ligands 
for the Eph family of receptor tyrosine kinases. Ephrins belong to either of two classes: 
ephrin-As are anchored to the membrane by a glycosylphosphatidylinositol linkage and 
bind EphA receptors, and ephrin-Bs have a transmembrane domain and bind EphB 
receptors129. The functional link between EphA receptors, Rho GTPases and the 
cytoskeleton130 suggests that the ephrin signaling pathway also influences actin 
cytoskeletal dynamics in the growth cone131, 132. 
Recently, a new axon guidance cue, draxin, has been identified. It does not show 
any homology with known axon guidance cues and inhibits neurite outgrowth from 
dorsal spinal cord and cortical explants in vitro. Draxin-knockout mice show 
defasciculation of spinal cord commissural axons and absence of all forebrain 
commissures133. 
 
The role of calcium, cyclic AMP, and cyclic GMP in guidance responses 
 
The internal state of the growth cone is extremely important in deciding how a 
guidance cue is interpreted by the developing axon. The intracellular calcium 
concentration, cyclic nucleotide levels, and membrane potential are all reported to 
modulate the transduction of guidance cues134 and play an essential role in axcon 
growth, survival and regeneration. Neurons maintain a baseline intracellular Ca2+ 
concentration at the resting state, termed the resting Ca2+ concentration64. Cytoplasmic 
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Ca2+ levels determine whether a growth cone responds by turning away from or toward 
a guidance cue. One proposed mechanism how calcium signaling brings about growth 
cone turning is the creation of cytoplasmic Ca2+ gradients downstream of the action of 
guidance cues135. Netrin-1 signaling involves for example increases in Ca2+ that are 
highest on the side of the growth cone facing the source of the factor136. It has been 
suggested that netrin-1 acts on its receptor to ultimately open plasma membrane Ca2+ 
channels. Ca2+ influx then activates Ca2+ induced Ca2+ release from internal stores and 
these sources contribute to local amplifications of Ca2+ levels137. Reduction of Ca2+ 
signals by blocking either of these two sources can convert an induced attractive 
response into repulsion136. 
Localized spontaneous Ca2+ transients of different frequencies occur in restricted 
regions of axons and their branches. Higher frequencies occur in more rapidly extending 
processes whereas lower frequencies occur in processes that stall or retract. Global Ca2+ 
transients inhibit extension of the primary axon, whereas localized Ca2+ transients 
evoked by netrin-1 signaling could promote branching of the axon in regions of high-
frequency Ca2+ transients138. 
Calmodulin, CaM, is an abundant intracellular Ca2+ receptor in filopodia and 
growth cones139. Upon Ca2+ binding, Ca2+/CaM can associate with a wide range of 
targets, including kinases, such as Ca2+/CaM dependent protein kinases (CaMK) I, II 
and IV140, and phosphatases, such as calcineurin (CaN)141. Moreover, CaMKII, and 
protein kinase C (PKC), which can both be activated by Ca2+, can activate Rho 
GTPases142.  
Because membrane potential has the ability to influence the levels of second 
messengers like cAMP143 and to determine the amount of extracellular Ca2+ that enters 
the cell144 it is possible that its tight regulation is critical in ensuring that cues are 
correctly interpreted by the growth cone145. Ca2+ can regulate the production of cAMP 
and cGMP via its action on adenylyl cyclases and nitric oxide synthase, NOS, 
respectively. Moreover, cyclic nucleotides can act by modulating Ca2+ channels146 
resulting in distinct patterns of Ca2+ signals that underlie attractive or repulsive growth 
cone steering. Thus, Ca2+ regulation of growth cone motility depends on both the 
spatiotemporal patterns of Ca2+ signals and the internal state of the neuron147.  
Second messengers such as cAMP and cGMP are also known to regulate 
attractive and repulsive axonal guidance by ligands like the netrins and semaphorins. In 
case of the netrin signaling pathway, a high cAMP:cGMP ratio favors attraction, 
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whereas a low ratio favors repulsion. cAMP signaling modulates both DCC- mediated 
attraction and DCC-Unc5-mediated repulsion146. During local application of normally 
attractive neurotrophin BDNF the reduction of cAMP level also leads to repulsive 
turning of the growth cones148. Moreover, cyclic nucleotide signaling directly modulates 
the activity of L-type Ca2+ channels, LCC, in axonal growth cones146. Furthermore, 
cGMP signaling suppresses LCC activity and is required for growth-cone repulsion 
mediated by the DCC-Unc5 receptor complex149. 
Likewise, Sema3A/NRP1 repulsive signaling can be switched into 
chemoattraction by the distribution of sGC150 and an increase in intracellular cGMP 
concentration151. cAMP analogs have no significant effect on the repulsion induced by 
semaphorin3 but convert the repulsion induced by myelin associated glycoprotein 
(MAG) into attraction151. Thus, the dependence on cyclic nucleotide signaling pathways 
might differ among different types of repulsive signals146. 
 
The axon guidance cue netrin-1 
 
As already mentioned, netrins (the “one who guides” in Sanskrit) are 
extracellular molecules that play an important role in neuronal migration and axon 
guidance. They are laminin-related molecules that function by interacting with the 
transmembrane receptor of the immunoglobulin superfamily deleted in colorectal 
cancer, DCC152/Frazzled, and Unc5153 in several neuronal populations. The first 
identified member of the netrin family was Unc-6, characterized in C. elegans154. Soon 
after, homologues of the product of the unc-6 gene in C. elegans, netrin-A and netrin-B 
were described in Drosophila155, and in Zebrafish. In chicken netrin-1 and netrin-2 have 
been reported to be diffusible factors secreted by floor plate cells that promote the 
outgrowth of commissural neurons156, 157. In mice, humans and rats, netrin-1, -2, 
-3/NTL2, -4/β and G-netrins have been cloned, of which netrin-1, -2, -3/NTL2 and -G 
are closely related to the laminin-γ chains158. The homology between the murine 
netrin-1 protein and chick netrin-1 is 89%50. The greatest identity between the netrins 
and Unc-6 is found in the domain V which is rich in epidermal growth factor repeat 
structures157 (Figure 4). 
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Figure 4: The homology between different netrins and the structure of netrin. 
The table shows the percentage of identity between mouse netrin and netrins of other organisms. The 
netrin gene is thought to have derived from the laminin-γ gene. The protein bears a globular domain, three 
EGF repeats and the positively charged C domain159. The arrows indicate the binding sites for different 
receptors. 
 
Netrin-1 is widely expressed both in the developing nervous system and in 
mesodermal tissues160. It is expressed by floor plate cells and its gradient extends many 
cell diameters dorsal to the floor plate161. Floor plate cells have been shown to attract 
commissural axons coming from dorsal parts of the neural tube162, 163. 
The first indication that netrin-1 is involved in neuronal migration and axon 
guidance came from the observation that in netrin-1 null mice, the ventral commissure 
of the spinal cord was reduced and the basilar pontine nuclei are completely missing. 
Netrin-1 was then shown to attract the tangential migration of DCC-expressing pontine 
neurons from the rhombic lip to the midline and the hindbrain164,165. Additionally, in the 
mutant mice, commissural axons do not cross the midline; instead they show 
misorientation of fiber tracts and pathfinding errors. Both the corpus callosum and the 
hippocampal commissure are completely absent in homozygous mutants and the 
anterior commissure shows variances. However, two dorsal commissures appear intact 
in the mutant animals49, 166. 
Mice deficient in netrin-1 die within a few days; they cannot move their 
forelimbs independently of one another and do not suckle milk. Mice that are DCC-
deficient show a phenotype similar to netrin-1-deficient mice and lack the main 
commissures of the CNS50. In Drosophila, mutation in frazzled results in reduced or 
absent axon commissures, however, many axons still cross the midline normally167. 
In the hippocampus at E14-E18, netrin-1 is highly expressed in the fimbria, 
which is the route followed by developing hippocampal axons to reach the hippocampal 
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commissure. High expression was detected just above the emerging corpus callosum 
and below the hippocampal commissure. 
Netrin-1 expression levels in embryonic and adult striatum or spinal cord do not 
differ, suggesting that it not only influences the development of striatal circuitry but 
may also participate in the maintenance and plasticity of connections in the adult 
CNS168. At early postnatal stages, overall netrin-1 expression decreased but is still 
noticeable in the septum, dentate gyrus and in some hippocampal interneurons63. In the 
adult, netrin-1 is also expressed on spinal interneurons and motoneurons, cells of the 
central canal, the meninges and on mature oligodendrocytes but not astrocytes. Netrin-1 
protein in white matter is enriched adjacent to paranodal loops of myelin in nodes of 
Ranvier. The majority of the protein is not freely soluble but is associated with 
membranes or the extracellular matrix. Thus, netrin-1 may also contribute to the 
maintenance of appropriate axon-glial interactions in the mature nervous system169. 
Outside the nervous system, netrin-1 is expressed in the limb-primordium, somatic 
mesoderm, mammary gland, pancreas, dorsal aorta and cardiac muscle158. 
In the developing mouse spinal cord, netrin-1 is expressed in the floor plate from 
E10.5 until E11.5 and the netrin-1 receptor Unc5c is expressed in DRG neurons. 
Netrin-1 acts additionally as an early ventral spinal cord-derived chemorepellent for 
DRG axons but may not act as a repellent at later stages, as the expression levels of 
netrin receptor Unc5c is downregulated in the DRG neurons of late stage embryos170, 
171. The central projections of DRG neuron axons in the spinal cord are tightly regulated 
spatially and temporally. During development, DRG neurons enter the spinal cord at the 
dorsal root entry zone (DREZ) and then grow to the marginal zone of the spinal cord 
longitudinally to form the dorsal funiculus. Netrin-1 is transiently expressed or 
upregulated in the dorsolateral region, adjacent to the DREZ, during the waiting period, 
from day E11.5 to E13.5, and the loss of netrin-1 results in a delay between the 
formation of the dorsal funiculus and the extension of collaterals into the dorsal mantle 
layer172. Moreover, netrin-1 and DCC might play a role in promoting outgrowth and 
guidance of pioneering olfactory axons toward the olfactory bulb primordium173. In 
addition, netrin-1 attracts retinal ganglion cell axons toward the optic disc174 and all 
precerebellar neurons toward the midline165, 175, 176. Netrin-1 also increases cortical 
branching, which is essential for establishing CNS connectivity, without affecting 
outgrowth of the primary axon117. 
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Conversely, netrin-1 and DCC mediate the repulsion of the cerebellar neurons 
from the external granule layer and the striatal neurons from the subventricular zone177. 
Netrin-1 also repels migrating granule cells exiting explants taken from external 
granular layer from postnatal cerebellum178. Netrin was also shown to be crucial for the 
initial dispersal of spinal cord oligodendrocyte precursors, allowing polarization and 
directional migration, and their subsequent development in the white matter. In the 
spinal cord of netrin-1 mutant mice, oligodendrocyte precursors fail to disperse from the 
ventral midline 179. 
 
The netrin-1-signaling pathway 
 
The translation of the netrin-1 signal is dependent on which receptor is involved 
in the signal transduction pathway, DCC or Unc5. Signaling by netrin-1 binding to DCC 
results in attraction whereas intracellular signaling by Unc5 leads to repulsion. Upon 
netrin binding, the receptors form homodimers or heterodimers but only DCC 
homodimers transmit attraction. Apparently, netrin-1 induced formation of a DCC/Unc5 
heterodimer converts DCC-mediated attraction to DCC/Unc5-mediated repulsion. The 
dimers become phosphorylated and, via Ca2+ influx and diverse signaling molecules, 
influence the ratio between cAMP and cGMP which controls the response of the growth 
cone (Figure 5). DCC further activates the mitogen-activated protein kinase (MAPK) 
which leads to the recruitment of ERK-1/2 to a DCC receptor complex180. 
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Figure 5: Attractive or repulsive signaling by netrin-1.  
Depending on the receptor bound by netrin-1, attractive of repulsive signaling pathways can be activated. 
Binding of netrin-1 to DCC or Unc5 induces homodimerization or heterodimerization of the receptors and 
activation of downstream signaling pathways. These activate actin and microtubule machineries and 
eventually result in a turning of the growth cone159. 
 
DCC is distributed both on the cell surface and in an intracellular vesicular pool 
in embryonic spinal commissural neurons. Membrane depolarization and increasing the 
intracellular concentration of cAMP or activating cAMP dependent protein kinase 
(PKA) in these cells produces a netrin-1-dependent increase in plasma membrane bound 
DCC. This further increases commissural axon outgrowth and chemoattractive turning 
in response to netrin-1181, 182. 
Besides DCC and Unc5, netrins also bind to integrins183. Integrins could have 
complementary functions in the response of neurons to netrin migration signaling. 
Further evidence for the cooperative roles of integrins and DCC/Unc5 is that the 
integrin ligand laminin-1 is able to convert netrin-mediated attraction into repulsion in 
neurons from Xenopus.  
A major downstream target of the Ca2+ influx induced by netrin is the 
Calcium/calmodulin-dependent protein kinase II, CaMKII, which is required for axon 
branching and axon outgrowth138. CaMKII, CaN, and protein-phosphatase-1 (PP1) 
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provide a mechanism to control the direction of Ca2+-dependent growth cone turning. 
When the Ca2+ elevation is large enough, it leads to activation of CaMKII resulting in 
netrin-1 induced attraction, while a modest local Ca2+ signal acting through CaN and 
PP-1 produces repulsion. This repulsion can be inhibited by activation of soluble 
adenylyl cyclase (sAC), producing cAMP which negatively regulates CaN-PP1184. 
Studies on the role of Ca2+ and cyclic nucleotides in regulating growth cone turning 
behaviors of Xenopus spinal neurons have shown that the examined guidance cues can 
be classified into two groups. In group I, which includes netrin-1, BDNF, acetylcholine, 
NGF and MAG, the turning responses are abolished by depleting extracellular Ca2+, and 
the level of cytosolic cAMP or the activity of PKA is critical in determining whether the 
turning response is attractive or repulsive148, 185, 186. Low cAMP levels lead to the 
conversion of attraction into repulsion and in the presence of laminin-1 the amount of 
cAMP decreases in the growth cones. Thus, repulsion takes place in regions in which 
laminin and netrin are coexpressed, which may help to drive axons to sites where only 
netrin is present2, 185. In group II, which includes semaphorin3 and NT-3, the turning 
responses are independent of extracellular Ca2+ and are regulated by cGMP or cGMP 
dependent protein kinase (PKG)151. 
Another mechanism by which netrin signaling occurs is the stimulation of 
tyrosine phosphorylation of DCC by PTK2 and recruitment of Src to the receptor which 
is essential for axon outgrowth and turning106. Moreover, tyrosine phosphorylation of 
DCC causes N-WASP, Pak1 and FAK to associate with the intracellular domain of 
DCC and induces activation of phospholipase C (PLC) and the Rho GTPases Rac and 
Cdc42. These effectors collaborate to alter the axonal cytoskeleton187. For instance, 
attractive netrin-1 signaling promotes the formation of a protein complex including 
DOCK180, a member of GEFs for Rho GTPases and DCC, leading to activation of 
Rac1188. Rac1, a member of the Rho family of small GTPases, coordinates dynamic 
instability of microtubules and actin polymerization during lamellipodial protrusion in 
epithelial cells189. Interestingly, Rac1 has been implicated in netrin signaling. After 
netrin-1 binding to DCC, Rac1 is activated by the Rho-GEF Trio or by high cAMP 
levels190, 191. 
Contrary, RhoA signaling decreases the amount of plasma membrane bound 
DCC, thereby reducing the netrin-1-mediated axonal outgrowth and chemoattractive 
axon turning. In spinal commissural neurons netrin-1 was shown to inhibit RhoA, 
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leading to a recruitment of DCC to the plasma membrane and to a positive feedback 
mechanism192. 
Concerning filopodial formation on hippocampal neurons, netrin-1 promotes 
phosphorylation of Ena/VASP proteins through activation of PKA193. Ena/VASP 
proteins regulate elongation at the growing end of actin filaments by antagonizing actin 
capping proteins that normally terminate actin filament elongation194. 
Another study has shown that netrin-1 may execute its guidance action also 
through the regulation of a newly identified microtubule-plus end binding protein 
neuron navigator-1, NAV1, a mouse homolog of Unc-53, which regulates directional 
cell migration in C. elegans195. 
Similar to other guidance cues, netrin has been implicated in cancer mechanisms 
too. DCC, whose expression is lost in numerous cancers, was suggested to be a putative 
tumour suppressor which appears to be dependent on its ability to trigger apoptosis 
when disengaged from its ligand netrin-1. Netrin-1 was shown to inhibit the 
proapoptotic activity of DCC in developing spinal cord commissural neurons196. 
 Additionally, netrin plays a role in angiogenesis, the induction of which is 
mediated by an increase in endothelial nitric oxide production. Netrin-1 induces a time-
dependent phosphorylation of eNOSs1179, s116 and a rapid dephosphorylation of 
eNOSt497197. 
 
Semaphorins and their signaling 
 
Semaphorins are a large family of guidance molecules comprising secreted, or 
transmembrane or GPI-linked proteins which can be grouped into eight classes on the 
basis of their structure198 (Figure 6). Their expression was best described in the nervous 
system but they are also expressed in many other tissues, giving the semaphorins a wide 
range of functions. They are involved in generation of neural connectivity, 
angiogenesis, immunoregulation and cancer. In the nervous system many pathologic 
conditions, such as multiple sclerosis199, epilepsy200 or Alzheimer’s disease201 are in part 
due to misregulation of Sema3A or 3F expression. 
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Figure 6: Protein structures of the semaphorin family.  
Semaphorins are grouped into eight classes, class 1, 4, 5 and 6 are transmembrane proteins, class 2, 3 and 
V are secreted forms and class 7 semaphorin contains a GPI moiety at its carboxy terminus202. 
 
In the nervous tissue of vertebrates semaphorins of the classes 4-7 were found to 
be expressed202. All classes of semaphorins except class 2 bind the plexin family of 
transmembrane receptors. Several other proteins have been identified to act as 
semaphorin receptors, such as CD72 and β1-integrin. Class 3 semaphorins especially 
bind neuropilin (NRP) which allows indirect binding to plexins203. The intracellular 
domain of plexin is responsible for initiating the signal transduction cascade leading to 
growth cone collapse, axon repulsion or growth cone turning204. The cytoplasmic 
domains of plexins bind and activate GTPases or their regulators, act on MAP Kinases 
and other kinases205 and thereby lead to cytoskeletal rearrangement and repulsive axon 
guidance206. Semaphorin3 and semaphorin4 and their receptors neuropilin-1 and -2 are 
expressed in the hippocampus. Hence, the hippocampal axons can be repelled by two 
distinct semaphorins via two different receptors207. 
Genetic analyses of semaphorin function in flies and in mice suggest that they 
primarily act as short-range inhibitory cues that repel axons away from inappropriate 
regions, or guide them through repulsive corridors208, 209. Repellent guidance cues 
induce growth cone collapse and promote axon retraction. Their signaling results in 
depolymerization of growth cone F-actin characterized by the loss of protrusive 
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lamellipodia and filopodia, which is of fundamental importance during refinement of 
axonal projections66, 210. One plexin signaling pathway even leads to Rac1 induced 
inhibition of integrin-mediated adhesion allowing detachment from the substratum and 
retraction211. Semaphorins may also limit the regrowth of axons after an injury212 as 
several class 3 secreted semaphorins are highly expressed after CNS lesions213 and 
expression of the transmembrane semaphorin 4D is upregulated by oligodendrocytes 
after spinal cord lesion214. 
Interestingly, semaphorins may also act as attractive cues for certain axons, 
signaling at least in part via NRP1150, 209.  
 
Semaphorin 3A 
 
Class 3 semaphorins bind NRP1 and NRP2 which can complex at the surface of 
growth cones with plexins and semaphorins to form a holoreceptor essential for 
mediating repulsive semaphorin signaling in neurogenesis215. The prototypic member of 
this class is Sema3A, previously designated collapsin-1 or semD/III. It acts as a 
diffusible repulsive guidance cue in vivo for the peripheral projections of embryonic 
DRG neurons.  
Drosophila mutants in the gene encoding a related semaphorin gene die after 
eclosion216. In Sema3A null mice many axonal errors are detected and the mice die soon 
after birth. The initial trajectory of neurons in the DRG is abnormal, suggesting that 
Sema3A instructs neuronal polarity, in addition to its classic repellent role217. The 
cerebral cortex of mutant mice shows abnormally oriented neuronal processes, 
especially of the large pyramidal neurons218. 
Cdk5 and GSK-3β play a critical role in Sema3A signaling. Cdk5 and GSK-3β 
phosphorylate collapsing response mediating protein-2 (CRMP2) causing reduction of 
its affinity to tubulin. Sema3A stimulation enhances the levels of the phosphorylated 
form of CRMP2. This phosphorylation is essential for Sema3A-induced growth cone 
collapse in DRG neurons219, 220. Pharmacological blocking of GSK-3 prevents Sema3A-
induced growth cone collapse, but activation of GSK-3 alone does not induce growth 
cone collapse221. 
Sema3A, similar to semaphorin3F, inhibits the activity of phosphatidylinositol 
3-kinase (PI3K) and contributes to growth cone collapse and axon retraction. The 
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suppression of PI3K-signaling occurs concomitant with the activation of GSK-3, which 
depends on the phosphatase activity of the tyrosine phosphatase PTEN. The main 
substrate of PTEN is PIP3 which is produced by PI3-Kinase, which in turn regulates the 
activity of numerous downstream signaling proteins including GEFs, Akt and PDKs222. 
PTEN is highly enriched in the axonal compartment of the central domain of sensory 
growth cones during axonal extension, where it co-localizes with microtubules and 
accumulates rapidly at the growth cone membrane following exposure to Sema3A. 
Neuronal PTEN associates with microtubules and functions as an essential mediator of 
PI3K and GSK-3 signaling in response to Sema3A223. Specifically, inhibition of PI3K 
activates the actin-myosin II system for generating cellular contractile forces, while also 
blocking the formation of F-actin structures that serve as precursors to the protrusion of 
filopodia224. 
When guidance cues induce growth cone collapse and axon retraction the 
upstream regulators of myosin II, RhoA and the RhoA-kinase ROCK have been shown 
to be signaling intermediates225. ROCK positively regulates the activity of myosin II by 
increasing the phosphorylation of myosin II regulatory light chains226 and it is required 
for Sema3A-induced activation of myosin II in axons227. 
 In Xenopus spinal neurons and rat DRG explants, the repellent effect of Sema3A 
can be switched into attraction by increasing the concentration of intracellular cGMP 
levels. Interestingly, also elevation of NO-levels in these cells has the same effect151. 
 
Nitric oxide production and its effects 
Nitric oxide synthases 
 
The nitric oxide synthases, NOS, were first identified in 1989. There have been 
identified three distinct isoforms of NOS, products of different genes, with different 
localization, regulation, catalytic properties and inhibitor sensitivity. In the neuronal 
tissue, the predominating form is the neuronal NOS (nNOS) also known as NOS-1. The 
inducible form of NOS is iNOS which is found in a wide range of tissues, it is also 
known as NOS-2. The third isoform is the endothelial NOS (eNOS or NOS-3) which is 
found mainly in vascular endothelial cells but it is also expressed in neurons and glia 
cells. The isoforms differ in being constitutively (nNOS and eNOS) or inducibly 
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expressed (iNOS) and in their calcium-dependence (nNOS and eNOS) or -independence 
(iNOS) (Figure 7). 
 
 
Figure 7: The three nitric oxide synthases. 
All three nitric oxide synthases bear an oxygenase and a reductase domain and binding sites for FMN. 
nNOS is the only one with a PDZ domain at its N-terminus that targets nNOS to synaptic sites in brain 
and skeletal muscle. The NOSs have all recognition sites for CaM and the reductase domains include 
binding sites for FAD and NADPH228. 
 
The enzymes are usually referred to as dimeric in their active form, where each 
NOS monomer is associated with calmodulin. The NOS enzymes catalyze a reaction of 
L-arginine, NADPH, and oxygen to the free radical NO, citrulline and NADP. The 
cellular and tissue specific localization of NOSs can be regulated by transcriptional 
regulation, protein-protein interactions, and alternative mRNA splicing or covalent 
modifications. CaM is known to be necessary for the enzymatic activity of all three 
isoforms and for activation of CaMKII. Also phosphorylation has an effect on nNOS 
and eNOS activity. The protein kinase Akt phosphorylates eNOS at Ser1179 which 
results in an increase in NO production229. In contrast, the phosphorylation of nNOS at 
Ser847 by CaMKII leads to a decrease in synthase activity230. Conversely, CaMKII is 
known to be regulated by autophosphorylation which increases its Ca2+-independent 
activity and NO reversibly inhibits CaMKII by S-nitrosylating it at Cys6. This 
inactivation may contribute to NO-induced neurotoxicity in brain231. On the other hand, 
phosphorylation by PKC increases nNOS activity232 and dephosphorylation by CaN 
activates nNOS. Moreover, PKG and PKA phosphorylate nNOS thereby inhibiting its 
catalytic activity5. In contrast, eNOS is rapidly and strongly activated and 
phosphorylated in the presence of PKGII and PKA. This activation is independent of 
Ca2+/CaM. Since NO activates sGC and cGMP activates PKGII, this suggests a positive 
feedback mechanism for NO/cGMP233. 
Mice lacking nNOS show slowed Wallerian degeneration, a delay in 
regeneration and a disturbed pruning of uncontrolled axon sprouts. A lack of eNOS is 
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well tolerated, although a delay in nerve revascularization is observed. Thus, after 
peripheral nerve lesion, regular NOS activity is essential for cell survival and 
recovery234. 
nNOS appears to be targeted to membranes by binding to PSD-95 that associates 
with N-methyl-D-aspartate receptors (NMDAR) at synapses235. NO has been implicated 
in hippocampal long term potentiation (LTP) but mutant mice for either nNOS or eNOS 
do not show a significant reduction in LTP. Only mice double mutant for nNOS and 
eNOS show significant reduction in LTP in stratum oriens, suggesting that neuronal and 
endothelial NOS forms can compensate for each other in mice with a single mutation236. 
In PC12 cells NO production is a part of the mechanism of laminin-induced 
neurite outgrowth. Inhibition of nNOS prevents the formation of NO and prevents 
neurite outgrowth237. DRG neurons express nNOS during early development, while in 
the adult the enzyme expression decreases238. Following peripheral nerve injury, DRG 
neurons reexpress nNOS and inall three isoforms of NOS are upregulated in the affected 
nerve. At the same time cGMP synthesis is increased in satellite glia cells239, suggesting 
that NOS play an essential role in regeneration240. 
 
NO 
 
NO is a gaseous freely diffusible intercellular messenger molecule that regulates 
a wide variety of physiological processes in the cardiovascular and immune system, 
central and peripheral nervous system, including neurotransmitter release, plasticity and 
apoptosis, and elsewhere241-244. How NO signals are decoded and translated into 
downstream physiological effects is poorly understood. The best known NO receptor is 
the enzyme sGC the activity of which results in cGMP accumulation in target cells. It is 
known that NO binds to a haem prosthetic group on the receptor and triggers a 
conformational change that increases the catalysis of cGMP synthesis by several 
hundred-fold245. Thus, Ca2+ signals which activate NOS may either upregulate the 
activity of cGMP-dependent pathways246.  
NO has the capacity to interact with and modify a wide variety of molecules: 
free radicals such as the superoxide anion, key redox regulators such as glutathione, and 
macromolecules like DNA or proteins. Binding of a NO group to a free thiol of an 
aminoacid is called S-nitrosylation. NO can influence protein function by S-
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nitrosylation of specific cysteines. S-nitrosylation is a reversible and specific 
modification and, in contrast to phosphorylation, enzyme-independent. S-nitrosylation 
has emerged as a potent protein modification. Proteins like hemoglobin, NMDAR, 
p21ras and I-κB have been found to undergo S-nitrosylation resulting in changes of their 
activities247-251. Over the past decade, the number of reported protein substrates for 
S-nitrosylation has grown to well over a hundred252. NO is generated by NOS after 
NMDAR stimulation and feedback S-nitrosylation of NMDAR and of NOS is 
inhibitory253 (Figure 8). 
 
 
Figure 8: Activation of nNOS and downstream targets of NO. 
In neurons NMDAR serves as Ca2+ channel regulating nNOS (NOS type 1) activity and is at the same 
time a substrate for nNOS-dependent S-nitrosylation within a negative feedback-loop (red arrows). nNOS 
is linked to NMDAR via the scaffold protein PSD95 and to the small G-protein Dexras via the adaptor 
protein Capon. Dexras is activated by S-nitrosylation (green arrows). Another important target of NO is 
the sGC which starts cGMP synthesis upon activation by NO253. 
 
In the central nervous system, NO has an array of functions, such as the 
regulation of synaptic plasticity, the sleep-wake cycle, hormone secretion, and 
neurotransmission. NO production is associated with cognitive function, control of 
appetite, body temperature and neurosecretion254, 255. In the peripheral nervous system, 
NO regulates the non-adrenergic, non-cholinergic relaxation of smooth muscle cells256. 
It acts as neurotransmitter in both the CNS and PNS by mechanisms that are dependent 
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on cGMP257. Important downstream effectors of cGMP are PKG, PIP3-kinase, the 
antiapoptotic Akt serine/threonine kinase and cyclic nucleotide-gated channels258.  
On the one hand, NO acts neuroprotive. For instance, in the NMDA-mediated 
neurotoxicity by S-nitrosylation of the NR1 and NR2 subunits of the NMDAR259. NO 
can also confer cytoprotection through the inhibition of caspase activity by 
S-nitrosylating cysteines of the catalytic site260. 
On the other hand, NO is harmful under pathological conditions that involve the 
production of reactive oxygen species, such as superoxide anions, and the formation of 
peroxynitrite254 whose prolonged stimulation of NMDAR causes excitotoxic cell 
death254. NO and peroxynitrite may also kill neurons by indirect activation of caspases 
or by caspase-independent disruption of mitochondrial function7 since NO can 
reversibly inhibit brain mitochondrial ATP synthesis261. For instance cortical NO 
production increases during hypoxia in the immature brain and is associated with 
neurotoxicity, mitochondrial dysfunction and decrease in mitochondrial size. The 
effects of hypoxia on mitochondrial movement and morphology can be partially 
prevented by NOS inhibitors262. 
In cerebrospinal fluid (CSF) nitrite is a reliable indicator of NO production 
Physiological concentrations in brain under normal conditions are around 1nM NO and 
1µM nitrite. During pathological conditions, NO level can reach up to 1µM while nitrite 
levels are around 100µM. An increase in nitrite level in CSF is considered an indicator 
of intrathecal NO production and a sign of brain inflammation7. 
 
S-nitrosylation 
 
The crucial difference between S-nitrosylation and phosphorylation is that 
phosphorylation is enzyme driven, whereas S-nitrosylation is achieved through the non-
catalysed chemical modification of a protein residue263. It is regulated precisely in time 
and space264. Only a fraction of cysteine residues present in proteins in the free-thiol 
state become nitrosylated. However, the molecular mechanisms underlying this 
specificity are not understood. For example common structural motif that might 
determine the reactivity of individual cysteins are present only in a subset of proteins 
amenable to S-nitosylation265. 
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S-nitrosylation is a light sensitive and very labile covalent modification which is 
hard to detect and the cleavage of the S-NO bond can occur without the help of specific 
enzymes266. Hence, whether or not nitrosylation occurs depends on the concentration of 
the nitrosylating agent and the proximity of the target proteins and NO synthases267. A 
method called biotin-switch has been developed to identify S-nitrosylated proteins. In 
this assay S-nitrosylated cysteines are converted to biotinylated cysteines and these can 
then be detected by immunoblotting or chromatography268.  
In diverse cell types a portion of basal level of S-nitrosylated cysteines is stable 
in the presence of NOS inhibitors247. A well-characterized example of such modularity 
is provided by the multiprotein complex that incorporates nNOS, PSD93/95 and 
NMDAR. S-nitrosylation of caspase-3, caspase-9, apoptosis-signal-regulating kinase 1 
(ASK1) and c-Jun-N-terminal kinase (JNK) blocks their activity and inhibits apoptosis, 
whereas S-nitrosylation of matrix metalloproteinase-9 (MMP9) and nuclear factor B 
promotes cell death253. In addition, the hypoxia-inducible factors HIF that respond to 
low oxygen concentrations is a well characterized example of S-nitrosylation269. 
 
MAP1B, NO and netrin-1 
 
When the intracellular NO-levels increase, axons from different types of 
neurons, such as chick sensory neurons or mouse DRG neurons, retract dramatically. In 
retracting neurons the mass of microtubules is not decreasing during retraction 
suggesting a backward retreat of cytoskeletal elements rather than their wholesale 
depolymerisation270. MAP1B was found to play a critical role in this process. 
Nitrosylation of the MAP1B LC1 leads to its enhanced interaction with microtubules 
and subsequently, MAP1B dependent growth cone collapse and axon retraction occurs1. 
Moreover, MAP1B was suggested to be involved in netrin-1 signal transduction. 
Netrin-1 stimulates the GSK-3β and Cdk5-dependent mode I phosphorylation of 
MAP1B, thereby it is potentially regulating microtubule and actin dynamics. 
Furthermore, the chemoattractive effect of netrin-1 of MAP1B-deficient neurons is 
compromised, suggesting that MAP1B may be an essential downstream effector in the 
chemoattractive netrin-1 signaling pathway. Another evidence for MAP1B requirement 
for correct transduction of the netrin-1 signal is that MAP1B null mice display a similar 
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migration defect of pontine nuclei as netrin-1 mutants and both lack commissural 
structures in the brain3. 
Since netrin-1 signaling involves changes in Ca2+ levels and Ca2+ is known to 
activate nNOS, this raises the question whether nNOS is part of the signal transduction 
pathway downstream of netrin-1. NO production regulates the activity of sGC which 
further influences the ratio between cAMP and cGMP. This proportion eventually 
controls whether a growth cone turns towards or away from a netrin-1 source. 
Considering that the S-nitrosylation of MAP1B is necessary for NO-induced retraction, 
I would like to address the question whether S-nitrosylated MAP1B is important in the 
interpretation of axon guidance cues like netrin-1 or Sema3A. 
 
NO and MAP1B in oligodendrocytes 
 
During myelination, the process of a myelinating cell wraps around an axon to 
elaborate a myelin sheath. The myelin sheath is a fatty insulation composed of modified 
plasma membrane that surrounds axons and promotes the rapid and efficient conduction 
of electrical impulses along myelinated axons (Figure 9). The majority of CNS 
myelination occurs postnatally271. The myelin sheath itself can be divided into two 
domains, compact and non-compact myelin, each of which contains a non-overlapping 
set of proteins. Compact myelin forms the bulk of the myelin sheath; non-compact 
myelin is found in paranodes and in Schmidt-Lantermann incisures272. 
In the CNS, oligodendrocytes are the glial cells responsible for the formation 
and maintenance of myelin. In the peripheral nervous system Schwann cells are the 
myelin forming cells. They elaborate a myelin sheath around a single axonal segment, 
whereas an oligodendrocyte is able to myelinate up to 60 axons273. Oligodendrocytes 
derive from stem cell precursors which arise in the subventricular zone of the 
developing CNS. Growth, differentiation and survival of CNS glial progenitors and 
their progeny are influenced by PDGF, bFGF, IGF-1 and 2, NT-3, CNTF, retinoic acid, 
glial growth factors, sonic hedgehog, interleukin-6 and LIF274. In the spinal cord, 
oligodendrocyte precursors appear to share a developmental lineage with motor 
neurons, although they may also develop from restricted glial precursors. Immature 
oligodendrocyte precursors are highly migratory. They migrate from their site of origin 
to developing white matter tracts using a variety of guidance cues. The final match of 
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oligodendrocyte and axon number is accomplished through a combination of local 
regulation of cell proliferation, differentiation and cell death. Not all oligodendrocyte 
precursors differentiate during development, and the adult CNS contains a significant 
population of precursors271. 
 
 
Figure 9: Ensheathment of an axon by an oligodendrocyte. 
Myelinating glia cells wrap around an axon in order to allow saltatory conduction of action potentials 
along the axon and to provide protection. Microtubules and local protein translation play an essential role 
in maintenance of the myelin sheath. 
 
Myelin contains a high percentage of lipids, such as cholesterine and 
galactocerebroside, GalC, and special proteins like myelin basic protein, MBP, myelin 
associated glycoprotein, MAG, proteolipid-protein, PLP and others. Oligodendrocytes 
express two proteins that are not expressed by Schwann cells, myelin-oligodendrocyte 
glycoprotein, MOG, on their outer cell membrane275 and myelin-oligodendrocyte basic 
protein, MOBP276. 
Because the development of neuronal morphology is known to depend on the 
presence of highly organized microtubule arrays, it may be hypothesized that the 
properties of microtubules influence the form and function of oligodendrocytes as well. 
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The oligodendrocyte have polarized microtubules oriented with their plus-end towards 
the distal part of the processes277. Morphogenesis of and myelination by 
oligodendrocytes depends on export of RNA from the nucleus to the perikaryon, 
assembly of the RNA into RNA granules, transport of RNA granules along 
microtubules, and localization and translational activation in the myelin compartment. 
mRNAs of MBP and MOBP have been localized to the myelin compartment in 
oligodendrocytes. Furthermore, several membrane components, including PLP and 
sulfatide, are transported through the Golgi to the plasma membrane or myelin. The 
maintenance of membrane sheets by oligodendrocytes in culture is a dynamic process, 
requiring ongoing microtubule turnover and transport of molecules through the Golgi278. 
Concerning the retrograde movement of RNA granules in oligodendrocytes, it is 
possible that the minus-end motor, cytoplasmic dynein is also involved, given the plus-
end-distal polarity of the microtubules in oligodendrocyte processes 279. 
Neuronal electrical activity has been shown to be critical for the proliferation of 
the progenitors of oligodendrocytes. Moreover, adhesion molecules, which bring the 
axon and glial cell into close apposition and transduce signals between these cells, are 
essential for correct myelination. Demyelination-induced disruption of these axonal 
signals and axoglial interaction is likely to inhibit myelin repair273. 
 
MAP1B in oligodendrocytes 
 
Oligodendrocytes differentiate from a bipolar A2B5-positive progenitor to an 
O4-positive preoligodendrocyte and further into a complex process-bearing GalC-
positive oligodendrocyte. These processes are rich in microtubules and their 
development requires reorganization of the cytoskeleton. MAP1B is first detectable in 
O4+ preoligodendrocytes prior to terminally differentiated myelin-forming 
oligodendrocyte, but not in astrocytes. The expression of MAP1B is limited to the cell 
body and the processes, whereas flattened membranes are not MAP1B positive280. The 
timing of MAP1B expression implies a possible role of MAP1B microtubule 
interactions in the formation and stabilization of myelin-forming processes6. The 
distinct subcellular localizations and patterns of developmental expression of MAP1B, 
MAP4 and MAP2c suggest that these MAPs have different roles in the regulation of the 
microtubule network during the differentiation of oligodendrocytes281. MAP1B 
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deficiency causes delayed myelin development, suggesting the functional importance of 
MAP1B in oligodendroglia282. 
The transition from premyelinating oligodendrocytes into myelin-bearing cells is 
accompanied by a dramatic upregulation in expression of the RNA binding QKI 
proteins which facilitate movement of mRNAs to myelin via the cytoskeleton. MAP1B 
mRNA was found to be posttranscriptionally regulated by the selective RNA-binding 
protein QKI283.  
MAG, which is expressed in periaxonal membranes of myelinating glia where it 
is believed to function in glia-axon interactions, binds to a phosphorylated neuronal 
isoform of MAP1B expressed as a membrane glycoprotein on the surface of DRG 
neurons but not to the isoform expressed in glial cells. This interaction of MAG and 
MAP1B also suggests its requirement for normal long term maintenance of myelinated 
axons284. 
In Schwann cells the expression of MAP1B is induced following sciatic nerve 
lesion and regeneration and in cultured primary Schwann cells. The isoform expressed 
in Schwann cells is similar to MAP1B expressed in neurons but shows a different 
phosphorylation state32. 
 
NO and neurodegenerative diseases 
 
The presence of nNOS has never been found in oligodendrocytes whereas eNOS 
has been detected in primary cultures of oligodendrocytes. It was present at all stages of 
maturation from bipolar to membrane-bearing oligodendrocytes expressing MBP and 
MOG. Oligodendrocytes grown for several days in the general NOS inhibitor L-NMMA 
show marked changes in arborization. The cells show flattened cell bodies and thinner, 
less ramified processes suggesting that NO might play a role in the organization of the 
oligodendrocyte cytoskeleton and differentiation7. 
Nitric oxide production seems to play a role in diverse neurodegenerative 
diseases like Alzheimer’s disease, Parkinson’s disease or multiple sclerosis (MS). MS is 
the most common cause of chronic neurologic disability resulting from interruption of 
myelinated tracts in the central nervous system. The autoimmune disease experimental 
allergic (or autoimmune) encephalomyelitis, EAE, and MS share common clinical, 
histologic, immunologic and genetic features; hence EAE is widely considered to be a 
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relevant animal model for the human disease. It can be induced in a variety of animal 
species by immunization with myelin proteins or peptide derivatives285.  
For many years MS was considered an immune-mediated disorder. 
Investigations revealed that a neurodegenerative process, unresponsive to 
immunosuppression, was responsible for progressive neurological impairment286. Even 
though myelin loss is the key event of MS, substantial axonal damage in active lesions 
has already been described too287. This axonal destruction in plaques leads to Wallerian 
degeneration288. Macrophages and activated microglia have also been reported to be in 
close contact with degenerating axons. These cells produce inflammatory mediators 
such as NO. It is suggested that NO injures axons by inhibiting mitochondrial 
respiration289. Both physiological and pathological actions of NO are mediated by its 
targets that become structurally modified by reactive NO or its derivatives peroxynitrite, 
formed after the reaction with superoxide, and S-nitroso-L-glutathione (GSNO)290.  
In vitro, NO induces ATP depletion and loss of mitochondrial membrane 
potential, DNA damage, morphological changes and necrotic cell death in rat 
oligodendrocytes7. The vulnerability of developing oligodendrocytes to NO also 
involves translocation of the apoptosis-inducing factor from mitochondria to nuclei291. 
Peroxynitrite induces strong primary axonal damage with characteristics of primary 
acute axonopathy, together with severe myelin alteration, demyelination and 
nitrotyrosine formation. It damages cells by modifying cellular compounds by 
peroxidation of lipids, DNA and proteins. Nitrotyrosine has been detected in MS 
demyelinating lesions associated with lipid-laden macrophages, cell debris, myelinated 
axons292 and in EAE lesions293. Moreover, high levels of NO lead to irreversible 
decompaction of CNS myelin, but not PNS myelin294. 
Oligodendrocytes can be stimulated to express iNOS by inflammatory cytokines, 
which are known to accumulate in the MS brain. Tumor necrosis factor-α and IFNγ 
cause elevated NO production by iNOS in primary cultures of rat oligodendrocytes. 
Simultaneously, NO-mediated mtDNA damage occurs295. Both macrophages and 
astrocytes are considered to be the main cellular sources of iNOS expression in MS 
lesions296. In EAE, iNOS mRNA expression within the CNS is enhanced both at onset 
and peak of clinical signs297 and nitrotyrosine has been detected in lesions292. Moreover, 
antibodies reactive with nitroso-S-cysteine coupled to serum albumin are elevated in 
sera from MS patients298. Anti-SNO-cysteine antibodies are also increased at times of 
MS attacks and in progressive disease, suggesting a potential relevance of these 
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antibodies as biological markers for clinical activity299. Interestingly, the NOS inhibitor 
L-NAME has a protective effect in MOG induced EAE, the extent of CNS 
inflammation and demyelination300. 
Referring to in vitro experiments, developing oligodendrocytes are more 
sensitive to high NO concentrations than mature ones in particular with regard to the 
maintenance of their mitochondrial transmembrane potential301. Thus, also the 
remyelination, involving immature oligodendrocytes generated from precursors could 
be affected by high NO-levels. 
In consideration of the facts that MAP1B is expressed in glial cells and these 
cells are sensitive to NO, the question arises if S-nitrosylation of MAP1B LC1 might 
affect the functionality of oligodendrocytes. 
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The role of NO in the netrin-1 axon guidance signaling pathway 
Netrin-1 induces retraction in wild-type and MAP1B-/- DRG neurons 
 
 Different groups showed that the guidance cue netrin-1 is essential for proper 
development of the nervous system in mice where it can act either as attractive or 
repulsive cue dependent on the receptor through which it signals. Some analogies in the 
phenotypes of mice lacking netrin-149, DCC50, or MAP1B4 were observed and MAP1B 
was shown to be necessary for the correct transduction of attractive netrin-1 signaling3. 
This prompted me to explore the role of MAP1B in netrin-1 signaling in more detail. 
Dorsal root ganglia (DRG) neurons isolated from adult mice are a well established 
model for the investigation of axon guidance signaling pathways. Thus, wild-type and 
MAP1B-/- DRG neurons were cultured on poly-L-lysine (PLL) and laminin coated glass 
coverslips for 24hrs (Figure 10A). Since the presence of laminin was shown to switch 
the attractive netrin-1 signaling to a repulsive one2, DRG neurons cultured on laminin 
were expected to be repelled by netrin-1. Whether neurites are attracted or repelled by a 
guidance cue can be assessed by observing the growth cone turning toward or away 
from the source of the cue. In case of bath application, the appraisal of retracted neurons 
is the only way to analyse the nature of the response. Hence, in the case of DRG 
neurons grown on laminin and treated with 250ng/ml netrin-1, repulsion would be seen 
at the retraction of their axons. Indeed, after a treatment with netrin-1, axons of DRG 
neurons exhibited typical features of retraction. In wild-type and MAP1B-/- DRG 
neurons, netrin-1 treatment induced collapse of growth cones, formation of sinusoidal 
microtubule bundles along the axon shaft and trailing remnants (Figure 10B). No 
difference in the phenotype and no delay in the response to the treatment could be 
observed between wild-type and MAP1B-/- DRG neurons. The quantitative analysis of 
the response of wild-type and MAP1B-/- DRG neurons to netrin-1 revealed a significant 
increase of retracted neurons after the incubation for 21hrs with netrin-1 (Figure 10C). 
In untreated samples, the percentage of retracted wild-type DRG neurons was 10% and 
for MAP1B-/- DRG neurons it was 11%. This amount of retracted neurons might be due 
to changes in temperature or due to the stress cells undergo during fixation. However, 
after the treatment with netrin-1, 34% of wild-type DRG neurons and 40% of MAP1B-/- 
DRG neurons showed retraction. The similarity in the reaction of wild-type and 
MAP1B-/- DRG neurons to the axon guidance cue suggests that MAP1B does not play 
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an essential role in the repulsive netrin-1 signaling pathway, in contrast to the results 
observed for attractive netrin-1 signaling3. 
 
 
Figure 10: Expression of MAP1B in mouse DRG neurons and netrin-1 induced retraction. 
Mouse DRG neurons were isolated from wild-type and MAP1B-/- mice and cultured for 24hrs on PLL-
laminin coated coverslips. A) Neurons were fixed and stained for MAP1B-750 and tubulin. In wild-type 
DRG neurons MAP1B was expressed in the cell body and in all axons and co-localized with tubulin. In 
MAP1B-/- DRG neurons only background staining of MAP1B was visible. Many of these neurons showed 
increased branching of axons. B) Neurons were treated with 250ng/ml netrin-1 for 4-5hrs. Cells were 
visualized in vivo by phase contrast microscopy (Zeiss). Both wild-type and MAP1B-/- DRG neurons 
showed axon retraction. Typical retraction included the collapse of the growth cone (black arrows), 
sinusoidal bends along the axon shaft (arrowheads) and a trailing remnant (white arrows). There was no 
difference in the morphology of the nerve cells after netrin-1 treatment between wild-type and MAP1B-/- 
DRG neurons. C) The graph shows the quantitative analysis of the retracted neurons in culture after 
netrin-1 treatment. Wild-type and MAP1B-/- DRG neurons, were left untreated or treated for 21hrs with 
250ng/ml netrin-1, as indicated, fixed, stained for tubulin and analysed by confocal microscopy. For 
quantitative analysis, approximately 100 cells in each of 6 independent experiments were assessed for 
microtubule configuration. DRG neurons with one axon exhibiting features of retraction were considered 
as retracted. In untreated samples the amount of retracting neurons was in the range of 10 to 11%. After 
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netrin-1 treatment, wild-type cultures showed 34% and MAP1B-/- cultures showed 40% of retracted DRG 
neurons. Error bars represent standard errors of the mean. Asterisks indicate that the values for cells 
treated with netrin-1 were significantly different from corresponding values of untreated cells (***, 
p<0.001). 
 
The role of laminin in NO-induced axon retraction 
 
 The presence of the extracellular matrix component laminin was shown to be 
responsible for at least one phenotypic difference between wild-type and MAP1B-/- 
DRG neurons. Grown on PLL-laminin coated coverslips, MAP1B-/- DRG neurons 
exhibit a more branched phenotype than wild-type DRG neurons. This morphological 
distinction was never observed when DRG neurons were grown on PLL or PDL only 
(Krupa, PhD Thesis 2009). This raised the question whether laminin also plays a role in 
the signal transduction of MAP1B-S-nitrosylation. Therefore, DRG neurons from wild-
type and MAP1B-/- mice were cultured on PLL-laminin and on PDL for 24hrs. Then, 
cells were treated either with 1µM calcimycin for 15min or with 100µM SNAP for 1h. 
In case of calcimycin treatment, intracellular NO production was visualized with DAF-
FM DA. This cell permeable dye is cleaved in the cell by esterases and reacts in the 
presence of oxygen with NO yielding the photostable fluorescent product DAF-FM T. 
Since SNAP is a NO-donor, DAF-FM DA was not used for these samples. In wild-type 
DRG neurons, a clear increase in DAF-FM T fluorescence was observed following 
calcimycin treatment, independent of the substrate on which DRG neurons grew (Figure 
11A). Calcimycin and SNAP treatment led to significant increase in axon retraction in 
wild-type DRG neurons grown on PLL-laminin. In contrast, irrespective to NO 
production, wild-type DRG neurons did not exhibit an increase of retracted neurons 
when cultured on PDL (Figure 11B). In MAP1B-/- DRG neurons, DAF-FM DA staining 
did not reveal any change in intracellular NO production (Figure 12A). Moreover, the 
calcimycin and SNAP induced axon retraction did not occur, independent of the 
substrate (Figure 12B). This suggests that laminin might be necessary to mediate NO-
induced axon retraction in wild-type DRG neurons. 
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Figure 11: Calcimycin and SNAP induce axon retraction only in wild-type DRG neurons in the 
presence of laminin 
Mouse DRG neurons were isolated from wild-type mice, cultured for 24hrs on PLL-laminin or PDL 
coated coverslips and were left untreated or were treated with 1µM calcimycin for 15min or 100µM 
SNAP for 1h, as indicated. A) Before fixation, cells were incubated with the cell permeable, photo-stable 
fluorescent indicator for intracellular NO-levels DAF-FM DA (5µM) for 1h. Then cells were fixed and 
stained for tubulin. Untreated wild-type DRG neurons showed basic NO-levels revealed by the very weak 
DAF-FM T fluorescent signal on both coatings. Calcimycin treatment led to an increase in NO 
production, independent of the coating. B) For the quantitative analysis, approximately 100 cells in each 
of 3 independent experiments were assessed for microtubule configuration. DRG neurons with one axon 
exhibiting features of retraction were considered as retracted. In untreated samples the amount of 
retracting neurons was in the range of 6 to 8%. After treatment with calcimycin or SNAP, wild-type 
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cultures showed 36% and 39% of retracted neurons, respectively. Error bars represent standard errors of 
the mean. Asterisks indicate that the values for cells treated with calcimycin or SNAP were significantly 
different from corresponding values of untreated cells and the values for cells treated with calcimycin or 
SNAP on PLL-laminin were significantly different from corresponding values of cells treated with 
calcimycin or SNAP on PDL (*, p<0.05; **, p<0.005). 
 
 
Figure 12: Calcimycin and SNAP do not induce axon retraction in MAP1B-/- DRG neurons. 
Mouse DRG neurons were isolated from MAP1B-/- mice, cultured for 24hrs on PLL-laminin or PDL 
coated coverslips and were left untreated or were treated with 1µM calcimycin for 15min or 100µM 
SNAP for 1h, as indicated. A) Before fixation, cells were incubated with the cell permeable, photo-stable 
fluorescent indicator for intracellular NO-levels DAF-FM DA (5µM) for 1h. Then cells were fixed and 
stained for tubulin. Untreated MAP1B-/- DRG neurons showed basic NO-levels revealed by the very weak 
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DAF-FM T fluorescent signal on both coatings, but calcimycin treatment did not lead to an increase in 
NO production. B) For the quantitative analysis, approximately 100 cells in each of 3 independent 
experiments were assessed for microtubule configuration. DRG neurons with one axon exhibiting 
features of retraction were considered as retracted. In untreated samples the amount of retracting neurons 
was in the range of 6 to 8%. After treatment with calcimycin or SNAP, MAP1B-/- cultures did not show 
an increased amount of retracted neurons. Error bars represent standard errors of the mean.  
 
Netrin-1 induced retraction involves production of intracellular NO 
 
 The repulsive netrin-1 signaling induced by the presence of laminin increases the 
intracellular cGMP concentration. This might require the activation of sGC which can 
be triggered by NO binding. In order to investigate whether NO production is involved 
in the repulsive netrin-1 signal transduction pathway, I visualized intracellular NO-
levels with the fluorescent indicator DAF-FM DA. Wild-type and MAP1B-/- DRG 
neurons were cultured on PLL-laminin coated coverslips and incubated for 21hrs with 
netrin-1 and 1h with DAF-FM DA prior to fixation and staining for tubulin. Untreated 
cells showed a weak fluorescent signal in the cell body and some parts of their axons 
stemming from basal NO-levels in the cell (Figure 13). In contrast, after netrin-1 
treatment, a striking increase in the strength of the fluorescent signal of DAF-FM T 
could be observed in wild-type and MAP1B-/- DRG neurons. The strongest signal and 
hence presumably the highest concentration of NO was seen in the collapsed growth 
cones of retracted axons. This might be observed because of the difference in the 
thickness of a growth cone compared to an axon. Nevertheless, this result suggests that 
the Ca2+ influx induced by binding of netrin-1 to its receptors activates, among other 
enzymes, a nitric oxide synthase. However, up to now it remains elusive whether the 
activation of NOS leading to a visible increase of NO-levels is the main reason for 
eventual axon retraction or if NO is only a side product and nonrelevant for netrin-1 
induced repulsion in the presence of laminin. In any case, the similarity between the 
responses of wild-type and MAP1B-/- DRG neurons to netrin-1 demonstrates that 
S-nitrosylation of MAP1B is not a necessary step in the repulsive netrin-1 signaling 
downstream of NOS activation even though it might occur in wild-type neurons. 
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Figure 13: NO production in netrin-treated wild-type and MAP1B-/- DRG neurons. 
Mouse DRG neurons were isolated from wild-type (left panel) and MAP1B-/- mice (right panel), cultured 
for 24hrs on PLL-laminin coated coverslips and were left untreated or were treated with 250ng/ml netrin-
1 for 21hrs, as indicated. Before fixation, cells were incubated with the cell permeable, photo-stable 
fluorescent indicator for intracellular NO-levels DAF-FM DA (5µM) for 1h. Then cells were fixed and 
stained for tubulin. Untreated wild-type or MAP1B-/- DRG neurons showed basic NO-levels revealed by 
the very weak DAF-FM T fluorescent signal. In contrast, wild-type and MAP1B-/- DRG neurons which 
were treated with netrin-1 exhibited a strong fluorescent signal stemming from the reaction of DAF-FM 
DA with high levels of intracellular NO. Especially in the collapsed growth cones of treated neurons a 
strong signal was observed (white arrows). 
 
Inhibition of nNOS reduces netrin-1 induced axon retraction in wild-type DRG neurons 
 
 Whether the increase of intracellular NO-levels is crucial for induction of axon 
retraction after netrin-1 treatment of DRG neurons on laminin can be investigated by 
inhibiting NOS and the subsequent NO production. Wild-type and MAP1B-/- DRG 
neurons were treated with 250ng/ml netrin-1 for 21hrs, with the specific nNOS inhibitor 
NPA at a concentration of 300µM for 21hrs or treated with netrin-1 in the presence of 
NPA for 21hrs. Figure 14 shows the percentage of retracted neurons after these 
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treatments. Incubation of wild-type and MAP1B-/- DRG neurons with NPA served as 
control and did not induce any retraction. Compared to the retraction in samples treated 
with netrin-1, a significant reduction was observed in samples treated with netrin-1 in 
the presence of NPA. This effect occurred in both wild-type and MAP1B-/- DRG 
neurons. The percentage of retracted wild-type DRG neurons was reduced from 34% to 
19% and in MAP1B-/- DRG neurons it was reduced from 40% to 29%. Although the 
differences in percentages of retraction were significant in both genotypes, the effect of 
nNOS inhibition in MAP1B-/- DRG neurons (11% difference in percentage points) was 
less dramatic than in the case of wild-type neurons (14% difference in percentage 
points). 
 
 
Figure 14: Percentage of retracted wild-type and MAP1B-/- DRG neurons following treatment with 
netrin-1 and inhibition of nNOS with NPA. 
Mouse DRG neurons were isolated from wild-type and MAP1B-/- mice. Cells were cultured for 24hrs on 
PLL-laminin coated coverslips, were left untreated or were treated with 250ng/ml netrin-1 for 21hrs, with 
300µM NPA for 21hrs, or with 250ng/ml netrin-1 in the presence of 300µM NPA for 21hrs, as indicated, 
fixed and stained for tubulin. For quantitative analysis, approximately 100 cells in each of 3 independent 
experiments were assessed for microtubule configuration. DRG neurons with one axon exhibiting 
features of retraction were considered as retracted. In untreated or NPA-treated samples the amount of 
retracting neurons was in the range of 6 to 11%. After netrin-1 treatment wild-type cultures showed 34% 
and MAP1B-/- DRG cultures showed 40% of retracted neurons. NPA treatment reduced the netrin-1-
induced retraction to 19% in wild-type and to 29% in MAP1B-/- DRG neurons. Error bars represent 
standard errors of the mean. Asterisks indicate that the values for cells treated with netrin-1 were 
significantly different from corresponding values of untreated cells and the values for cells treated with 
netrin-1 in the presence of NPA were significantly different from corresponding values of cells treated 
with netrin-1 alone (***, p<0.001). 
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 In order to confirm the importance of NOS activation during repulsive netrin-1 
signal transduction, I visualized NO production in neurons after these treatments. Figure 
15 shows the level of intracellular NO in wild-type DRG neurons. In correlation with 
the determined percentage of retracted neurons, the NO-levels in untreated samples 
remained very low. In contrast, neurons treated with 250ng/ml netrin-1 for 21hrs 
showed again a strong fluorescent signal stemming from the reaction of DAF-FM DA 
with NO. Interestingly, in neurons treated with netrin-1 in the presence of 300µM NPA 
the fluorescent signal was observed only in growth cones but not along axons and was 
strikingly reduced. The level of intracellular NO after simultaneous treatment with 
netrin-1 and NPA was comparable to the NO level after NPA treatment alone. Although 
DRG neurons incubated with netrin-1 and NPA or NPA alone exhibit slightly higher 
NO-levels than untreated neurons, the NO production seemed to stay below the 
threshold concentration necessary to induce retraction. This result suggests that in wild-
type DRG neurons repulsive netrin-1 signal transduction involves activation of nNOS 
and subsequent increase in NO-levels in the cells leading to axon retraction. 
 
 
Figure 15: NPA reduces NO production in wild-type DRG neurons during treatment with netrin-1. 
DRG neurons were isolated from wild-type mice, cultured for 24hrs on PLL-laminin coated coverslips, 
were left untreated or were treated with 250ng/ml netrin-1 for 21hrs, with 300µM NPA for 21hrs, or with 
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250ng/ml netrin-1 in the presence of 300µM NPA for 21hrs, as indicated. Before fixation, cells were 
incubated with the cell permeable, photo-stable fluorescent indicator for intracellular NO-levels DAF-FM 
DA (5µM) for 1h. Then cells were fixed and stained for tubulin. Untreated and NPA treated wild-type 
DRG neurons showed basic NO-levels displayed by very weak DAF-FM T fluorescence. In contrast, 
DRG neurons which were treated with netrin-1 exhibited a strong fluorescent signal stemming from the 
reaction of DAF-FM DA with intracellular NO (white arrows). Neurons that were treated with 250ng/ml 
netrin-1 in the presence of 300µM NPA for 21hrs showed reduced levels of intracellular NO (yellow 
arrows) resembling those of neurons treated with NPA. 
 
 In contrast, in MAP1B-/- DRG neurons the intracellular NO level was not 
reduced as dramatically by the inhibition of nNOS as in wild-type neurons (Figure 16). 
A strong fluorescent signal was observed after netrin-1 treatment and this signal 
strength remained in the presence of NPA, especially in growth cones. This result 
correlated with the percentage of retracted neurons seen in figure 14 and it showed that 
nNOS is not the main producer of NO in the MAP1B-/- neurons after treatment with 
netrin-1 although it could play a role as NPA had an effect in preventing netrin-1 
induced axon retraction, at least partially. However, the activation of a NOS enzyme 
was confirmed as NO production was switched on. 
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Figure 16: NPA does not reduce NO production in MAP1B-/- DRG neurons during treatment with 
netrin-1. 
DRG neurons were isolated from MAP1B-/- mice, cultured for 24hrs on PLL-laminin coated coverslips, 
were left untreated or were treated with 250ng/ml netrin-1 for 21hrs, with 300µM NPA for 21hrs, or with 
250ng/ml netrin-1 in the presence of 300µM NPA for 21hrs, as indicated. Before fixation, cells were 
incubated with the cell permeable, photo-stable fluorescent indicator for intracellular NO DAF-FM DA 
(5µM) for 1h. Then cells were fixed and stained for tubulin. Untreated and NPA treated MAP1B-/- DRG 
neurons showed basic NO-levels revealed by very weak DAF-FM DA fluorescence. In contrast, DRG 
neurons which were treated with netrin-1 exhibited a strong fluorescent signal indicative of increased 
intracellular NO-levels. Neurons that were treated with 250ng/ml netrin-1 in the presence of 300µM NPA 
for 21hrs showed only weak reduction of intracellular NO-levels compared to cells treated with netrin-1 
only. Strong fluorescence could be seen most notably in the growth cones (white arrows) but also along 
axons. 
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nNOS and eNOS expression and localization in wild-type and MAP1B-/- DRG neurons 
 
In order to determine why nNOS inhibition is less effective in prevention of 
netrin-1 induced axon retraction in MAP1B-/- DRG neurons than in wild-type neurons, I 
performed immunofluorescence and immunoblotting assays to detect and localize 
nNOS in wild-type and MAP1B-/- DRG neurons. Figure 17A shows the stainings of 
untreated DRG neurons for nNOS, actin and tubulin. In wild-type DRG neurons nNOS 
localized to the cell body, to axons and partially to growth cones, whereas in MAP1B-/- 
DRG neurons the expression of nNOS was strongly reduced. Only a faint staining in the 
cell body and in primary axons was observed. This difference in the expression level of 
nNOS between wild-type and MAP1B-/- DRG neurons was seen in four independent 
experiments. Other NOS enzymes probably being activated by netrin-1 are endothelial 
and inducible NOS. Since iNOS plays a role predominantly in immune and 
cardiovascular systems and its activation is not calcium dependent, the expression of 
eNOS was investigated in DRG neurons. As far as it can be deduced from 
immunofluorescence analyses, wild-type and MAP1B-/- DRG neurons exhibited the 
same expression pattern of eNOS (Figure 17B). In both cell types, the enzyme was 
localized in the cell bodies, along axons, where it co-localized with tubulin, and 
sometimes in growth cones, where it co-localized with actin. Although the expression 
level seemed to be lower than for nNOS, this cannot be ascertained since different 
antibodies were used to detect the respective enzyme. 
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Figure 17: Expression and localization of nNOS and eNOS in untreated DRG neurons of wild-type 
and MAP1B-/- mice. 
Mouse DRG neurons were isolated from wild-type and MAP1B-/- mice. Neurons were cultured for 24hrs 
on PLL-laminin coated coverslips, fixed and stained for tubulin, actin and nNOS (A) or eNOS (B). Wild-
type DRG neurons expressed nNOS mainly in their cell bodies and in the axons were it co-localized with 
tubulin (white arrows). In the growth cones nNOS was found only sporadically. MAP1B-/- DRG neurons 
exhibited a much lower expression level of nNOS. Only a weak staining was observed in the cell body 
and the axons (yellow arrows). In contrast, eNOS was expressed at similar levels in wild-type and 
MAP1B-/- DRG neurons (white arrows). It co-localized with tubulin in the cell body and in axons and was 
also found in the growth cones. 
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 The reduced nNOS expression in MAP1B-/- mice could also be confirmed by 
immunoblot assays (Figure 18). Dorsal root ganglia lysates and total brain lysates of 
adult or newborn wild-type and MAP1B-/- mice were examined. Actin or tubulin served 
as loading control. nNOS expression was almost not detectable in MAP1B-/- DRGs 
compared to wild-type DRGs and only very weak signals were obtained in extracts from 
brains of newborn or adult mice. In contrast, nNOS showed a relatively strong 
expression in wild-type brains, independent of the age of the mice. Concerning eNOS, 
the expression level was very low in all tissues that were investigated but no big 
difference could be observed between wild-type and MAP1B-/- mice. 
 
 
Figure 18: Immunoblot analyses of wild-type and MAP1B-/- DRGs and brains of adult and newborn 
mice for nNOS and eNOS. 
Wild-type and MAP1B-/- lysates were prepared from DRGs and from brains of adult and newborn mice 
and loaded on a 10% PAA gel for detection of nNOS and eNOS. Actin or tubulin was used as loading 
control. (A) Immunoblotting showed that the expression of nNOS is strongly reduced in MAP1B-/- DRGs 
and brains compared to lysates of wild-type mice. In contrast, although weakly expressed, eNOS shows 
similar expression levels in both genotypes, independent of the tissue examined (B). 
 
 nNOS and NO production were shown to play an important role in the repulsive 
effect of netrin-1 on wild-type DRG neurons. Next I checked whether nNOS changes its 
localization upon activation during netrin-1 treatment. As the strongest fluorescent 
signal stemming from NO production was observed in the growth cone of retracting 
DRG neurons, one could expect nNOS to relocalize from the cell body and axons of 
DRG neurons to their growth cones, at least partially. Therefore, wild-type DRG 
neurons were cultured as usual, treated with 250ng/ml netrin-1 or with netrin-1 in the 
presence of 300µM NPA for 21hrs, stained for tubulin, actin and nNOS and were 
compared to untreated neurons (Figure 19). When neurons were left untreated or treated 
with NPA, nNOS was almost never found in the growth cones of axons, only along 
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axons themselves. In contrast, when DRG neurons were incubated with netrin-1, nNOS 
was found more often in growth cones, although the relocalization of nNOS did not 
occur in all examined cells. Additionally, in certain neurons a stronger fluorescent 
signal for nNOS was observed. Unfortunately, it was not feasible to perform 
immunoblot analysis of cultured DRG neurons because the yield of protein was to low 
to detect nNOS. The expression and localization of eNOS was also tested in wild-type 
DRG neurons but did not show any difference induced by netrin-1 treatment (data not 
shown). 
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Figure 19: Expression and localization of nNOS in wild-type DRG neurons after treatment with 
netrin-1 and/or NPA. 
Mouse DRG neurons were isolated from wild-type mice, were cultured for 24hrs on PLL-laminin coated 
coverslips, were left untreated, or were treated with 250ng/ml netrin-1 for 21hrs, with 300µM NPA for 
21hrs, or with 250ng/ml netrin-1 in the presence of 300µM NPA for 21hrs, as indicated. Neurons were 
then fixed and stained for tubulin, actin and nNOS. A) Upon treatment with netrin-1, a fraction of wild-
type DRG neurons showed a slight increase in nNOS fluorescent signal (green arrows). This could not be 
observed after NPA treatment or NPA + netrin-1 treatment, as far as it could be stated after 
immunofluorescences analysis. Additionally, a change in nNOS localization to the growth cones of DRG 
neurons occurred after treatment with netrin-1 (yellow arrows) which could not be observed without 
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treatment or after treatment with netrin-1 in the presence of NPA (white arrows). White boxes indicate the 
area shown at higher magnification in the lowest panel (B). 
 
Inhibition of eNOS reduces netrin-1 induced retraction in MAP1B-/- DRG neurons 
 
 In MAP1B-/- DRG neurons nNOS expression was shown to be lower than in 
wild-type DRG neurons and inhibition of nNOS with NPA did not have the same strong 
effect in inhibiting netrin-1 induced retraction of axons. In contrast, eNOS was shown to 
be expressed at a similar level as in wild-type cells. Thus, the next step in the 
investigation of signaling molecules downstream of netrin-1 in MAP1B-/- neurons was 
to inhibit eNOS specifically during incubation with netrin-1. The specific inhibitor for 
eNOS is L-NIO which was used at a concentration of 10µM. The graph in Figure 20 
shows the reaction of wild-type and MAP1B-/- DRG neurons to netrin-1 treatment in the 
presence of L-NIO. L-NIO itself led to a relatively high percentage of retraction, but it 
was still far below the percentage of retracted cells after netrin-1 treatment. 
Simultaneous incubation of DRG neurons with netrin-1 and L-NIO did almost not affect 
the reaction of wild-type DRG neurons to netrin-1; the percentage of retracted neurons 
remained at 28%. In MAP1B-/- DRG neurons, L-NIO had a much stronger effect on the 
retraction. L-NIO reduced the amount of retracted neurons significantly by 26 
percentage points to 14%. This result suggests that eNOS activity is not essential for 
repulsive netrin-1 signaling in wild-type DRG neurons but might play an important role 
in MAP1B-/- DRG neurons, in contrast to nNOS. 
 
 
Figure 20: L-NIO reduces netrin-1 induced retraction in MAP1B-/- DRG neurons. 
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Mouse DRG neurons were isolated from wild-type and MAP1B-/- mice. Cells were cultured for 24hrs on 
PLL-laminin coated coverslips, were left untreated or were treated with 250ng/ml netrin-1 for 21hrs, with 
10µM L-NIO for 21hrs, or with 250ng/ml netrin-1 in the presence of 10µM L-NIO for 21hrs, as 
indicated, fixed, and stained for tubulin. For quantitative analysis, approximately 100 cells in each of 3 
independent experiments were assessed for microtubule configuration. DRG neurons with one axon 
exhibiting features of retraction were considered as retracted. In untreated samples the amount of 
retracting neurons was in the range of 10 to 11%. After L-NIO treatment, the percentage of retracted 
neurons reached 17 to 19%. After netrin-1 treatment, wild-type cultures showed 34% and MAP1B-/- DRG 
cultures showed 40% of retracted neurons. L-NIO treatment reduced the netrin-1-induced retraction to 
28% in wild-type and to 14% in MAP1B-/- DRG neurons. Error bars represent standard error of the mean. 
Asterisks indicate that the values for cells treated with netrin-1 were significantly different from 
corresponding values of untreated cells and that the values for cells treated with netrin-1 in the presence 
of L-NIO were significantly different from corresponding values of cells treated with netrin-1 only (***, 
p<0.001). 
 
 Seeing that NO production by eNOS might not play a role in induction of 
retraction by netrin-1 in wild-type DRG neurons, the inhibition of eNOS should not lead 
to reduced intracellular NO-levels after netrin-1 treatment in these cells. In order to 
confirm this hypothesis, DRG neurons of wild-type mice were cultured and treated as 
before and stained for tubulin. Additionally, the NO-levels were visualized with DAF-
FM DA. Incubation of wild-type DRG neurons with L-NIO led to a weak increase of 
NO production in axons. Moreover, inhibition of eNOS was not efficient in reducing 
netrin-1 induced NO production. A strong increase in DAF-FM T signal could be 
observed after incubation with netrin-1 and L-NIO which was comparable to the NO-
levels after treatment with netrin-1 alone (Figure 21). 
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Figure 21: NO production in wild-type DRG neurons after treatment with netrin-1 and L-NIO. 
DRG neurons were isolated from wild-type mice, cultured for 24hrs on PLL-laminin coated coverslips, 
were left untreated or were treated with 250ng/ml netrin-1 for 21hrs, with 10µM L-NIO for 21hrs, or with 
250ng/ml netrin-1 in the presence of 10µM L-NIO for 21hrs, as indicated. Before fixation, cells were 
incubated with the cell permeable, photo-stable fluorescent indicator for intracellular NO-levels DAF-FM 
DA (5µM) for 1h. Then cells were fixed and stained for tubulin. Untreated and L-NIO treated wild-type 
DRG neurons showed basic NO-levels as revealed by very weak DAF-FM DA fluorescence. In contrast, 
DRG neurons which were treated with netrin-1 exhibited a strong fluorescent signal stemming from the 
reaction of DAF-FM DA with intracellular NO. Neurons that were treated with 250ng/ml netrin-1 in the 
presence of 10µM L-NIO for 21hrs showed intracellular NO-levels comparable to neurons treated with 
netrin-1 only. Strong fluorescence could be seen most notably in the growth cones showing retraction or 
collapse (white arrows). 
 
 In contrast to wild-type DRG neurons, the NO production of MAP1B-/- DRG 
neurons during netrin-1 treatment could be impeded successfully by L-NIO. Compared 
to netrin-1 treated cells, the fluorescent signal of neurons treated with netrin-1 and 
L-NIO was reduced dramatically (Figure 22). This correlates with the percentage of 
retraction assessed in Figure 20 and confirms the idea that eNOS seems to be more 
important for MAP1B-/- DRG neurons reacting to the repulsive netrin-1 signal than for 
wild-type neurons. 
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Figure 22: NO production in MAP1B-/- DRG neurons after treatment with netrin-1 and L-NIO. 
DRG neurons were isolated from MAP1B-/- mice, cultured for 24hrs on PLL-laminin coated coverslips, 
were left untreated or were treated with 250ng/ml netrin-1 for 21hrs, with 10µM L-NIO for 21hrs, or with 
250ng/ml netrin-1 in the presence of 10µM L-NIO for 21hrs, as indicated. Before fixation, cells were 
incubated with the cell permeable, photo-stable fluorescent indicator for intracellular NO-levels DAF-FM 
DA (5µM) for 1h. Then cells were fixed and stained for tubulin. Untreated and L-NIO treated MAP1B-/- 
DRG neurons showed basic NO-levels as revealed by very weak DAF-FM T fluorescence. In contrast, 
DRG neurons which were treated with netrin-1 exhibited a strong fluorescent signal stemming from the 
reaction of DAF-FM DA with intracellular NO (white arrows). Presence of L-NIO during netrin-1 
treatment inhibited NO production and led to NO-levels comparable to untreated neurons (yellow 
arrows). 
 
Binding of netrin-1 to its receptor was suggested to have an influence on the 
localization and activity of nNOS in wild-type DRG neurons. Since in MAP1B-/- DRG 
neurons eNOS seems to be more important, the question arose whether the localization 
of eNOS changes as well upon netrin-1 signaling. Therefore MAP1B-/- DRG neurons 
were cultured as usual, treated with 250ng/ml netrin-1, or with netrin-1 in the presence 
of 10µM L-NIO for 21hrs, stained for tubulin, actin and eNOS and the localization and 
expression levels of the enzyme in treated cells was compared to the one in untreated 
neurons (Figure 23). Only a small number of DRG neurons showed relocalization of 
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eNOS following the netrin-1 treatment. However, no change in localization could be 
observed in untreated samples compared to DRG neurons treated with netrin-1, L-NIO 
or both. In these samples, some growth cones were found to show an eNOS signal. 
 
 
Figure 23: Localization of eNOS in MAP1B-/- DRG neurons after treatment with netrin-1 and L-
NIO. 
Mouse DRG neurons were isolated from MAP1B-/- mice, were cultured for 24hrs on PLL-laminin coated 
coverslips, were left untreated or were treated with 250ng/ml netrin-1 for 21hrs, with 10µM L-NIO for 
21hrs, or with 250ng/ml netrin-1 in the presence of 10µM L-NIO for 21hrs, as indicated, fixed and 
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stained for tubulin, actin and eNOS. In untreated neurons, eNOS was predominantly found in the cell 
body and along axons but not in growth cones (white arrows), whereas after netrin-1 and/or L-NIO 
treatment, eNOS staining revealed a partial relocalization of eNOS to growth cones (yellow arrows). 
White boxes indicate the area shown at higher magnification in the lowest panel (B). 
 
Soluble guanylyl cyclase as downstream target of netrin-1 induced NO synthesis 
 
 There are two possible signaling mechanisms that might be initiated by NO 
production: first, S-nitrosylation of proteins and second, activation of soluble guanylyl 
cyclase (sGC) by binding of NO. MAP1B was shown not to be necessary for the 
repulsive netrin-1 signaling pathway; therefore, its nitrosylation might not be essential 
either. Other potential targets of protein S-nitrosylation have not been investigated due 
to the impossibility of a biotin switch on DRG neurons which do not provide enough 
material for this assay. Whether sGC is activated during the process of netrin-1 induced 
repulsion was tested by inhibiting the enzyme with its specific inhibitor LY83583. 
Another more prominent inhibitor of sGC, ODQ, was already tested by a former PhD 
student and was found to induce retraction on its own (Trancikova, PhD Thesis 2007). 
Due to this result, I performed experiments where I inhibited sGC specifically with 
LY83583. DRG neurons of wild-type and MAP1B-/- mice were grown on PLL-laminin 
coated coverslips, left untreated or were treated with 250ng/ml netrin-1, or with netrin-1 
in the presence of 1µM LY83583. LY83583 per se caused a significantly high 
percentage of wild-type DRG neurons to retract (Figure 24). It has also been observed 
for ODQ that the inhibition of sGC did not have this strong effect in MAP1B-/- DRG 
neurons. They exhibited an insignificant increase in retraction by 7%. When applied 
additionally to netrin-1 treated DRG neurons, LY83583 even increased the amount of 
retracted axons. This effect could be observed in both wild-type and MAP1B-/- DRG 
neurons.  
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Figure 24: LY induces axon retraction in wild-type DRG neurons. 
Mouse DRG neurons were isolated from wild-type and MAP1B-/- mice. Cells were cultured for 24hrs on 
PLL-laminin coated coverslips, were left untreated or were treated with 250ng/ml netrin-1 for 21hrs, with 
1µM LY83583 for 21hrs (LY), or with 250ng/ml netrin-1 in the presence of 1µM LY83583 for 21hrs, as 
indicated, fixed and stained for tubulin. For quantitative analysis, approximately 100 cells in each of 2 
independent experiments were assessed for microtubule configuration. DRG neurons with one axon 
exhibiting features of retraction were considered as retracted. In untreated treated samples the amount of 
retracting neurons was in the range of 10 to 11%. After netrin-1 treatment, wild-type cultures showed 
34% and MAP1B-/- DRG cultures showed 40% of retracted neurons. After LY83583 treatment, the 
percentage of retracted wild-type neurons was 32% and the percentage of retracted MAP1B-/- DRG 
neurons was 17%. LY83583 treatment increased the netrin-1-induced retraction to 43% in wild-type and 
to 49% in MAP1B-/- DRG neurons. Error bars represent standard errors of the mean. Asterisks indicate 
that the values for cells treated with netrin-1 or LY83583 were significantly different from corresponding 
values of untreated cells (***, p<0.001). 
 
 Direct comparison of the levels of retraction induced by treatment with 1µM 
LY83583 for 1h or with 10µM ODQ for 30min confirmed the previous results of 
Trancikova, PhD Thesis 2007, especially in wild-type DRG cultures. In these neurons 
both inhibitors of sGC led to a significant increase in the percentage of retracted cells 
compared to retraction observed in untreated samples, although the incubation time was 
reduced dramatically from 21hrs to 1h. Moreover, the experiments showed that 
MAP1B-/- DRG neurons did not respond as wild-type DRG neurons to inhibition of the 
cGMP pathway, no matter which inhibitor was used (Figure 25). The possible 
explanation for the retraction induced by inhibition of sGC lies in a negative feedback 
mechanism in which cGMP dependent protein kinase, PKG, plays an essential role. 
After the production of cGMP due to activation of sGC by NO, PKG becomes 
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activated. One target of PKG is nNOS, which is phosphorylated by the kinase on a 
specific cysteine resulting in the inactivation of nNOS5. This mechanism assures that 
nNOS is not capable of producing excessive amounts of NO which could be toxic to the 
cell. It is also important to be capable of switching off a signal in order to respond to 
another one. With the inhibition of sGC by ODQ or LY83583, this negative feedback 
mechanism is shut down, thus, nNOS is not inactivated by phosphorylation by PKG and 
produces continuously NO, probably resulting in axon retraction. This hypothesis also 
explains the weak response in MAP1B-/- DRG neurons which were shown to lack nNOS 
at least partially. Moreover, MAP1B-/- DRG neurons do not respond to the NO-donor 
SNAP either1, thus, it might be the lack of MAP1B which led to this result. However, in 
order to substantiate this theory, the simultaneous inhibition of nNOS during treatment 
with either ODQ or LY83853 should prevent axon retraction. Indeed, the presence of 
NPA during treatment of wild-type DRG neurons with the sGC inhibitors caused a 
significant reduction in levels of retracted neurons. The percentage of retracted neurons 
following treatment with LY83583 or ODQ in the presence of NPA was reduced by 25 
percentage points (Figure 25). These results show that short time incubation of wild-
type DRG neurons with inhibitors of sGC led to retraction as it was the case for long 
time incubation. Moreover, the feedback mechanism involving PKG activation by 
cGMP resulting in nNOS inactivation was confirmed. 
 
 
Figure 25: Percentage of retracted DRG neurons after treatment with LY, ODQ and NPA. 
Mouse DRG neurons were isolated from wild-type and MAP1B-/- mice. Cells were cultured for 24hrs on 
PLL-laminin coated coverslips, were left untreated or were treated with 1µM LY83583 for 1h, with 
10µM ODQ for 30min, with 300µM NPA for 1h, or with 1µM LY83583 in the presence of 300µM NPA 
for 1h, or with 10µM ODQ in the presence of 300µM NPA, as indicated, fixed and stained for tubulin. 
For quantitative analysis, approximately 100 cells in each of 3 or more independent experiments were 
assessed for microtubule configuration. DRG neurons with one axon exhibiting features of retraction 
were considered as retracted. In untreated samples the amount of retracting neurons was in the range of 
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4%. Treatment with LY83583 or ODQ resulted in wild-type cultures to 33% and 35% of retracted 
neurons, respectively. In MAP1B-/- DRG cultures, LY83583 did not have such a striking effect, only 7% 
of the neurons were retracted. MAP1B-/- DRG neurons did not react to ODQ treatment; the amount of 
retracted neurons was similar to untreated samples (5%). In wild-type DRG neurons, the presence of NPA 
during treatment with LY83583 or ODQ prevented retraction of neurons significantly. The percentage of 
retraction induced by LY83583 or ODQ was reduced by NPA by 25 percentage points. Error bars 
represent standard errors of the mean. Asterisks indicate that the values for cells treated with LY83583 or 
ODQ were significantly different from corresponding values of untreated cells and that the values for 
cells treated with LY83583 or ODQ in the presence of NPA were significantly different from 
corresponding values of cells treated with LY83583 or ODQ only (***, p<0.001). 
 
 When the negative feedback mechanism via PKG is disabled due to inhibition of 
sGC, the levels of intracellular NO should increase. Indeed, the amount of retracted 
DRG neurons after inhibition of sGC correlated with the observed increase in 
intracellular NO-levels visualized with DAF-FM DA. Wild-type DRG neurons were 
cultured on PLL-laminin coated coverslips and treated as before with 1µM LY83583 for 
1h or with LY83583 in the presence of 300µM NPA (Figure 26). The same assay was 
performed with the sGC inhibitor ODQ in presence or not of NPA (Figure 27). Both 
experiments showed a clear increase in fluorescence stemming from reaction of DAF-
FM DA with intracellular NO after inhibition of sGC, no matter which sGC inhibitor 
was used. Apparently, inhibition of sGC ruptured the signal cascade which is negatively 
regulating nNOS activity. Therefore, nNOS was still capable of synthesizing NO, but in 
the presence of NPA the levels of intracellular NO production were reduced drastically. 
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Figure 26: NO production in wild-type DRG neurons after treatment with LY83583 and NPA. 
DRG neurons were isolated from wild-type mice, cultured for 24hrs on PLL-laminin coated coverslips, 
were left untreated or were treated with 1µM LY83583 for 1h, with 300µM NPA for 1h or with 1µM 
LY83583 in the presence of 300µM NPA for 1h, as indicated. Before fixation, cells were incubated with 
the cell permeable, photo-stable fluorescent indicator for intracellular NO-levels DAF-FM DA (5µM) for 
1h. Then cells were fixed and stained for tubulin. Untreated and NPA treated DRG neurons showed basic 
NO-levels displayed by very weak DAF-FM DA fluorescence. In contrast, DRG neurons which were 
treated with LY83583 exhibited a strong fluorescent signal stemming from the reaction of DAF-FM DA 
with intracellular NO (white arrows). The presence of NPA during LY83583 treatment inhibited NO 
production and led to NO-levels comparable to untreated neurons (yellow arrows). 
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Figure 27: NO production in wild-type DRG neurons after treatment with ODQ and NPA. 
DRG neurons were isolated from wild-type mice, cultured for 24hrs on PLL-laminin coated coverslips, 
were left untreated or were treated with 1µM ODQ for 30min, with 300µM NPA for 1h or with 1µM 
ODQ in the presence of NPA, as indicated. Before fixation, cells were incubated with the cell permeable, 
photo-stable fluorescent indicator for intracellular NO-levels DAF-FM DA (5µM) for 1h. Then cells were 
fixed and stained for tubulin. Untreated and NPA treated DRG neurons showed basic NO-levels 
displayed by very weak DAF-FM DA fluorescence. In contrast, DRG neurons which were treated with 
ODQ exhibited a fluorescent signal stemming from the reaction of DAF-FM DA with intracellular NO 
(white arrows). The presence of NPA during ODQ treatment inhibited NO production and led to NO-
levels comparable to untreated neurons (yellow arrows). 
 
 Compared to wild-type DRG neurons which showed a much higher percentage 
of retraction and a correspondingly high level of intracellular NO-levels following 
inhibition of sGC, MAP1B-/- DRG neurons exhibited only a weak fluorescent signal 
stemming from DAF-FM DA reaction with NO after sGC inhibition with LY83583 
(Figure 28) or ODQ (Figure 29). This result correlates with the lack of retraction in 
MAP1B-/- DRG neurons and the lower expression level of nNOS. 
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Figure 28: NO production in MAP1B-/- DRG neurons after treatment with LY83583 and NPA. 
DRG neurons were isolated from MAP1B-/- mice, cultured for 24hrs on PLL-laminin coated coverslips, 
were left untreated or were treated with 1µM LY83583 for 1h, with 300µM NPA for 1h or with 1µM 
LY83583 in the presence of 300µM NPA for 1h, as indicated. Before fixation, cells were incubated with 
the cell permeable, photo-stable fluorescent indicator for intracellular NO-levels DAF-FM DA (5µM) for 
1h. Then cells were fixed and stained for tubulin. Untreated and NPA treated DRG neurons showed basic 
NO-levels displayed by very weak DAF-FM DA fluorescence. In contrast, some MAP1B-/- DRG neurons 
which were treated with LY83583 exhibited a weak fluorescent signal stemming from the reaction of 
DAF-FM DA with intracellular NO (white arrows). The presence of NPA during netrin-1 treatment 
inhibited the little NO production and led to NO-levels comparable to untreated neurons (yellow arrows). 
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Figure 29: NO production in MAP1B-/- DRG neurons after treatment with ODQ and NPA. 
DRG neurons were isolated from MAP1B-/- mice, cultured for 24hrs on PLL-laminin coated coverslips, 
were left untreated or were treated with 1µM ODQ for 30min, with 300µM NPA for 1h or with 1µM 
ODQ in the presence of 300µM NPA, as indicated. Before fixation, cells were incubated with the cell 
permeable, photo-stable fluorescent indicator for intracellular NO-levels DAF-FM DA (5µM) for 1h. 
Then cells were fixed and stained for tubulin. Untreated and NPA treated DRG neurons showed basic 
NO-levels displayed by almost invisible DAF-FM T fluorescence. In contrast, DRG neurons which were 
treated with ODQ exhibited a slightly increased fluorescent signal stemming from the reaction of DAF-
FM DA with intracellular NO (white arrows). The presence of NPA during ODQ treatment inhibited any 
NO production and led to NO-levels comparable to untreated neurons (yellow arrows). 
 
The role of NOS in the Sema3A signaling pathway 
 
 Sema3A acts mainly as repellent guidance cue and induces axon retraction and 
growth cone collapse. Moreover, Sema3A induced growth cone collapse involves Rho-
GTPases, cyclic nucleotides151, PKA and PKG302, and several other kinases such as 
MAPK, Cdk5 and GSK3-β203. All these features make of Sema3A a guidance cue which 
is especially interesting concerning the question whether NOS might be involved in one 
of the pathways leading to growth inhibitory effects. Therefore I wanted to investigate 
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ddition, no indication of intracellular NO production was seen in these neurons.  
 
how different kinds of explants react to the guidance cue when applied in the medium. 
The first experiments were performed with hippocampal explants from newborn wild-
type and MAP1B-/- mice. For these experiments hippocampi of P0 to P1 mice were 
dissected, cut into 3 to 4 pieces and were directly transferred into MatrigelTM. The 
MatrigelTM was allowed to dry for 1 hour and then growth medium for hippocampal 
neurons was added to each well. This medium was supplemented with the nNOS 
inhibitors, NPA or L-NAME, or with Sema3A at concentrations 50ng/ml or 100ng/ml, 
or the combination of a nNOS inhibitor with Sema3A. The neurites were allowed to 
grow out of the explants for 2 to 3 days. After this period, explants were analyzed by 
phase contrast microscopy and the lengths of neurites were measured. Then, the relative 
outgrowth of neurites was calculated by comparing the average lengths of neurites 
grown in differently supplemented growth medium to the lengths of neurites grown in 
normal growth medium without any supplement. Figure 30 shows the results of 7 
independent experiments with wild-type hippocampal explants and 4 independent 
experiments performed with MAP1B-/- mice. Hippocampal explants of wild-type mice 
showed increased outgrowth when cultured in media supplemented with nNOS 
inhibitors. This effect could not be observed for hippocampal explants of MAP1B-/- 
mice. Concerning the growth inhibitory effect of Sema3A, wild-type hippocampal 
explants showed a significant reduction in neurite length after growth in medium 
supplemented with 100ng/ml Sema3A but not when medium was supplemented with 
50ng/ml Sema3A only. However, inhibition of nNOS had again a significant effect on 
the outgrowth of neurites. Addition of NPA or L-NAME led to a significant increase in 
neurite length compared to corresponding values of neurites grown in media 
supplemented with 50ng/ml or 100ng/ml Sema3A. In general, neurite outgrowth of 
MAP1B-/- hippocampal explants was largely unaffected by any of the treatments. The 
visualization of intracellular NO-levels with DAF-FM DA was not possible with 
explant cultures and therefore dissociated hippocampal neurons were cultured and 
treated with the guidance cue and inhibitors. Unfortunately, dissociated neurons from 
hippocampi of newborn mice did not react to Sema3A treatments. No signs of axon 
retraction or growth cone collapse could be found after treatment with Sema3A. In 
a
                                                                                                              Part I - Results  
 
Figure 30: Relative outgrowth of neurites from hippocampal explants of newborn wild-type and 
MAP1B-/- mice. 
Hippocampal explants were isolated from newborn wild-type and MAP1B-/- mice and cultured in 
MatrigelTM. The medium was left unchanged or was supplemented with 300µM NPA, 300µM L-NAME, 
50ng/ml or 100ng/ml Sema3A, with 50ng/ml or 100ng/ml Sema3A in the presence of 300µM NPA or 
300µM L-NAME. The neurites were allowed to grow out for 2-3 days without changing the medium. 
Hippocampal explants were analysed by phase contrast microscopy of living cells and neurite length was 
assessed with appropriate software (AxioVision Rel. 4.7, Zeiss). From each of 7 wild-type and 4 
MAP1B-/- experiments the lengths of 5 to 10 neurites per hippocampal explant were measured and the 
relative outgrowth compared to the outgrowth of untreated explants was calculated. Error bars represent 
standard errors of the mean. Asterisks indicate that the values for explants treated with Sema3A were 
significantly different from corresponding values of untreated explants and that the values for explants 
treated with Sema3A in the presence of NPA or L-NAME were significantly different from 
corresponding values of explants treated with Sema3A only (*, p<0.05; **, p<0.005). 
 
Similar experiments were performed with DRG explants of adult wild-type and 
MAP1B-/- mice. In total 8 independent experiments with wild-type DRG explants and 5 
independent experiments with MAP1B-/- DRG explants were taken into account. The 
experiments including studies of L-NIO effects were performed only 3 times. DRGs 
were dissected as usual from adult mice and directly transferred into MatrigelTM. After 1 
hour incubation, DRG growth medium supplemented with the nNOS inhibitors, NPA or 
L-NAME, with the eNOS inhibitor L-NIO, or with Sema3A, at concentrations 50ng/ml 
or 100ng/ml, or with the combination of a NOS inhibitor with Sema3A was added. The 
neurites were then allowed to grow out of the explants for 2 to 3 days. After this period, 
explants were analyzed by phase contrast microscopy and the lengths of 5 to 10 neurites 
per ganglion were measured. Then, the relative outgrowth of neurites was calculated by 
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comparing the average lengths of neurites obtained in differently supplemented DRG 
growth medium to neurites obtained in normal DRG growth medium without any 
supplement (Figure 31). In case of wild-type DRG explants, the inhibition of NOS 
enzymes generally led to an increase in neurite length suggesting that inhibition of NO 
production acts in favor of outgrowth. In contrast to NOS inhibition, treatment with 
50ng/ml or 100ng/ml Sema3A led to significant reduction in neurite lengths, whereby 
the concentration of Sema3A was not critical. The simultaneous bath application of 
nNOS inhibitors and Sema3A increased the length of neurites significantly compared to 
neurites of explants grown in Sema3A-supplemented medium. Here, the nature of the 
inhibitor did not play a role as NPA and L-NAME were both successfully rescuing the 
growth inhibitory effect of Sema3A treatment. However, compared to the inhibition of 
nNOS, the inhibition of eNOS by L-NIO did not have such a striking effect in 
preventing the Sema3A dependent reduction of outgrowth in wild-type DRG explants.  
In contrast, DRG explants from MAP1B-/- mice did not show any comparable 
reaction. Their outgrowth did not increase during growth in medium supplemented with 
nNOS inhibitors, only slightly in the presence of L-NIO. This is plausible since the role 
of nNOS in MAP1B-/- DRG neurons was already shown to be negligible. Moreover, 
MAP1B-/- DRG explants exhibited a reduced response to Sema3A compared to wild-
type DRG explants. Their neurites were not significantly inhibited in their outgrowth 
and even additional inhibition of nNOS did not help to overcome the weak effect of 
Sema3A. In contrast, L-NIO abolished the weak negative effect of Sema3A on neurite 
outgrowth. 
These results show that in wild-type DRG explants, indeed, nNOS seems to play 
a role in the growth inhibitory signaling pathway activated by Sema3A and this effect 
can be abrogated by inhibiting nNOS. Unfortunately, the visualization of intracellular 
NO-levels with DAF-FM DA was not possible with explant cultures and therefore 
dissociated DRG neurons were cultured and treated with the guidance cue and NOS 
inhibitors. This experiment has been performed twice but no reaction to Sema3A 
leading to retraction or growth cone collapse could be observed in these neurons (data 
not shown). Moreover, no increase in NO-levels was detected. Probably the dissociated 
DRG neurons of adult mice do not respond to treatment with Sema3A. 
 
                                                                                                              Part I - Results  
 8
 
Figure 31: Relative outgrowth of neurites from DRG explants of adult wild-type and MAP1B-/- 
mice. 
DRG explants were isolated from adult wild-type and MAP1B-/- mice and cultured in MatrigelTM. The 
medium was left unchanged or was supplemented with 300µM NPA, 300µM L-NAME, 10µM L-NIO, 
50ng/ml or 100ng/ml Sema3A, or with 50ng/ml or 100ng/ml Sema3A in the presence of 300µM NPA, 
300µM L-NAME or 10µM L-NIO. The neurites were allowed to grow out for 2-3 days without changing 
the medium. DRG explants were analyzed by phase contrast microscopy of living cells and neurite length 
was assessed with appropriate software (AxioVision Rel. 4.7, Zeiss). From each of 8 wild-type and 5 
MAP1B-/- experiments the lengths of 8 to 10 neurites per ganglion were measured and the relative 
outgrowth compared to the outgrowth of untreated neurites was calculated. Experiments including L-NIO 
treatment were performed 3 times. Error bars represent standard errors of the mean. Asterisks indicate 
that the values for neurites treated with NPA were significantly different from corresponding values of 
untreated neurites, that the values for neurites treated with Sema3A were significantly different from 
corresponding values of untreated neurites and that the values for neurites treated with Sema3A in the 
presence of NPA or L-NAME were significantly different from corresponding values of neurites treated 
with Sema3A (*, p<0.05; ***, p<0.001). 
 
However, these results confirm the data obtained for hippocampal explants and 
emphasize the role of nNOS in the response to Sema3A of neurites growing out of wild-
type explants. Similar effects of Sema3A and nNOS inhibition could be observed 
independent of the age of mice used for these experiments which suggests that Sema3A 
acts in a comparable manner in the nervous system of newborn and adult mice. 
Moreover, my results demonstrate the importance of NOS and MAP1B in Sema3A 
signaling. 
7
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PART I DISCUSSION 
 
 Many axon guidance cues can act either as attractive or repulsive signals. 
This is also true for netrin-1. The Tessier-Lavigne laboratory demonstrated that the 
chemoattractive guidance receptor for netrin-1 is DCC, the mammalian orthologue for 
Unc40152, whereas the family of Unc5 receptors mediates repulsive netrin-1 
signaling106. In contrast to short range signaling, long range signaling requires a netrin-1 
gradient which is stabilized through interactions with components of the extracellular 
matrix, such as laminin. Activation of DCC triggers activation of Rac1 and Cdc42 
promoting lamellipodium and filopodium extension, respectively159. The mechanism 
underlying the attractive signaling was studied by many groups. One of them, Del Rio 
et al., was able to show that MAP1B phosphorylation by GSK3-β and CDK5 occurs 
during netrin-1 signal transduction and that the lack of MAP1B impairs netrin-1 
mediated chemoattraction in vitro and in vivo. They suggested that MAP1B might be an 
essential downstream effector of the attractive netrin-1 signaling pathway3. In addition, 
the phenotypes of MAP1B-/- mice4 and netrin-1-/- mice49 share some similarities, 
although the lack of netrin-1 causes much more severe effects. Both mutants exhibit 
defects in forebrain commissures such as the generation of corpus callosum or 
hippocampal commissure suggesting that both proteins are essential for proper axon 
guidance during brain development. 
Much less work has been done regarding chemorepulsive netrin-1 signaling. The 
repulsive response to netrin-1 is mediated by Unc5-dependent RhoA activation and a 
decrease in the ratio of cAMP to cGMP. Growth cones respond to a repulsive guidance 
cue secreted from a local source by turning away from this source. If the repulsive 
factor surrounds the growing neuron, as it is the case for bath application, the growth 
cone collapses and the axon retracts. One mechanism of axon retraction was shown to 
involve S-nitrosylation of MAP1B as an essential part of the signal transduction 
pathway1. Calcium influx leading to the activation of nNOS and subsequent MAP1B 
S-nitrosylation eventually results in axon retraction in wild-type but not in MAP1B-/- 
DRG neurons. 
Netrin-1 has been shown to act as a repulsive signal for growth cones when 
neurons are grown on substrates containing laminin2. Since the established protocol for 
culturing mouse DRG neurons utilizes PLL-laminin coated glass coverslips, I expected 
the neurons to retract when treated with netrin-1. Indeed, I observed a significant 
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increase in retracting axons in netrin-1 treated samples. The binding of netrin-1 to its 
receptors leads to an increase in intracellular calcium levels. Ca2+ signaling is extremely 
important in controlling growth cone steering, although the precise role of Ca2+ signals 
in directional sensing and steering of the growth cone is unclear135. A small local Ca2+ 
was found to mediate repulsion, whereas a modest elevation of Ca2+ results in 
attraction303. Cyclic nucleotide signaling directly modulates the activity of L-type Ca2+ 
channels (LCCs) in the axonal growth cones. Moreover, cGMP suppresses LCC activity 
triggered by netrin-1 and is required for growth cone repulsion mediated by the DCC-
Unc5 receptor complex146. 
I wondered whether the expected change in calcium concentration after netrin-1 
binding would induce nNOS activation. As consequence of nNOS activation, the 
increased NO synthesis could result in MAP1B S-nitrosylation and MAP1B-dependent 
axon retraction. Moreover, in the presence of laminin, the response to netrin-1 includes 
a decrease in the ratio of cAMP and cGMP concentrations, suggesting that sGC 
becomes activated. sGC is a target of NO and is activated by its binding. Thus, it 
appeared plausible that nNOS is the signaling molecule linking the calcium influx and 
the presence of laminin to the repulsion mediated by netrin-1. 
Additionally, phosphorylation of MAP1B might also be a critical step during 
repulsive netrin-1 signaling in the presence of laminin. Phosphorylation of MAP1B by 
Cdk5 occurs after activation of the kinase by laminin53. Since the presence of laminin 
switches the neuronal response to netrin-1 from attraction to repulsion the question 
arose whether MAP1B and its phosphorylation play a role in the chemorepellent netrin-
1 signaling pathway. 
In order to test the hypothesis that MAP1B is involved in repulsive netrin-1 
signaling as well, DRG neurons of wild-type and MAP1B-/- mice were cultured on PLL-
laminin coated coverslips. After bath application of netrin-1 for 21hrs the response of 
axons was analyzed. As expected, the presence of laminin led to a repulsive effect of 
netrin-1 resulting in typical axon retraction including all three characteristics: sinusoidal 
microtubule bundles along the axon shaft, a collapsed growth cone and a trailing 
remnant. Interestingly, the axons of wild-type and MAP1B-/- DRG neurons showed a 
similar reaction to the treatment. Both cell types exhibited comparable percentages of 
retracted neurons suggesting that the lack of MAP1B did not impair the signal 
transduction downstream of netrin-1. This result showed that, in contrast to the 
attractive netrin-1 signaling, MAP1B is not necessary for the correct signal transduction 
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of the repulsive netrin-1 signaling. Consequently, neither S-nitrosylation nor 
phosphorylation of MAP1B appear to be relevant for this signaling pathway. However, 
these modifications might have occurred in presence of MAP1B. 
Since MAP1B is dispensable for repulsive netrin-1 signaling, it seems that a 
completely different mechanism can be activated by netrin-1 in the presence of laminin 
compared to attractive signaling. Probably not only the ratio between cAMP to cGMP is 
important but many other factors too, that are not needed for attraction. Another 
possible explanation for the difference between the results obtained for the attractive 
versus repulsive netrin-1 pathway is that different cells were used for the studies. Del 
Rio worked mainly with embryonic tissues and cells. They isolated hippocampal and 
spinal explants or dissociated neurons from cortex or the lower rhombic lip whereas I 
used DRG neurons of adult mice. Thus, not only the source of the cells but also the 
developmental stage might play a role in the responses to the guidance cue.  
 However, the irrelevance of MAP1B does not eliminate the possible 
involvement of nNOS in this pathway. The activation of nNOS was investigated with 
the cell permeable fluorescent indicator for intracellular NO, DAF-FM DA. In the 
presence of oxygen, DAF-FM DA reacts with NO yielding the fluorescent dye DAF-
FM T. The incubation of netrin-1 treated cells with this dye revealed a clear increase in 
intracellular NO following activation of the netrin-1 signaling pathway. In wild-type 
and MAP1B-/- DRG neurons high levels of NO were observed along axons and 
especially in collapsed growth cones. Once more, the response of the neurons was not 
MAP1B dependent. This shows that, first, a NOS was activated downstream of netrin-1. 
Since netrin-1 binding to its receptors induces changes in the intracellular Ca2+ levels, it 
is likely that this change is responsible for the activation of NOS. Secondly, 
S-nitrosylation of MAP1B was not essential for the mechanism although it might have 
occurred in wild-type DRG neurons, what has not been tested. 
In order to confirm the activation of a NOS downstream of netrin-1 and its 
importance in mediating axon retraction by producing high levels of NO, the specific 
nNOS inhibitor NPA was used. DRG neurons from wild-type and MAP1B-/- mice were 
cultured and treated with netrin-1 or with netrin-1 in the presence of NPA, and the 
percentage of retracted axons was quantified. Compared to neurons exposed to netrin-1 
alone, those treated with netrin-1 and NPA showed a significant reduction in retracted 
axons. The level of retraction in wild-type DRG neurons could be reduced to the level 
observed in untreated samples, whereas MAP1B-/- DRG neurons responded in a less 
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striking manner. In correlation with the assessed retraction, the DAF-FM T signal in 
wild-type DRG neurons was abolished by NPA whereas in MAP1B-/- DRG neurons 
only a weak reduction of the fluorescence could be seen. I concluded from these results 
that in wild-type DRG neurons, indeed, nNOS is involved in the repulsive netrin-1 
signaling pathway and that the increase of NO is a crucial step in induction of axon 
retraction. In contrast, nNOS is of minor importance in MAP1B-/- DRG neurons. In 
these neurons another NOS might play a role since NO production comparable to that 
observed in wild-type neurons was observed. 
To find out why nNOS inhibition was less effective in preventing axon 
retraction in MAP1B-/- DRG neurons than in wild-type DRG neurons, I tested wild-type 
and MAP1B-/- DRG neurons for expression of nNOS and eNOS. eNOS is found mainly 
in endothelial cells but it is also expressed in neurons and glia cells. It is, like nNOS, a 
constitutively expressed NOS and its activation is Ca2+ dependent. Immunofluorescence 
analysis clearly revealed a difference in expression level of nNOS between the two cell 
types. In MAP1B-/- DRG neurons nNOS expression was reduced dramatically, whereas 
the levels of eNOS expression seemed to be comparable between wild-type and 
MAP1B-/- DRG neurons. These results were confirmed by western blot analysis of 
lysates of DRGs and brains from adult or newborn mice. 
Acute control of nNOS activity is mediated by allosteric enzyme regulation, by 
posttranslational modification and by subcellular targeting of the enzyme. However, in 
case of MAP1B-/- neurons I observed changes in nNOS expression levels. How the lack 
of MAP1B influences the expression level of nNOS still remains elusive. However, 
direct interactions of a variety of proteins bearing a PDZ domain with the PDZ domain 
of nNOS have been shown to influence the subcellular distribution and activity of the 
enzyme, such as PSD-95 or PSD-93304. MAP1B for instance was shown to bind the 
PDZ domain of nNOS. The interaction between the two proteins does not occur 
exclusively through this domain, though (Trancikova, PhD Thesis 2007). This 
interaction might have an influence on the stability of the enzyme. 
Another possible reason for the reduced nNOS expression could be at the level 
of mRNA. The mRNA of nNOS is structurally diverse as a consequence of alternative 
promoters and alternative splicing305. The expression of nNOS in MAP1B-/- DRG 
neurons was principally reduced to the cell body and primary axons and not always 
completely absent. MAP1B has been shown to colocalize with staufen1-containing RNP 
complexes in DRG neurons306 (Steffel, PhD Thesis 2007). Thus, MAP1B might also 
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play a role in the stabilization or transport of mRNA. At least for eNOS it has been 
suggested that RNA binding proteins are involved in regulation of eNOS transcription. 
A similar mechanism could be assumed for nNOS mRNA stability, transport and 
following transcription. One could investigate whether the transcription of nNOS is 
impaired in cells lacking MAP1B by performing quantitative RT PCR. In addition, a 
pulse chase experiment could be performed with a neuronal cell line transfected with 
siRNA against MAP1B in order to follow nNOS protein-synthesis. Moreover, 
transfecting MAP1B-/- DRG neurons with full length MAP1B or MAP1B-LC1 should 
provide an indication of the role of MAP1B in the stability of nNOS at the mRNA and 
protein level. Another explanation for the reduced signal from antibodies against nNOS 
in MAP1B-/- mice is the regulation of the enzyme through alternative transcripts. It is 
known that the isoforms nNOS-β and nNOS-γ lack the PDZ domain which is 
responsible for targeting nNOS to synaptic membranes228. Moreover, all our antibodies 
against nNOS detect the PDZ domain of the enzyme, and thus, would not recognize the 
different isoform which might be expressed in MAP1B-/- DRG neurons. 
In any case, it was important to clarify whether eNOS could substitute for 
nNOS. The first approach was to inhibit eNOS with the specific inhibitor L-NIO during 
treatment with netrin-1 and to evaluate axon retraction under these conditions. 
Additionally, the level of intracellular NO production was analyzed with DAF-FM DA. 
In wild-type DRG neurons L-NIO was not successful in preventing retraction induced 
by netrin-1. Moreover, the level of NO synthesis was not reduced in netrin-1 treated 
DRG neurons. In contrast, MAP1B-/- DRG neurons showed a much better response to 
L-NIO. Inhibition of eNOS reduced the amount of retracted axons after netrin-1 
treatment to the levels of retraction seen in untreated DRG neurons and the fluorescent 
signal from DAF-FM T was almost abolished. Hence, in MAP1B-/- DRG neurons 
netrin-1 signaling involves NO production, but the main responsible enzyme here is 
eNOS.  
Thus, NO production seems to be a key event mediating netrin-1 induced axon 
retraction in wild-type and in MAP1B-/- DRG neurons. Whether nNOS is available is 
not the most important fact. Since the expression level of eNOS in MAP1B-/- DRGs or 
brains is quite similar to that in wild-type DRGs or brains, it is not an upregulation of 
eNOS expression which provides relief. There might be a feedback mechanism which 
activates eNOS if nNOS is not expressed or stable enough. Interestingly, eNOS is not 
taking over from nNOS when nNOS is inhibited, only when the expression or 
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stabilization of nNOS is impaired. Otherwise a specific inhibition of nNOS alone would 
not have been that effective and simultaneous inhibition of eNOS would have been 
necessary to see a decrease in retraction. Why eNOS becomes only more important 
when nNOS expression is reduced and not when nNOS is simply inhibited remains 
elusive. A plausible cause could be the availability of Ca2+/CaM. Activation of both 
enzymes, nNOS and eNOS, is dependent on increase in intracellular Ca2+ which leads to 
the binding of Ca2+/CaM to the NOS. nNOS and eNOS translocate upon Ca2+/CaM 
binding from membrane associated PSD95 and caveolin, respectively, to the cytoplasm 
where they produce NO305, 307. Perhaps the concentration of Ca2+/CaM is a rate limiting 
factor and nNOS might a higher affinity to Ca2+/CaM than eNOS. Inhibition of nNOS 
by NPA might not interfere with the binding of Ca2+/CaM to nNOS and therefore no 
Ca2+/CaM is free to bind eNOS and induce its translocation from caveolin to the 
cytoplasm. The suggestion that eNOS adopts the role of nNOS in tissues with reduced 
nNOS expression would also help to explain the phenotype observed in nNOS mutant 
mice. These mice did not show any histopathological abnormalities in neuronal tissues 
and other enzymes were suggested to generate NO in their brains308. In contrast to the 
weak phenotypic changes in single knockout mice for nNOS or eNOS, the mice mutant 
for both enzymes showed a significantly reduced long term potentiation suggesting that 
neuronal and endothelial isoforms can compensate for each other236. 
Obviously, laminin does not only play a role in giving support to neuronal 
migration but it is also essential for the correct interpretation of the guidance signals 
according to the environmental situation of the neuron. On the one hand, I could show 
that the production of NO is a necessary event during the transduction of the repulsive 
netrin-1 signaling pathway and on the other hand, the repulsion does not occur when 
laminin is not available. A similar effect has been observed in DRG neurons that were 
submitted to high NO concentrations. Wild-type DRG neurons cultured on PLL-laminin 
retract their axons extensively when exposed to the NO-donor SNAP or to the ionophor 
calcimycin which activates nNOS1. By contrast, wild-type DRG neurons do not show 
any response to these treatments when they were grown on PLL only. Thus, laminin 
might be essential for transduction of NO-mediated signaling. Moreover, the differential 
branching observed between wild-type and MAP1B-/- DRG neurons is abolished by the 
lack of laminin suggesting that some functions of MAP1B are laminin-dependent 
(Krupa, PhD Thesis 2009). The NO production downstream of netrin-1 signaling in the 
presence of laminin might be an important feature of neurons when they are at risk to be 
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misdirected into inappropriate zones. These zones might provide an environment with 
higher concentration of laminin than those where netrin-1 attracted neurons should 
extend. Thereby the response to netrin-1 switches from attraction to repulsion. It would 
be interesting to find out in which zones of the developing nervous system laminin 
surrounds neurons supposed to respond to netrin-1 signaling. Probably these neurons 
are repelled and produce increased amounts of NO. 
Since NO production seemed to be essential for the repulsive netrin-1 signaling I 
wondered what could be the downstream effectors of NO. There are two possibilities in 
which NO can act as signaling molecule: posttranslational modification of proteins by 
protein-S-nitrosylation and activation of sGC. Protein-S-nitrosylation of MAP1B might 
not play an essential role since the responses of DRG neurons to netrin-1 were 
independent of the   MAP1B. Other proteins have not been tested for S-nitrosylation 
because the only way to detect this posttranslational modification is to perform a biotin 
switch. For this experiment one would need large amounts of proteins and the yield of 
proteins from DRG neurons is simply too small. Thus, protein-S-nitrosylation 
downstream of netrin-1 has not been investigated in more detail. The other target of NO 
is sGC which becomes activated by binding of NO. Subsequently, the amount of 
intracellular cGMP increases and the ratio between cAMP and cGMP is altered. This 
change could lead to the switch from attraction to repulsion mediated by laminin2. 
In order to analyse whether the activation of sGC and the subsequent increase in 
cGMP formation are the crucial events leading to axon retraction, I inhibited sGC with 
the specific inhibitors ODQ or LY83583 during treatment with netrin-1. Surprisingly, in 
wild-type DRG neurons treatment with netrin-1 and ODQ or netrin-1 and LY83583 led 
to a significant increase in axon retraction. The observed dramatic increase in axon 
retraction following this double treatment was in the first moment an indication that 
sGC cannot be the main downstream target of NO in the repulsive netrin-1 signaling 
pathway. However, even treatment with ODQ or LY83583 per se led to a rapid, 
MAP1B dependent axon retraction and at the same time to a MAP1B dependent 
increase in intracellular NO synthesis. These results indicate that the inhibition of sGC 
interferes probably with a feedback mechanism working via cGMP dependent protein 
kinase, PKG. PKG is activated by cGMP and one of its targets is nNOS, which becomes 
inactivated when phosphorylated by PKG5. When sGC is inhibited by ODQ or 
LY83583, this negative feedback is switched off and nNOS remains active and will 
continue to produce NO which eventually results in axon retraction. The axon retraction 
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following sGC inhibition was observed to be MAP1B dependent, as MAP1B-/- DRG 
neurons showed greatly reduced response to treatment with ODQ or LY83583. Hence, 
S-nitrosylation of MAP1B might be relevant for the induction of axon retraction when 
cGMP production is reduced. Another explanation for the MAP1B dependence would 
be that PKG does not act on eNOS and another mechanism is responsible for the proper 
inactivation of eNOS, which is not affected by ODQ or LY83583. 
Netrin-1 signaling might not be the only axon guidance cue which involves NO 
production during signal transduction. Other well characterized repellent axon guidance 
cues are for instance the semaphorins. Sema3A activity was shown to be regulated by 
NGF through TrkA309. NGF was shown to reduce the expression of nNOS310. In 
addition, NGF and NO interact during embryonic development and assure survival of 
neurons311. A probable mechanism underlying Sema3A regulation by NGF could be the 
prevention of NO synthesis which provides the second messenger molecule mediating 
repulsive signals. 
In the first attempt to investigate whether NOS and NO play a role in the 
Sema3A signaling I cultured DRG neurons from adult mice and hippocampal neurons 
from newborn mice on PLL or on PLL-laminin coated coverslips. The neurons were 
incubated with different concentrations of Sema3A. None of the neurons showed 
reaction (data not shown). Perhaps the length of the incubation or the concentrations of 
Sema3A were not optimal to induce retraction or growth cone collapse in DRG or 
hippocampal neurons. It was shown previously that embryonic mouse DRG neurons are 
less sensitive to Sema3A-induced growth cone collapse than to axon outgrowth 
inhibition309. Thus, I cultured explants of DRGs and hippocampus from adult and 
newborn mice, respectively. In agreement with the previous findings, I observed a 
significant reduction in the lengths of neurites when the explants were grown in media 
supplemented with Sema3A. The presence of NGF generally enhanced growth 
dramatically and helped thereby to abrogate the growth inhibitory effect of Sema3A 
(data not shown). A similar effect was observed when nNOS was inhibited during 
explant culture. Explants from wild-type DRGs or hippocampus exhibited a significant 
increase in neurite length when exposed to NPA, suggesting that NO production might 
negatively affect neurite outgrowth. Moreover, a significant change was observed in 
explants cultured in medium containing Sema3A and NPA compared to explants grown 
in medium supplemented with Sema3A only. This difference could be due to the effects 
of nNOS inhibition promoting axon elongation. On the other hand, Sema3A could have 
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induced NO production by nNOS resulting in the observed decrease of neurite length, 
which was overridden by its inhibition. The lack of clarity after these results demands 
investigation of intracellular NO production after Sema3A treatments. For this purpose, 
dissociated neurons that react to the repulsive cue would be required. The establishment 
of Sema3A-sensitive neuronal cultures will make it feasible to investigate intracellular 
NO production in response to the guidance cue with DAF-FM DA. Since semaphorins 
are important for axon guidance during development of the nervous system, embryonic 
neurons could be advantageous. 
Regarding the role of MAP1B in signal transduction downstream of semaphorins, 
Sema3A was especially interesting for me because Cdk5 and GSK3-β are involved in 
Sema3A induced growth cone collapse219 and these kinases also phosphorylate 
MAP1B53, 312. An additional hint suggesting MAP1B to be important for Sema3A 
signaling was the finding of Good et al. who observed co-localization of Sema3A and 
phosphorylated MAP1B in hippocampus of Alzheimer’s disease (AD) patients313. 
Moreover, hippocampal immunolabeling of Sema3A and phosphorylated MAP1B 
increases in intensity with the progressive severity of AD and hyper-phosphorylation of 
MAP1B is observed during the progression of AD314. In correlation with this finding, 
very recent data show that Sema3A-stimulation of embryonic hippocampal neurons 
causes a dramatic increase in MAP1B protein levels within distal axons315. Moreover, 
the Sema3A induced growth cone collapse might be partially dependent on FMRP, the 
protein whose mutation is the main cause for fragile X syndrome, and which is binding 
to the MAP1B mRNA in neuronal processes316. The diminished response of MAP1B-/- 
explants to Sema3A in neurite outgrowth suggests that, indeed, MAP1B might be 
involved in the downstream signaling of Sema3A. The MAP1B-/- explants did not show 
any significant increase in length in the presence ofnNOS inhibitors and no decrease 
when Sema3A was supplied. This correlates with the results obtained for nNOS 
expression in MAP1B-/- mice and it suggests that Sema3A might mediate some of its 
effects through MAP1B phosphorylation. Further work will be required to elucidate a 
potential MAP1B-mediated mechanism in Sema3A regulated neurite outgrowth. 
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In consideration of the facts that MAP1B is expressed in glial cells and that 
these cells are sensitive to nitric oxide, the question arose if S-nitrosylation of MAP1B 
LC1 might play a role in nitric oxide toxicity and whether this posttranslational 
modification might affect oligodendrocyte function. I wanted to investigate whether the 
lack of MAP1B influences the cellular morphology, their ability to differentiate and to 
maintain myelination. Moreover, I was interested in whether the S-nitrosylation of 
MAP1B LC1 is involved in the pathways leading to NO-induced cell death and if the 
lack of MAP1B might therefore help the cells to resist the toxic effect of NO. 
 
Morphology and differentiation of oligodendrocytes 
Expression of MAP1B in oligodendrocytes and OLN93 cells 
 
Oligodendrocytes were isolated from newborn wild-type and MAP1B-/- mouse 
brains. After the initial enrichment procedure, they were cultured for two to five days in 
differentiation medium. The duration varied depending on the desired stage of 
differentiation. After two days in culture, oligodendrocytes had attained the 
oligodendrocyte precursor (OPC) stage where no myelin proteins are expressed yet. In 
order to reach the stage of terminal differentiation where cells express myelin specific 
proteins such as MBP and MAG, they had to be cultured for at least 5 days in the 
differentiation medium. However, every culture of oligodendrocytes is very 
heterogenous and not all cells show the same level of differentiation when they are 
fixed. Some cells exhibit first branches already after one night in culture whereas others 
are still bipolar and migrate or proliferate. Oligodendrocytes from wild-type mice were 
all positively stained for MAP1B, independent of their stage of differentiation. Figure 
32 shows that MAP1B is expressed throughout the cell body and overlaps with tubulin 
staining (in green) except at the tips of the processes where MAP1B does not seem to be 
expressed. At first glance, the staining of MAP1B-/- oligodendrocytes shows that the 
morphology of these cells is not disturbed by the lack of MAP1B. The difference in 
appearance between wild-type and MAP1B-/- cells in the picture stems from the fact that 
the wild-type cell in the picture is slightly delayed in the differentiation process 
compared to the MAP1B-/- cell. This can be seen at the shape of the processes. In case 
of the wild-type cell, the processes exhibit a straight, less branched appearance (white 
arrowheads) whereas in the MAP1B-/- oligodendrocyte processes start to approach 
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others and look more curved, especially at the tips, where they are already in touch with 
other processes from the same cell (white arrows). In later differentiation stages the 
myelin sheath will be generated at these sites. 
 
 
Figure 32: Expression of MAP1B in oligodendrocytes. 
Wild-type and MAP1B-/- oligodendrocytes were cultured for five days in differentiation medium on poly-
D-lysine coated coverslips, fixed and stained for tubulin in green and MAP1B-750 in red. The upper 
panel shows a wild-type oligodendrocyte which was fixed in an earlier differentiation stage than the 
MAP1B-/- oligodendrocyte showed beneath. This is visible on the straightness of the processes (white 
arrowheads). MAP1B is expressed in the cell body and in major processes. The lower panel shows a 
MAP1B-/- oligodendrocyte with only background staining of MAP1B-750. The arrows indicate the 
typical morphology of the process tips when oligodendrocytes are on the verge of myelin production. 
Tips of processes contact with other tips of the same cell and build a network of microtubules which will 
provide the cytoskeletal frame for the myelin sheath. 
 
As alternative to primary oligodendrocytes, a cell line (OLN93) derived from rat 
oligodendrocytes was generated by Richter-Landsberg et al317. Since the yield of 
primary oligodendrocytes is always very low, I performed several experiments with this 
cell line. In the undifferentiated stage, OLN93 cells look quite similar to elongated 
fibroblasts with one or two processes. They are not yet branched and express already 
MAP1B. When the cells are cultured on poly-L-lysine (PLL) coated coverslips in 
differentiation medium they start to differentiate. Thus, they develop processes and, 
eventually, express all myelin specific proteins, such as MBP or MAG. The expression 
of MAP1B persists at all stages of differentiation (Figure 33 A), similar to primary 
wild-type oligodendrocytes. MAP1B is expressed throughout the cell and co-localizes 
with tubulin. In the level of expression undifferentiated OLN93 do not differ from 
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differentiated ones. Lysates of differentiated and undifferentiated OLN93 cells were 
analysed by western blot for the expression of MAP1B with antibodies against MAP1B 
LC1 (Figure 33 B). Tubulin was used as loading control. Before cell lysis, the medium 
was supplemented for the last 4 days with 3 different NOS inhibitors NPA, L-NAME or 
L-NIO. The long term inhibition of NOS did not change the appearance of the culture 
(not shown) and had no effect on the expression of MAP1B LC1. Additionally, whether 
the cells were allowed to differentiate or not did not change expression level of LC1. 
Thus, MAP1B expression in OLN93 could be confirmed by western blot. OLN93 cells 
therefore can to be used for experiments investigating some properties of LC1 in 
oligodendrocytes. 
 
 
Figure 33: Expression of MAP1B in the oligodendrocyte cell line OLN93. 
A) The rat oligodendrocyte cell line OLN93 was cultured in normal growth medium on uncoated glass 
coverslips (upper panel) or in differentiation medium on poly-L-lysine (PLL)-coated coverslips (lower 
panel) and stained for α1-tubulin (green) and MAP1B-750 (red). The cells express MAP1B independent 
of the stage of differentiation in the cell body and in processes. MAP1B co-localizes with tubulin. B) The 
western blot analysis shows the expression of MAP1B LC1 in OLN93. Cells grown on uncoated dishes 
(unc) were not differentiated in contrast to cells grown on PLL. In differentiated cells, the expression 
level of LC1 is slightly increased compared undifferentiated cells grown on uncoated coverslips. 
Treatments with the indicated NOS inhibitors for 4 days did not change LC1 levels. 
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Expression of nitric oxide synthases in oligodendrocytes 
 
In oligodendrocytes only inducible and endothelial nitric oxide synthases have 
been found to be expressed7. As nNOS plays an essential role in DRG neurons during 
axon elongation, axon retraction and growth cone response to different guidance cues, I 
wanted to check nNOS expression in oligodendrocytes once more. Therefore, I 
performed immunofluorescence on primary oligodendrocytes (Figure 34 A). Unlike 
previous data, I found that primary cells express nNOS. A weak staining was observed 
in the cell body and in the primary and secondary processes. In contrast to DRG 
neurons, no difference in the expression level of nNOS between wild-type and 
MAP1B-/- oligodendrocytes could be detected. Nevertheless, even a weakly expressed 
nNOS might be involved in process elongation or retraction, as it is the case for DRG 
neurons. Regarding the discrepancy between former analyses and my results, one could 
argue that the antibody reacted unspecifically. Unfortunately, no nNOS-lacking cells 
were available for control experiments. Moreover, nNOS has seldomly been 
investigated in oligodendrocytes since initially they were not found in oligodendrocytes 
in guinea pig optic nerve318, but one has to mention that this group did not find eNOS 
either which was later shown to be expressed (Boullerne 2005, unpublished data, 
Descovich, PhD Thesis 2009). 
Regarding eNOS, the expression is relatively strong in oligodendrocytes. The 
synthase is located in the cell body, in major processes and also in thinner ones, like it is 
the case for MAP1B expression (Figure 34 B). In terms of expression level, MAP1B-/- 
cells show a slightly stronger staining than wild-type cells, especially in the cell body. 
Comparing expression levels of eNOS and nNOS based on the strength of the staining 
is not possible. However, the strong expression of eNOS suggests that eNOS might be 
an important NO producer in oligodendrocytes, particularly in MAP1B-/- cells. 
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Figure 34: Expression and localization of nNOS and eNOS in wild-type and MAP1B-/- primary 
oligodendrocytes. 
Wild-type and MAP1B-/- oligodendrocytes were cultured for five days in differentiation medium on poly-
D-lysine coated coverslips, fixed and stained for tubulin and nNOS or eNOS. A) nNOS is expressed 
weakly in both wild-type and MAP1B-/- oligodendrocytes, mainly in the cell body and in primary 
processes. No differences in the expression level or localization could be observed between the two 
genotypes. B) The staining for eNOS shows expression in the cell body and in all processes of both wild-
type and MAP1B-/- oligodendrocytes. The signal looks stronger in MAP1B-/- cells (arrow) suggesting a 
higher expression level of eNOS in MAP1B-/- oligodendrocytes. 
 
In order to investigate nNOS expression levels in OLN93, these cells were 
cultured in normal growth medium on uncoated coverslips or in differentiation medium 
on PLL-coated coverslips. Immunofluorescence and western blot analysis were 
performed (Figure 35). As it is the case in primary wild-type oligodendrocytes, nNOS is 
only weakly expressed, independent of the stage of differentiation. nNOS is mainly 
expressed in the cell body and primary processes. Strong eNOS expression is visible 
throughout the whole cells including all processes of differentiated OLN93. 
For the western blot analysis (Figure 36), OLN93 were cultured on uncoated 
coverslips in normal growth medium or on PLL-coated ones in differentiation medium. 
4 days before cell lysis, cells were left untreated or the medium was supplemented with 
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different NOS inhibitors. None of the treatments did alter the expression of nNOS. This 
confirms the hypothesis that NOS inhibitors do not have an influence on the expression 
of the enzyme but only act on its activity. Moreover, the weak expression of nNOS in 
OLN93 seen in immunofluorescences was confirmed. Unfortunately, the antibodies 
against eNOS were not working properly on western blot and it was not possible to 
investigate the dependence of the eNOS expression levels on MAP1B since no MAP1B 
negative OLN93 cells were available.  
 
 
Figure 35: Expression of nNOS and eNOS in OLN93. 
OLN93 cells were cultured in normal growth medium on uncoated coverslips (undifferentiated, upper 
panel) or in differentiation medium on PLL-coated coverslips (differentiated, lower panel) for 3 days. 
Then, cells were fixed and stained for tubulin, nNOS and eNOS. The oligodendrocyte cell line expresses 
in undifferentiated and differentiated stages nNOS and eNOS. The level of nNOS expression seems rather 
low and restricted to the cell body, whereas eNOS is strongly expressed throughout the cell, is found in 
cellular processes of differentiated cells (arrows) and co-localizes with tubulin. 
 
 
Figure 36: Western blot analysis of the expression of nNOS in OLN93. 
Western blot analyses were performed of OLN93 cells cultured for 4 days in normal growth medium on 
uncoated dishes (unc, undifferentiated) or cells grown in differentiation medium on PLL-coated dishes 
(PLL, differentiated). The cell line shows weak expression of nNOS, unaffected by the coating. 4 days 
 106
                                                                                                                    Part II - Results  
 107
before cell lysis, OLN93 were left untreated or the medium was supplemented with different NOS-
inhibitors. The level of nNOS-expression did not change upon these treatments. Expression of eNOS 
could not be analysed due to lack of satisfying antibodies against eNOS. 
 
Taken together, these results show that both mouse primary oligodendrocytes 
and the rat cell line OLN93 express MAP1B from early to late stages of differentiation. 
Additionally, both cell types express comparable amounts of NOS enzymes what makes 
OLN93 a useful model for primary oligodendrocytes regarding effects of NOS 
activating reagents.  
 
Localization of peroxisomes and mitochondria in oligodendrocytes 
 
In cells bearing processes, such as neurons or glia like oligodendrocytes, 
organelles like peroxisomes or mitochondria need to be transported along microtubules 
in order to reach parts distant from the cell body. Peroxisomes are responsible for 
removing toxic products in the cell and play a role in many metabolic pathways. Their 
localization and function might be affected by microtubule associated proteins. The lack 
of MAP1B could influence the velocity of their anterograde or retrograde transport and 
thereby modify the localization. In order to address this question, wild-type and 
MAP1B-/- oligodendrocytes were stained for peroxisomes after 5 days of differentiation 
(Figure 37A). Peroxisomes localized primarily to the cell body of oligodendrocytes. In 
addition, many peroxisomes were found along the processes, especially at the branch 
points. No role for MAP1B in peroxisomes transport could be found by 
immunofluorescence as wild-type and MAP1B-/- cells show the same distribution of 
these organelles. 
MAP1B has been shown to influence the retrograde transport of mitochondria in 
neurons27. Since mitochondria are the main energy provider for a cell, it is essential for 
these organelles to be located correctly in order to function in a proper way. A reagent 
called mitotracker is a way to stain mitochondria in the living cell in order to analyse 
their motility using time lapse microscopy. I wanted to investigate mitochondria 
movement in wild-type and MAP1B-/- oligodendrocytes and the effect of increased NO-
levels on their motility. Unfortunately, staining of mitochondria in live cells turned out 
to be very toxic for oligodendrocytes. Thus, I was not able to follow the mitochondrial 
movement in living cells. However, the localization of these organelles could be 
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investigated by the use of antibodies against ATP-synthase (Figure 37B). Mitochondria 
were localized mainly in the cell body and in the primary processes of oligodendrocytes 
and in smaller processes they were found too. There is no special enrichment at the tips 
although this is the site of local protein synthesis for the generation of the myelin sheath 
which requires much energy. Wild-type and MAP1B-/- oligodendrocytes displayed a 
similar number and localization of mitochondria. Thus, the MAP1B-dependent increase 
of retrograde mitochondrial motility, which can be seen in neurons, does not appear to 
take place in oligodendrocytes. Otherwise, an enrichment of mitochondria would have 
been seen in the cell body. 
 
 
Figure 37: Localization of peroxisomes and mitochondria in wild-type and MAP1B-/- 
oligodendrocytes. 
Wild-type and MAP1B-/- oligodendrocytes were cultured for five days in differentiation medium on poly-
D-lysine coated coverslips and fixed. A) Wild-type and MAP1B-/- oligodendrocytes were stained for 
peroxisomes and tubulin. No difference between wild-type and MAP1B-/- oligodendrocytes was observed 
concerning the distribution of peroxisomes. They were found distributed mainly in the cell body (white 
arrows) and at branch points (white arrowheads), but also along all processes. B) Wild-type and 
MAP1B-/- oligodendrocytes were stained for tubulin and mitochondria. Mitochondria were stained with 
antibodies against ATP-synthase. Wild-type and MAP1B-/- oligodendrocytes do not show any difference 
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in the localization of mitochondria. The organelles are found mainly in the cell body (yellow arrows) and 
are distributed uniformly along the processes. 
 
Expression and localization of EF1α in OPCs 
 
An important factor for protein synthesis is the elongation factor 1 alpha (EF1α). 
EF1α is required for polypeptide elongation during protein synthesis. It has been shown 
that MAP1B, EF1α and staufen1 co-localize in ribonucleoprotein (RNP) granules 
(Steffel, PhD Thesis 2007). In MAP1B-/- DRG neurons EF1α and staufen1 expression 
are reduced as well as the number of RNPs which suggests that MAP1B plays a role in 
generation of RNPs and/or their transport. The localization and expression level of 
EF1α were tested in wild-type and MAP1B-/- OPCs by immunofluorescence (Figure 
38). Wild-type and MAP1B-/- OPCs were cultured in differentiation medium, fixed and 
stained with antibodies against EF1α. In both cell types EF1α is expressed in the cell 
body and faintly in primary processes. EF1α was found in some branch points along the 
processes but not at the end of any process where it could have played a role in local 
synthesis of myelin specific proteins like MBP, MAG or galactocerebroside (GalC). A 
possible reason for that could be the early differentiation stage of the cells analysed. 
Perhaps EF1α is transported to the tips of processes right before the cell achieves 
terminal differentiation. It was not found in RNP-resembling structures and, in contrast 
to DRG neurons, no difference between wild-type and MAP1B-/- OPCs could be 
observed in the level of expression. 
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Figure 38: Expression and localization of EF1α in wild-type and MAP1B-/- OPCs. 
Wild-type and MAP1B-/- OPCs were cultured for 2 days in differentiation medium, fixed and stained for 
EF1α in red and tubulin in blue. EF1α is expressed weakly in the cell body (arrows), in primary processes 
and at some branch points. No EF1α could be found for instance at the tips of the processes (arrowheads) 
where it might play a role for local protein synthesis. The lack of MAP1B does not change the expression 
level or the localization of EF1α in the OPCs. 
 
Differentiation of wild-type and MAP1B-/- oligodendrocytes 
 
Previous experiments showed that the lack of MAP1B does not change the 
general morphology of oligodendrocytes at early stages of differentiation (Figure 32). 
However, the most important feature of these cells is the generation and maintenance of 
several myelin sheaths in order to protect nerve cell process and to allow rapid nerve 
conduction velocity. Oligodendrocyte precursor cells (OPC) are easy to distinguish 
from mature oligodendrocytes by their morphology. At early stages, OPCs exhibit 
straight processes with a few branches. Their processes can be very long and thin. 
Myelin specific proteins are not yet expressed or co-localize still with tubulin. In 
contrast, in terminally differentiated oligodendrocytes, the processes look completely 
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different. Primary processes become much thicker and the branching is enhanced. 
Nevertheless, the tips of the processes are very thin and interact with each other in order 
to form the characteristic shape of myelin bearing oligodendrocytes which can be seen 
in Figure 39. The microtubule scaffold of myelin sheaths is often hard to detect because 
of the delicate nature of the tubulin structures. At this stage, the cells express the myelin 
specific proteins mainly in the peripheral sheaths. Nevertheless, the co-localization with 
tubulin remains. During the differentiation, not only growth and branching take place 
but a complete rearrangement of the cytoskeleton is necessary to afford these 
remarkable morphological changes. Transport of ribosomes and mRNA encoding MBP, 
MAG and other proteins along microtubules is very important for the correct synthesis 
of myelin. Microtubule associated proteins and their ability to influence the stability of 
microtubules might play an important role in the mechanism of myelination and its 
maintenance. I compared the differentiation efficiency of wild-type and MAP1B-/- 
oligodendrocytes. To this end, oligodendrocytes were cultured for several days in 
differentiation medium until myelin sheaths became visible. Oligodendrocytes were 
then stained with antibodies against different markers for terminal differentiation. Such 
markers are GalC, MBP and MAG, which are essential components of myelin. 
Unfortunately, GalC antibodies did not work properly, thus, only MBP and MAG 
staining could be analysed. In culture, oligodendrocytes need 5-7 days to differentiate. 
However, the culture remains always very heterogenous and not all cells show the same 
stage of differentiation. Wild-type and MAP1B-/- oligodendrocytes both differentiated 
well in culture. At the beginning of the differentiation process, they showed the typical 
co-localization of tubulin and myelin specific proteins (not shown) and, at later stages, 
normal generation of myelin sheaths could be observed. Figure 39 shows terminally 
differentiated wild-type and MAP1B-/- oligodendrocytes stained in blue for tubulin, in 
red for MAG and in green for MBP. MAG and MBP are expressed at similar levels and 
show typical localization in flat myelin sheaths regardless of the presence of absence of 
MAP1B. 
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Figure 39: Differentiated wild-type and MAP1B-/- oligodendrocytes. 
Wild-type and MAP1B-/- oligodendrocytes were cultured for 5 days in differentiation medium until they 
reached terminal differentiation. Cells were fixed and stained for tubulin and MAG (A) or MBP (B). 
Wild-type and MAP1B-/- oligodendrocytes did not differ in morphology of myelin sheaths. MAG and 
MBP were expressed and correctly localized. Both cell types showed all characteristics of a myelin 
producing oligodendrocyte. Thus, MAP1B-/- oligodendrocytes did not seem to be impaired in 
differentiation. 
 
Next, I assessed the percentage of terminally differentiated oligodendrocytes 
compared to undifferentiated cells in wild-type and MAP1B-/- cultures (Figure 40). 
There was a difference in the number of MBP-expressing cells in wild-type and 
MAP1B-/- oligodendrocytes (7% in wild-type compared to 3% in MAP1B-/- 
oligodendrocytes). Likewise, I could observe that MAP1B-/- oligodendrocytes showed a 
higher ratio of differentiated cells expressing MAG than wild-type cells (6% in wild-
type cultures compared to 25% in MAP1B-/- cultures). A possible explanation is that 
generally, MAP1B-/- oligodendrocytes survived slightly better than their wild-type 
counterparts. Thus, there were always more MAP1B-/- cells that had the chance to 
differentiate than wild-type cells. However, the exact reason for this observation was 
not investigated in more detail. 
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Figure 40: Percentage of oligodendrocytes expressing MBP or MAG after 7 days of differentiation. 
Wild-type and MAP1B-/- oligodendrocytes were cultured for 7 days in differentiation medium until they 
reached terminal differentiation. Cells were fixed and stained for tubulin and MAG or MBP. The graph 
shows the percentage of MBP or MAG positive wild-type and MAP1B-/- oligodendrocytes. For 
quantitative analysis, approximately 100 cells were assessed for protein expression. Cells were considered 
expressing MBP or MAG when the protein was found in sheaths and was not colocalizing with tubulin 
only, as it is the case in early differentiation stages. There was a striking difference in the percentage of 
MBP expressing cells: in wild-type cultures 7% of the cells showed MBP expression after 7 days in 
culture in differentiation medium compared to 3% of MAP1B-/- oligodendrocytes. Regarding MAG 
expression, MAP1B-/- oligodendrocytes appear to differentiate better than wild-type cells: 6% of wild-
type cells express MAG after the same culture period, whereas in MAP1B-/- oligodendrocyte cultures, 
25% of the cells are MAG positive after 7 days. 
 
Effect of increased NO concentration on OPCs and oligodendrocytes 
Reaction of undifferentiated wild-type and MAP1B-/- OPCs to the NO-donor SNAP 
 
High concentrations of nitric oxide lead to MAP1B dependent axon retraction in 
mouse DRG neurons. Oligodendrocytes were also shown to be sensitive to increased 
NO-levels7. This raised the question whether S-nitrosylation of MAP1B mediates the 
toxic effect of NO in oligodendrocytes. In neurons S-nitrosylation of MAP1B leads to 
increased microtubule binding of the protein which finally leads to retraction of axons. 
There could be a related mechanism taking place in oligodendrocytes resulting in 
withdrawal of myelin bearing processes from neurites, including degeneration of myelin 
sheaths. Eventually, this would render nerve conduction impossible and cause 
neurodegenerative diseases. I used two different ways to increase the intracellular NO 
concentration: the first method is the treatment of cells with the NO-donor SNAP 
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(S-nitroso-N-acetylpenicillamine) and the second one is the treatment with calcimycin. 
Calcimycin induces calcium influx and thereby activates many different calcium-
dependent pathways in the cell. One of the targets is nNOS which becomes activated 
and produces NO.  
OPCs were cultured for 2 days in differentiation medium. At this stage they do 
not yet express myelin specific proteins. These undifferentiated OPCs should react 
stronger to high NO concentrations than differentiated oligodendrocytes7. I tried 
different incubation times and concentrations of SNAP. I started with 100µM for 1h, as 
it was used for DRG neurons. None of the oligodendrocytes reacted to this treatment 
(not shown). The cells looked completely unaffected and had long processes with an 
unchanged cytoskeletal morphology. Thus, I increased the concentration up to 1mM and 
the incubation time to 5hrs (Figure 41 left panel). Unexpectedly, still no effect could be 
observed. The microtubules showed a straight shape and no sign of depolymerization of 
microtubules or retraction. The cells were indistinguishable from untreated ones. The 
same was observed in SNAP treated OLN93 cells (data not shown). Similarly, EF1α did 
not exhibit any change in expression or intracellular localization. EF1α was still mainly 
found in the cell body and only in major processes. Regarding peroxisomes, also no 
difference occurred. Their distribution in the cell was not altered. Moreover, MAP1B-/- 
OPCs ignored the high NO-levels in the same way as wild-type cells and SNAP-treated 
MAP1B-/- OPCs did not differ at all from the untreated MAP1B-/- OPCs (Figure 41, 
right panel). 
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Figure 41: Localization of EF1α and peroxisomes after treatment with 1mM SNAP for 5hrs in 
undifferentiated OPCs. 
Wild-type and MAP1B-/- OPCs were cultured for 2 days in differentiation medium, were left untreated or 
were treated with 1mM SNAP for 5hrs, fixed and stained for tubulin, EF1α and peroxisomes. They did 
not show any difference in the microtubule organization or in the expression level and the localization of 
EF1α after the treatment with SNAP. Similarly, the distribution of peroxisomes remained unchanged at 
high NO-levels. 
 
Mitochondria have been shown to be damaged in different ways by NO. One 
example is the impairment of their motility in cortical neurons262. As already mentioned 
above, life cell imaging of mitochondria was not feasible in oligodendrocytes. Thus, 
whether SNAP affects movements of mitochondria could not be analysed. In order to 
investigate the influence of NO on mitochondrial localization in OPCs I stained the cells 
with antibodies against ATP-synthase and tubulin and compared the localization of 
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mitochondria in wild-type and MAP1B-/- cells untreated or treated with 1mM SNAP for 
5hrs (Figure 42). Regarding the localization of mitochondria, no difference between 
untreated and treated cells could be seen. Mitochondria were distributed in a normal 
way all over wild-type and MAP1B-/- OPCs after the SNAP treatment.  
 
 
Figure 42: Localization of mitochondria in wild-type and MAP1B-/- OPCs after treatment with 
1mM SNAP. 
Wild-type and MAP1B-/- OPCs were cultured for 2 days in differentiation medium, were left untreated or 
were treated with 1mM SNAP for 5hrs, fixed and stained for tubulin and mitochondria. Mitochondria 
were stained with an antibody against ATP-synthase. Treatment with SNAP did not have any effect on 
the localization of mitochondria in wild-type or MAP1B-/- oligodendrocytes. Wild-type and MAP1B-/- 
cells also showed similar distribution of mitochondria. 
 
Hence, the elevated NO-levels induced by the NO-donor SNAP did not appear 
to have an impact on anterograde or retrograde transport of peroxisomes and 
mitochondria. Moreover, their essential function for the survival of the 
oligodendrocytes might not be harmed either since the immunofluorescences analyses 
did not reveal any cellular damage of OPCs. However, tests for mitochondrial or 
peroxisomal functionality have not been performed. 
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Reaction of differentiated wild-type and MAP1B-/- oligodendrocytes to the NO-donor 
SNAP 
 
 Despite the prevailing view that undifferentiated oligodendrocytes are more 
sensitive to elevated NO-levels than differentiated cells, I treated more differentiated 
oligodendrocytes, which were cultured for 4 to 5 days in differentiation medium, with 
1mM SNAP for 5hrs before fixation and staining. However, the same complacency 
about SNAP treatment was observed in those cells (Figure 43). The microtubules 
remained unchanged in wild-type and MAP1B-/- oligodendrocytes. And once more, 
EF1α and peroxisomes localization was the same as in untreated cells. They were again 
found mainly in the cell body and in proximal parts of the cells. 
 
 
Figure 43: Localization of EF1α and peroxisomes after treatment with 1mM SNAP for 5hrs in early 
differentiated oligodendrocytes. 
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Wild-type and MAP1B-/- oligodendrocytes were allowed to differentiate for 4 days in culture and were 
left untreated or were treated with 1mM SNAP for 5hrs. The cells were stained for tubulin, EF1α and 
peroxisomes. The tubulin staining did not show any change or sign of retraction and the cells do not show 
any difference in the localization of EF1α and peroxisomes after the treatment. EF1α and peroxisomes 
show normal expression and localization respectively. Likewise, no difference was observed between 
untreated wild-type and MAP1B-/- oligodendrocytes. 
 
 In diverse neurodegenerative diseases elevated NO-levels have been found at 
sites of damaged nervous tissue. As I could show in previous experiments, MAP1B 
does obviously not play any role in the development of oligodendrocytes including the 
differentiation and generation of myelin in vitro. Nevertheless, the question remains 
whether the lack of MAP1B delays or enhances any reaction of myelinating 
oligodendrocytes to high NO-levels. Moreover, the possible role of MAP1B in the 
mechanism of demyelination was an interesting topic for this thesis. In order to 
investigate whether high intracellular NO-levels lead to destruction of myelin in a 
MAP1B-dependent way, I treated terminally differentiated oligodendrocytes with 
SNAP and stained them for tubulin and MAG (Figure 44). Despite the expected toxicity 
of the highly concentrated SNAP, the myelin sheaths of both wild-type and MAP1B-/- 
oligodendrocytes were not affected at all by this treatment. MAG-staining revealed 
spreadout myelin sheaths in wild-type and MAP1B-/- oligodendrocytes before and after 
SNAP treatment. Similarly, microtubules did not show any difference and 
oligododendroglial processes did neither retract nor collapse. These results show that, 
although high NO-levels in oligodendrocytes were suggested to be toxic for these cells, 
treatment with 1mM SNAP in vitro does not harm oligodendrocytes. Perhaps a longer 
treatment would have been necessary to see an effect of the drug on microtubules, 
organelle behavior or myelin sheaths. 
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Figure 44: Expression and localization of MAG in terminally differentiated wild-type and MAP1B-/- 
oligodendrocytes after a treatment with 1mM SNAP for 5hrs. 
Wild-type and MAP1B-/- oligodendrocytes were cultured for 5 days in differentiation medium until they 
reached terminal differentiation. Cells were left untreated or were treated with 1mM SNAP for 5hrs, fixed 
and stained for tubulin and MAG. Localization and expression level of MAG did not differ in wild-type 
or MAP1B-/- cells. Terminally differentiated oligodendrocytes did not show any reaction to the treatment 
with SNAP. The myelin sheaths remained undamaged and the tubulin network did not show any sign of 
retraction or collapse. 
 
Effect of calcium influx and subsequent NOS activation in oligodendrocytes 
 
The second way to increase the NO concentration is the addition of the ionophor 
calcimycin to the cells. This causes an influx of calcium which activates, among other 
things, nNOS and eNOS. In mouse DRG neurons calcimycin induces activation of 
nNOS and subsequently results in MAP1B-dependent axon retraction which can be 
prevented by inhibition of nNOS. I showed that oligodendrocytes express nNOS and 
eNOS, thus, calcimycin might lead also in these cells to increased NO-production and 
process retraction. Wild-type and MAP1B-/- oligodendrocytes were cultured 5 days in 
differentiation medium. 15min before fixation calcimycin was added to the medium. 
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Then oligodendrocytes were stained for tubulin and MBP in order to investigate the 
effect on the cytoskeleton and the myelin sheaths. Incubation with calcimycin led in 
most wild-type cells to complete lysis (Figure 45). The microtubule network collapsed 
completely, and the myelin sheaths were also destroyed. Only a few oligodendrocytes 
did not react that strongly (see figure 48 and 49). The calcimycin-induced calcium 
influx is a potential activator of several signaling pathways. In order to distinguish the 
effects of NOS activation by calcimycin from other Ca2+ dependent signaling pathways, 
cells were pretreated for one hour with the inhibitors of different NO-synthases. NPA 
(300µM) was used to specifically inhibit nNOS, L-NAME (300µM) for NOS inhibition 
(unspecific nNOS and eNOS inhibition) and L-NIO (10µM) for specific inhibition of 
eNOS. Control samples were left untreated or were treated with NOS inhibitor only. 
Those cells did not differ from untreated ones (not shown). Wild-type cells were 
pretreated with NPA or L-NAME before addition of calcimycin appeared to be 
protected against the toxicity of calcimycin. More cells were found undamaged in the 
culture than in the sample with calcimycin only. These cells exhibited mostly normal 
microtubule morphology and had even kept their myelin sheaths. In contrast, inhibition 
of eNOS with L-NIO did not prevent calcimycin induced cell collapse in wild-type 
oligodendrocytes. Whether these oligodendrocytes underwent apoptosis or necrosis was 
not tested. These results suggest that in wild-type oligodendrocytes, the toxicity of 
calcimycin is mediated by the activation of nNOS and increased NO production and this 
effect can be prevented by the inhibition of nNOS with NPA or L-NAME.  
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Figure 45: Inhibition of nNOS but not eNOS prevents calcimycin toxicity in wild-type 
oligodendrocytes. 
Wild-type oligodendrocytes were cultured for 5 days in differentiation medium. Terminally differentiated 
cells were treated with 1µM calcimycin for 15min or with NOS inhibitors NPA (300µM), L-NAME 
(300µM) or L-NIO (10µM) for 1h followed by treatment with 1µM calcimycin for 15min, as indicated. 
Control samples were left untreated or were treated with a NOS inhibitor only. These cells did not show 
any remarkable change compared to untreated samples (not shown). In contrast, oligodendrocytes reacted 
to the treatment with 1µM calcimycin for 15min with collapsed myelin sheaths and tubulin network. 
Inhibition of nNOS by NPA or L-NAME could prevent this striking effect, whereas inhibition of eNOS 
with L-NIO did not help to protect cells against the toxic calcium influx induced by calcimycin. 
 
 The same assay was performed with MAP1B-/- oligodendrocytes which were 
shown to express nNOS at the same level as wild-type oligodendrocytes, in contrast to 
eNOS expression, which might be slightly enhanced. Similar to wild-type cells, 
MAP1B-/- oligodendrocytes reacted to calcimycin by a complete collapse of the 
cytoskeleton including the myelin sheaths (Figure 46). Almost no cells survived in the 
calcimycin treated samples. Thus, MAP1B does not seem to be essential in the 
mechanisms activated by calcimycin that lead to collapse of oligodendrocytes. In 
contrast to wild-type oligodendrocytes, inhibition of nNOS by NPA did not prevent 
calcimycin-induced cell death. The same phenotype as in cells which were not 
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pretreated with a nNOS inhibitor was observed. Most of the cells showed complete 
collapse and only cell remnants could be found in the culture. However, L-NIO and 
L-NAME, which is also inhibiting eNOS, could rescue MAP1B-/- oligodendrocytes 
from cell death induced by calcimycin. This suggests that in MAP1B-/- 
oligodendrocytes, only inhibition of eNOS prevents collapse and cell death, and that 
eNOS and not nNOS is the most important NO producer in these cells. 
 
 
Figure 46: Inhibition of eNOS but not nNOS prevents calcimycin toxicity in MAP1B-/- 
oligodendrocytes. 
MAP1B-/- oligodendrocytes were cultured for 5 days in differentiation medium. Terminally differentiated 
cells were treated with 1µM calcimycin for 15min or with NOS inhibitors NPA (300µM), L-NAME 
(300µM) or L-NIO (10µM) for 1h followed by treatment with 1µM calcimycin for 15min, as indicated. 
Control samples were left untreated or were treated with a NOS inhibitor only. These cells did not show 
any remarkable change compared to untreated samples (not shown). In contrast, MAP1B-/- 
oligodendrocytes reacted to the treatment with 1µM calcimycin for 15min with collapsed myelin sheaths 
and tubulin network, as it was the case for wild-type cells. Inhibition of nNOS by NPA could not prevent 
this striking effect, whereas inhibition of eNOS with L-NIO or L-NAME, a NOS inhibitor with similar 
potency for nNOS and eNOS, protected cells against the toxic calcium influx induced by calcimycin. 
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 Taken together, these results indicate that in oligodendrocytes calcimycin leads 
to NOS activation resulting in oligodendrocyte cell death. Interestingly, in wild-type 
oligodendrocytes nNOS seems to play a more important role than in MAP1B-/- 
oligodendrocytes where mainly eNOS activity and its downstream targets damage the 
cells. How the lack of MAP1B leads to enhanced importance of eNOS in these cells 
remains elusive.  
 In order to confirm the previous results, I treated OLN93 cells with calcimycin 
(Figure 47). They reacted in the same way as wild-type oligodendrocytes and showed 
collapsed microtubules independent of the cellular differentiation stage. Again, 
inhibition of nNOS by NPA prevented calcimycin induced cell death. In those cells, the 
tubulin network did not show any sign of retraction and the processes remained 
elongated. Thus, in OLN93, the harmful effect of calcimycin is mediated via nNOS 
activation. 
 
 
Figure 47: Inhibition of nNOS prevents calcimycin toxicity in OLN93. 
OLN93 cells were cultured in normal growth medium on uncoated coverslips (undifferentiated, upper 
panel) or in differentiation medium on PLL-coated coverslips (differentiated, lower panel) for 3 days. 
Cells were left untreated or were treated with 1µM calcimycin for 15min, with 300µM NPA for 1h, or 
with 300µM NPA for 1h followed by treatment with 1µM calcimycin for 15min, as indicated, fixed and 
stained for tubulin and Hoechst. As in the case of wild-type oligodendrocytes, calcimycin lead to cell 
collapse and inhibition of nNOS by NPA helped to prevent this effect, independent of the stage of 
differentiation. 
 
 Some oligodendrocytes in the samples did not show a strong reaction to 
calcimycin treatment. In these cells, the analysis of the localization of EF1α and 
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peroxisomes was still possible (Figure 48). Once more wild-type and MAP1B-/- 
oligodendrocytes were treated with 1µM calcimycin for 15 minutes. In wild-type cells, 
EF1α and peroxisome localization was not disturbed by the treatment. Both showed the 
same distribution as in untreated oligodendrocytes (Figure 37A and Figure 38). In 
samples that were treated with L-NAME and calcimycin I observed also no change in 
EF1α or peroxisome distribution. The same was observed in MAP1B-/- 
oligodendrocytes (Figure 49). 
 
 
Figure 48: EF1α and peroxisome localization was not disturbed by the calcimycin treatment in 
wild-type oligodendrocytes. 
Wild-type oligodendrocytes were cultured for 5 days in differentiation medium. Terminally differentiated 
cells were left untreated, were treated with 1µM calcimycin for 15min, with 300µM L-NAME for 1h, or 
with 300µM L-NAME for 1h followed by a treatment with 1µM calcimycin for 15min, as indicated. A 
small fraction of wild-type oligodendrocytes treated with 1µM calcimycin for 15min showed only slightly 
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collapsed morphology. In these cells, the expression level of EF1α and its localization as well as 
peroxisomes distribution remained unchanged. 
 
 
Figure 49: EF1α and peroxisome localization was not disturbed by the calcimycin treatment in 
MAP1B-/- oligodendrocytes. 
MAP1B-/- oligodendrocytes were cultured for 5 days in differentiation medium. Terminally differentiated 
cells were left untreated, were treated with 1µM calcimycin for 15min, with 300µM L-NAME for 1h, or 
with 300µM L-NAME for 1h followed by a treatment with 1µM calcimycin for 15min, as indicated. A 
small fraction of wild-type oligodendrocytes treated with 1µM calcimycin for 15min showed only slightly 
collapsed morphology. In these cells, the expression level of EF1α and its localization as well as 
peroxisomes distribution remained unchanged. 
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Inhibition of NOS leads to process elongation 
 
In experiments with DRG-explants and hippocampal explants, I could show that 
long term inhibition of NOS leads to enhanced axon elongation. When oligodendrocytes 
were incubated for several hours in the NOS inhibitor L-NAME several cells started to 
elongate dramatically their processes. Figure 50 shows wild-type and MAP1B-/- 
oligodendrocytes stained for tubulin and peroxisomes after such a treatment. In both 
cases, oligodendrocytes display one or two extremely long processes whereas the other 
processes remain at a normal length. It seems that NOS activation does not only mediate 
retraction of processes but that its inhibition enables the cells to elongate special 
processes. In what these processes differ from others which do not elongate is unclear. 
However, tubulin staining and localization of peroxisomes is similar to the short 
processes. 
 
 
Figure 50: Excessive process elongation after treatment with NOS inhibitor L-NAME for 4hrs. 
Wild-type and MAP1B-/- OPCs were cultured for 2 days in differentiation medium. After incubation with 
300µM L-NAME for 4hrs, they were fixed and stained for tubulin and peroxisomes. This treatment 
induced the formation of a few very long processes in each cells, whereas the general appearance of the 
cells including the distribution of peroxisomes seemed not to be changed.  
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Presence of MAP1B reduces the effect of a microtubule destabilizing 
reagent on oligodendrocytes 
 
The lack of MAP1B does not seem to influence the reaction of oligodendrocytes 
to elevated NO-levels as I showed in several experiments. Nevertheless, MAP1B is 
known to stabilize microtubules. Thus, I investigated the response of wild-type and 
MAP1B-/- oligodendrocytes to the microtubule depolymerizing effect of nocodazole. 
The cells were incubated for 30 minutes with two different concentrations of 
nocodazole, 0.2mM and 0.5mM, fixed and stained for tubulin (Figure 51). Both wild-
type and MAP1B-/- oligodendrocytes reacted in a strong way to the treatment with 
nocodazole. The cells showed a collapsed microtubule network which assumed the 
appearance of dots along the processes. However, a difference in the strength of the 
reaction is visible. At 0.2mM nocodazole, MAP1B-/- oligodendrocytes reacted similar to 
the wild-type cells to 0.5mM nocodazole. Besides, at 0.5mM nocodazole MAP1B-/- 
oligodendrocytes showed complete destruction of the microtubule network, whereas 
microtubules in wild-type cells appeared to resist complete depolymerization. This 
difference could also be seen in mouse DRG neurons (data not shown). Thus, MAP1B-/- 
cells are more sensitive to microtubule depolymerization than wild-type cells, which 
confirms once more the microtubule stabilizing role of MAP1B. 
 
 
Figure 51: MAP1B-/- oligodendrocytes show a stronger reaction to nocodazole than wild-type cells. 
Wild-type and MAP1B-/- OPCs were cultured for 2 days in differentiation medium. The cells were treated 
with two different concentrations of nocodazole, 0.2mM and 0.5mM. At both concentrations I observed a 
strong effect on the cytoskeleton of the wild-type and MAP1B-/- oligodendrocytes. However, MAP1B-/- 
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cells displayed higher sensitivity to the microtubule-depolymerizing effect of the drug than wild-type 
cells. The level of cell collapse seemed stronger in MAP1B-/- oligodendrocytes at 0.2mM nocodazole than 
in wild-type cells at 0.5mM nocodazole. 
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PART II DISCUSSION 
The importance of MAP1B in neurons regarding dynamics of cytoskeletal 
components and axon growth and retraction is undisputed. In addition, a potential role 
of MAP1B has been proposed in myelinating glia cells4, 6, 45, 280. The protein is 
expressed in Schwann cells and oligodendrocytes and co-localizes with microtubules. 
MAP1B deficiency results, apart from axon guidance defects, in alternations of central45 
and peripheral4 myelination. In addition, MAP1B has been implicated in mRNA 
transport in neuronal processes306 (Steffel, PhD Thesis 2007). In oligodendrocytes, cells 
with long processes, the proper transport of mRNA, proteins and organelles to the tips 
of the myelin-bearing process or sites of local translation is essential for survival of the 
cells and their ability to build and maintain myelin sheaths. To investigate a potential 
role of MAP1B in these cells, wild-type and MAP1B-/- oligodendrocytes were compared 
concerning their ability to differentiate and the expression and localization of diverse 
proteins or organelles. I confirmed the expression of MAP1B and its co-localization 
with microtubules at different stages of differentiation in primary oligodendrocytes and 
in the oligodendrocyte cell line OLN93. Regarding the differentiation of 
oligodendrocytes, markers for differentiation, such as MBP or MAG, were used to 
distinguish OPCs from terminally differentiated oligodendrocytes bearing myelin 
sheaths at the end of the processes. In early diffentiation stages, these markers are not 
expressed and do not co-localize with tubulin. Although this co-localization never 
disappeared, an obvious change in the localization of these proteins was observed when 
oligodendrocytes differentiated. The myelin sheaths became visible as flat structures at 
the end of processes. However, oligodendrocyte differentiation seemed not to depend on 
the presence of MAP1B since MAP1B-/- cells differentiated normally and did not show 
any obvious difference in their morphology compared to wild-type oligodendrocytes. 
As it was already observed in several knockout studies, related proteins could have 
taken over for MAP1B. For instance tau319 and MAP2319, 320 were shown to be 
expressed in oligodendrocytes, although not continuously. The possible overlapping 
functions would have to be investigated in more detail using these knock-out mice. On 
the other hand, in order to avoid studies of double knock-out mice, one could think 
about making use of siRNA. However, I doubt that transfection of primary 
oligodendrocytes would be easy to perform as the culture and differentiation of these 
cells is very unreliable. The cells are very sensitive to many environmental factors and 
might not tolerate transfection. 
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Regarding the differentiation, the only difference which I could observe was that 
the number of differentiated cells was increased in MAP1B-/- cultures. Surprisingly, 
MAP1B-/- oligodendrocytes were generally easier to cultivate than the wild-type cells in 
terms of their survival. Wild-type oligodendrocytes that survived differentiated as fast 
as MAP1B-/- cells, but since they were fewer, they gave the false impression to be 
impaired in their ability to differentiate. Wether the lack of MAP1B causes an anti-
apoptotic effect was not investigated. The difference in differentiation could simply be 
due to variations in the genetic background as the wild-type mice used for dissection 
were not optimal controls for the appropriate MAP1B-/- mice. I observed for instance 
several times that the culture of oligodendrocytes from Black 6 mice was almost 
impossible with the protocol I used, although it worked pretty well for the 5B22 mouse 
line. 
The role of MAP1B in transport of organelles was also analyzed. In order to 
visualize mitochondria, oligodendrocytes were incubated with MitoTracker®, a 
mitochondrion-selective stain which diffuses across the plasma membrane and 
accumulates in mitochondria. In contrast to many other cell types studied, this treatment 
turned out to be toxic for oligodendrocytes. Time lapse microscopy could only be 
performed for a short interval where no difference in motility of mitochondria could be 
detected. Mitochondria were generally hardly mobile at all, in both wild-type and 
MAP1B-/- oligodendrocytes. This lack of movement could be due to the bad condition 
in which the cells had been during the image acquisition caused by incubation with the 
MitoTracker®. Thus, mitochondria motility could not be investigated in more detail. 
Alternatively, the localization of mitochondria was visualized in fixed cells using 
antibodies against ATP-synthase. This staining did not reveal any difference between 
wild-type and MAP1B-/- oligodendrocytes in the localization of the organelles. They 
were not accumulated in the cell body, which would have been reminiscent of the 
observed increase in retrograde mitochondrial movement in MAP1B-/- neurons shown 
by Jimenez-Mateos27. Likewise, peroxisomes were stained but their localization was not 
altered in MAP1B-/- oligodendrocytes either. Thus, either MAP1B does not play a role 
for organelle transport in oligodendrocytes or, as already mentioned, another MAP 
substituted MAP1B.  
The expression and localization of the elongation factor EF1α was also tested. 
EF1α is an important factor for protein synthesis and has been shown to co-localize with 
staufen1 and MAP1B in RNP granules. Interestingly, its expression was found to be 
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reduced in MAP1B-/- DRG neurons (Steffel, PhD Thesis 2007). The staining of OPCs 
for EF1α did not show any alteration in strength or localization between wild-type and 
MAP1B-/- cells. EF1α was localized in wild-type and MAP1B-/- oligodendrocytes in and 
close to the cell body and sometimes in branching points. Obviously, it is not possible to 
compare neurons with glia cells, but it would have been striking to see a cell type 
overlapping phenotype in MAP1B-/- cells. Moreover, the age of mice, wherefrom the 
cells have been isolated, differs, as DRG neurons were isolated from adult mice whereas 
OPCs have been taken from newborn mice. It remains unclear whether the terminal 
differentiated oligodendrocytes would have exhibited any difference in EF1α staining, 
but, since the process of differentiation was not impaired in MAP1B-/- cells, I would not 
expect to see a difference in such an experiment. 
In diverse neurodegenerative diseases, such as Alzheimer’s disease, multiple 
sclerosis or Parkinson’s disease, the NO-levels in brain around plaques were found to be 
increased, suggesting that NO is involved in cellular damage leading to these plaques254, 
321. The elevated NO-levels could stem from invading macrophages296 which are 
responsible for the degradation and removal of cell debris. It is still unclear wherefrom 
NO stems and whether NO is leading to cellular damage in these diseases or if it is a 
side product of the ongoing inflammation. However, physiologic concentrations in brain 
under normal conditions are around 1nM NO and 1µM nitrite. During pathologic 
conditions, NO level can reach up to 1µM while nitrite levels are around 100µM7. 
Increase of NO concentration leads in neurons to cytoskeletal changes resulting in axon 
retraction and growth cone collapse. Apparently, mature mouse oligodendrocytes are as 
sensitive to elevated NO-levels as neurons7. Damage of oligodendrocytes would be 
expected to lead to a reduction in neuronal signal transduction velocity, which is 
dependent on an intact myelin sheath, and to damage to neurons, further leading to 
neurodegenerative diseases. In studies investigating the toxic effect of NO to 
oligodendrocytes, groups were mainly assessing oligodendrocyte cell death induced by 
NO291, 322 and not morphological changes which might occur before apoptosis or 
necrosis. I wondered whether oligodendrocytes would react to NO in a similar way as 
neurons do, by retraction or growth cone collapse. The retraction observed in neurons 
following increased NO-levels, either obtained with NO-donors or via activation of 
nNOS, is mediated by MAP1B-S-nitrosylation. MAP1B is expressed in 
oligodendrocytes prior to terminal differentiation. In contrast, nNOS or eNOS have not 
been detected per se in oligodendrocytes7. Nevertheless, NO stemming from 
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extracellular sources, such as macrophages or NO-donors, should be as toxic as 
intracellularly produced NO.  
In order to investigate whether MAP1B is one mediator of NO-toxicity in 
oligodendrocytes, I cultured primary mouse oligodendrocytes of wild-type and 
MAP1B-/- newborn mice. Then, the response of these cells to increased NO-levels was 
analyzed by observing the morphological changes in their processes upon treatment 
with the NO-donor SNAP. I stained the cells after treatment with SNAP for 
microtubules and analyzed whether any sign of retraction occurred. Unfortunately, I did 
not find any response of the microtubules to increased NO-levels. Wild-type and 
MAP1B-/- oligodendrocytes remained completely unaffected when they were treated 
with 100µM SNAP, a concentration which caused up to 50% of DRG neurons to retract. 
Even to higher SNAP concentrations, such as 0.5mM or 1mM, oligodendrocytes did not 
respond. Also the possible effect of NO on the localization of mitochondria and 
peroxisomes and the expression and localization of EF1α were investigated by 
immunofluorescence. Both did not show any alteration after SNAP-treatment. This 
tolerance of increased NO-levels was observed in OPCs and in terminally differentiated 
oligodendrocytes. Finally, the incubation times for SNAP were changed from 1h to 
5hrs, but the cells did not react either. Considering incubation times of 12-24hrs used by 
the groups investigating cell death291, 322, one could think about increasing the duration 
of the treatment, but I think the most efficient way would be to perform time-lapse 
experiments in order to find the moment in which oligodendrocytes start to respond to 
their environment. Such experiments might be the best way to find the right moment for 
fixation after a treatment. For DRG neurons 1h is enough, but oligodendrocytes might 
need much longer for a cytoskeletal change than neurons. Since the physiological duty 
of a glia cell is to protect neurons from environmental changes it might be expected that 
they are not as sensitive to certain factors as neurons. Moreover, increasing 
concentrations of NO-donors might not anymore be physiologically relevant because 
such NO-levels would never be reached in the brain, not even under pathological 
conditions. Thus, a role of MAP1B and its nitrosylation in oligodendrocyte reaction to 
NO remains doubtful. 
The other possibility to increase NO-levels is by activation of a NOS-enzyme 
with the calcium-ionophore calcimycin. Since eNOS and nNOS have never been 
detected in oligodendrocytes, I first wanted to check the expression of these enzymes in 
primary cells and in OLN93. In contrast to previous reports, I found nNOS and eNOS 
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expression in primary oligodendrocytes and in the OLN93 cell line. Although the 
immunofluorescence signal from nNOS was very weak in primary cells and in OLN93, 
western blot analysis revealed a clear expression in the cell line. In contrast to DRG 
neurons, I could not find a difference in the strength of the immunofluorescent signal in 
the nNOS staining between wild-type and MAP1B-/- oligodendrocytes. The eNOS 
staining also did not reveal any difference between the two genotypes, suggesting that 
in oligodendrocytes MAP1B might not be involved in the regulation of expression or 
stability of either enzyme. 
The treatment with calcimycin leads to a calcium influx and subsequent 
activation of NOS. In contrast to the treatment with the NO-donor SNAP, 
oligodendrocytes were extremely sensitive to calcimycin treatment. The treatment with 
calcimycin was performed according to the protocol used for DRG neurons with 1µM 
calcimycin for 15min. Most of the oligodendrocytes showed severe collapse of the 
cytoskeleton and myelin sheaths or even complete cell lysis. Still, the presumed 
activation of NOS had to be confirmed, since calcium influx could have led to 
activation of several signaling pathways. This was done by inhibition of nNOS or eNOS 
with the appropriate inhibitor NPA or L-NIO, respectively. The inhibition of nNOS in 
wild-type oligodendrocytes and OLN93 could partially prevent the calcimycin-induced 
collapse, and the inhibition of eNOS was reducing MAP1B-/- oligodendrocyte cell 
death. In contrast, NPA did not have an effect in MAP1B-/- oligodendrocytes and L-NIO 
did not help wild-type cells to overcome the calcimycin treatment. Due to the fact that 
oligodendrocytes were only partially protected by NOS-inhibition, other signaling 
pathways might have become activated by calcimycin-induced calcium influx. Clear 
roles have been demonstrated for neurotransmitter-mediated calcium signaling in 
oligodendrocytes, for instance via glutamate or ATP released from axons or 
astrocytes323. Oligodendrocytes are highly vulnerable to perturbations in intracellular 
calcium and, like in neurons, dysregulation of calcium channels can be deleterious for 
glia cells and leads to apoptosis324.  
A further indication for the importance of NOS in oligodendrocytes was the 
observation that incubation of oligodendrocytes with the nonspecific NOS inhibitor 
L-NAME for several hours led to excessive process elongation in wild-type and 
MAP1B-/- cells. Surprisingly, only few but not all processes of one cell were affected. 
The morphology of the treated oligodendrocytes looked completely normal, except two 
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or three processes that were extremely long. In what these special processes differed 
from others has not been clarified yet. 
Despite the fact that NOS-inhibition could not impede calcimycin-induced 
collapse completely, I suggest that NOS enzymes are activated in oligodendrocytes by 
calcium influx. Since these cells react in a more drastic way than DRG neurons, the 
concentration or incubation time of calcimycin should be optimized in order to avoid 
extreme reactions such as cell death. In the treated samples there were no cells 
exhibiting a weak reaction or signs of retraction. Either cells looked unchanged or they 
were completely collapsed. Moreover, with a lower dose of calcimycin, perhaps a 
different response of wild-type and MAP1B-/- oligodendrocytes would be observed. In 
addition, it could be investigated whether the coating of the coverslips, on which the 
oligodendrocytes grew, is affecting the glial response. For instance the additional 
coating with laminin might influence the reaction to SNAP, as it was shown for DRG 
neurons. However, the fact that eNOS-inhibition does and nNOS-inhibition does not 
help MAP1B-/- oligodendrocytes to overcome the calcimycin toxicity is reminiscent of 
the findings in DRG neurons discussed in the first part of my PhD thesis. I could show 
that eNOS plays a special role in MAP1B-/- DRG neurons during the repulsive netrin-1 
pathway. Although nNOS seemed to be expressed to the same extend in wild-type and 
MAP1B-/- oligodendrocytes, in MAP1B-/- oligodendrocytes eNOS might be more 
important in the signaling downstream of calcium than nNOS. This raises again the 
matter how the lack of MAP1B could influence the activity of nNOS. This question 
remains unanswered and might be easier to solve by the use of a cell line and tools to 
knock down MAP1B.  
Despite some ambiguities, I could show that MAP1B might play a minor role in 
oligodendrocytes and that these cells are perhaps not that sensitive to elevated NO-
levels as previously claimed. However, the presence of NOS enzymes was found and 
NO might be relevant for process elongation during development. The question of NO 
involvement in oligodendrocyte pathology is not yet resolved and should be 
investigated in more detail. 
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MATERIALS AND METHODS 
Tissue culture 
Culture of cell lines 
 
The cell line OLN93 was cultured at 37°C in 8.5% CO2 in growth medium (Dulbeccos 
MEM supplemented with 10% FCS, 50U/ml Penicillin and 50µg/ml Streptomycin, 
Fungizone and L-Glutamine). The cells were fed every second day with preheated 
media, split every week. Therefore cells were first washed with PBS to remove all FCS-
containing medium, then incubated with 2ml Trypsin 0.25%; EDTA 0.5M. To stop the 
trypsin digestion 8ml medium were added and the cell suspension was centrifuged for 
3min at 300g. The cell pellet was resuspended in an appropriate volume of fresh 
medium and redistributed on 2-5 new petri dishes. For freezing, the cells were 
resuspended in FCS 10% DMSO to prevent crystallization and stored at -80°C in 
Styrofoam boxes and for long term storage in liquid nitrogen. 
 
Preparation of glass coverslips 
 
13mm coverslips were washed with acetone and twice with 96% EtOH, dryed and 
autoclaved. Coverslips were coated with 10µg/ml poly-L-lysine in H2O for 1h or longer 
at 37°C, washed 2-3 times with H2O and dryed. Additionally, PLL-coated coverslips 
could be coated with 10µg/ml laminin for at least 3h at 37°C, washed 3 times with H2O. 
PLL-laminin coated coverslips should not dry before cells are plated on them. 
Alternatively, coverslips were coated with poly-L-ornithine (Sigma P6282) 1h and 
fibronectin (Sigma F0895, 1µg/ml) 1h. 
 
Cultivation of dissociated adult DRG neurons 
 
Cultivation of mouse DRG neurons was performed following the protocol described by 
Tonge325. Mice were anesthetized with IsoFluoran (Abbott, Rungis, France) and killed 
by decapitation. DRG neurons were harvested in DMEM F-12 medium and 
enzymatically dissociated by collagenase (4000U/ml, Sigma, St. Louis, MO) for 90min 
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at 37°C followed by 0.125% Trypsin/EDTA (Invitrogen) and DNAseI (50μg/ml; 
Sigma) treatment for 12min at 37°C. DRG neurons were finally triturated several times 
with two fire-polished Pasteur pipettes of different size. After harvesting cells by 
centrifugation at 150 g for 5min, cells were resuspended in fresh DMEM-F-12 medium 
and washed further two times. Finally cells were resuspended in DRG growth medium 
(DMEM-F-12 medium supplemented with 20% horse serum, 0.7% glucose,  50 U/ml 
penicillin, 50µg/ml streptomycin326, and supplemented with N3327) and plated at a 
density of approximately 100 cells/cm2 on poly-L-Lysine and laminin-1 coated glass 
coverslips and incubated at 37°C, 5% CO2 for 24hrs. For analysis, mouse DRG neurons 
were treated with different reagents and fixed for immunofluorescences. For time lapse 
microscopy, medium was supplemented with 20mM Hepes, pH 7.4. 
 
Table 1: N3 components 
Chemical 
Stock 
concentration 
Volume for 
10ml N3 Concentration Company 
          
HBSS 
-Ca,-Mg   5.9ml   Invitrogen 
BSA 10mg/ml in HBSS 1ml 17.5µg/ml Sigma, A4261 
Apo-
transferrin 
500mg/ml in 
Hanks 2ml 175µg/ml 
Sigma, 
T1147 
Na-Selenite 100µg/ml in HBSS 100µl 17.5ng/ml Sigma, S9133 
Putrescine 80mg/ml in HBSS 400µl 56.1µg/ml Sigma, P5780 
Progesterone 125µg/ml in EtOH 100µl 21.9ng/ml Sigma, P6149 
Corticosterone 2mg/ml in EtOH 20µl 70.1ngml Sigma, C2505 
Tri-
iodothyronine 
200µg/ml  
in 0.01N NaOH 100µl 35ng/ml 
Sigma, 
T6397 
Insuline 25mg/ml  in 20mM HCl 400µl 17.5µg/ml 
Sigma, 
I6634 
 
Cultivation of dissociated embryonic DRG neurons 
 
 Mouse embryos were isolated from the mother at embryonic day 13.5. Embryos 
were placed into cold L15 medium, the vertebra was isolated and removed from the 
spinal cord. DRGs were dissected from the spinal cord and transferred into an 
eppendorf tube with cold DMEM-F12 medium. After a quick centrifugation step of 
2min at 1000rpm, the supernatant was removed and the DRGs were incubated in 
0.125% Trypsin/EDTA (Invitrogen) treatment for 30min at 37°C. The digestion was 
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stopped with DMEM containing 10% FCS and the suspension was centrifuged for 5min 
at 2000rpm. The supernatant was removed and 500µl NLA medium (Neurobasal 
medium, 2% B27 supplement (GIBCO), 10ng/ml NGF) was added to the DRGs. After 
that, the DRGs were dissociated mechanically with a 1ml tip until all large fragments 
had disappeared. The cells were then spotted in the middle of a dried PLL-coated 
coverslip and kept for at least 30min at 37°C. Finally, 300-500µl NLA medium were 
added to each well. The DRGs from 1 embryo were cultured on 6-12 coverslips 
(13mM). 
 
Cultivation of adult and embryonic DRG explants 
 
DRGs were isolated from mice as for regular culture of DRG neurons and transferred 
into cold DMEM-F12 medium. A 5-10µl drop of matrigel (BD Biosciences, 356230) 
was placed on uncoated coverslips, and then the ganglia were placed on it and covered 
with 10µl matrigel. After drying for 1h in the incubator, 500µl DRG growth medium 
was added to each well. For the outgrowth studies, reagents were added immediately 
and explants were cultured for 2-4 days without changing the medium. 
 
Cultivation of hippocampal neurons from newborn mice 
 
Hippocampi were dissected from P0 to P4 mice and placed in ice cold DMEM 
and washed three times with DMEM. The explants were then incubated in 5ml DMEM 
+ 5U/ml Papain (Sigma P4762) + 8.3µg/ml DNase I for 15min at 37°C to dissociate 
cells. 
After the dissociation the cells still form large aggregates and are washed 3x with 
hippocampi culture medium (Neurobasal medium, B27 supplement (Gibco 17504-044), 
N2, Penicillin, Streptomycin and L-Glutamine). 
The cells were resuspended in culture medium (approximately 1ml per 2 hippocampi); 
tissue was dissociated first with the blue tip until solution got homogenous, then with 
the yellow tip. Transfection with Amaxa electroporation kit can be done directly before 
plating the neurons on coverslips; transfection with Lipofectamine 2000 could be done 
after 24hrs of cultivation but was not successful. 
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Cells were seeded on poly-L-ornithine (Sigma P6282) and fibronectin (Sigma F0895, 
1µg/ml) coated coverslips at a density of 100-200 cells per cm2. After 1 day in culture 
hippocampi began to show a polarized morphology. 
 
Table 2: N2 components 
Chemical 
Stock 
concentration 
Volume for 
10ml N3 Concentration Company 
          
HBSS,-Ca,-
Mg   6.23ml   Invitrogen 
Apo-
transferrin 50mg/ml in Hanks 2ml 10mg/ml 
Sigma, 
T1147 
Na-Selenite 5µg/ml in HBSS 1.04ml 0.52µg/ml Sigma, S9133 
Putrescine 16.1mg/ml in HBSS 1ml 1.61mg/ml Sigma, P5780 
Progesterone 125µg/ml in EtOH 50µl 0.63µg/ml Sigma, P6149 
Insuline 25mg/ml in 20mM HCl 200µl 500µg/ml 
Sigma, 
I6634 
 
Cultivation and staining of hippocampal explants 
 
Hippocampi were dissected from P0 to P4 mice and placed in ice cold DMEM 
and washed three times with DMEM. A drop of approximately 5µl matrigel (BD 
Biosciences, 356230) was pipetted on a coverslip. Hippocampi were each cut into 3-4 
pieces, placed on the gel and covered with 10µl matrigel. After 1 h drying of the 
matrigel in the incubator, 500µl hippocampal growth medium was added to each well. 
The explants were kept in culture 2-4 days without changing the medium. For phase 
contrast microscopy, the explants were not fixed. For immunofluorescence explants 
were fixed with 4% PFA for 20min, blocked with 2% BSA in PBS and stained with 
primary antibodies for 3 h and secondary antibodies for 2h. Then the cultures were 
mounted in 50µl mowiol. 
 
Cultivation of oligodendrocytes from newborn mice 
 
Cultivation of mouse oligodendrocytes was performed following the protocol 
described by Holly Colognato. Mixed glial cultures were obtained from cerebrum of P0 
to P3 mice. The hemispheres were separated from the meninx, homogenized in 
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HEPES/MEM and digested for 25min in 0.3U/ml Papain (Sigma P4762) and 0.24mg/ml 
L-cystein (Sigma C7352) + 40µg/ml DNase at 37°C. The digestion was stopped with 
DMEM + 10% FCS, the suspension was pipetted up and down to obtain a homogeneous 
cell solution and centrifuged 5min at 300g. The cell pellet was resuspended in DMEM + 
10% FCS and cultured on 10µg/ml poly-D-lysine (Sigma P6407) coated tissue-culture 
flasks for up to 10 days at 37°C and 8.5% CO2. To assess differences in oligodendrocyte 
differentiation, oligodendrocyte precursors were obtained by differential shaking. The 
mixed cultures were shaken 12-24hrs at 200rpm at 37°C and 8.5% CO2. Immediately 
after shaking, oligodendrocyte progenitors, which are less adherent than fibroblasts and 
consequently in suspension, were centrifuged at 300g for 5min, the pellet was 
resuspended in 10ml DMEM 10% FCS. Cells are plated for 2hrs on normal uncoated 
tissue culture dishes in order to let settle down fibroblasts, while oligodendrocyte 
progenitors stay in suspension. These cells were then centrifuged and plated on 
100µg/ml poly-D-lysine coated glass coverslips at a density of approximately 100-200 
cells/cm2 in differentiation medium (DMEM supplemented with 2% FCS, 25µg/ml 
insuline, 130ng/ml progesterone, 100mM putrescine, 50µg/ml apo-transferrin, 5ng/ml 
sodium-selenite, 2mM sodium-pyruvate, 20ng/ml tri-iodothyronine, 10ng/ml D-biotin). 
Cells were kept in culture for up to 9 days in order to reach terminal differentiation. 
 
Time lapse microscopy and local application of reagents 
 
Primary neurons were cultured as described above on coated 3 cm coverslips (for 
time lapse in a 6 well plate) or on coverslips fixed with paraffine on a 6 cm petridish 
(for time lapse in the incubation chamber). After incubation of the cells for 24h, 20mM 
hepes, pH 7.4, cultures were placed in a chamber maintained at 37°C of an inverted 
microscope equipped with phase contrast and a Plan Apo 100x/0.7 numerical aperture 
lens. Acquisition and illumination devices were driven by MetaMorph software 
(Universal Imaging, West Chester, PA) or Axiophot (Zeiss). Pictures of cells were taken 
at different frequencies depending on the cell type and the treatment. 
For local application of guidance cues, a stock solution of netrin-1 (25µg/ml) or 
semaphoring (10µg/ml) was locally applied through a 0.5µM pipette attached to an 
Eppendorf microinjection system. The pipette was positioned close to the growth cone 
of an axon and was ejected continuously from the tip every with the pressure of 100hPa 
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for up to 8hrs. In order to determine the effect of NOS inhibition, the appropriate NOS 
inhibitor was added previously to the medium. 
Treatment of cells with different inhibitors or other reagents 
 
Primary cells were all treated according to the list in table 3 by simply adding the 
appropriate amount of the reagent to the growth medium. After the indicated incubation 
time, cells were fixed as usual. Cultured dissociated neurons or glia cells were incubated 
with inhibitors for 1h, whereas explants were allowed to grow for several days in the 
reagents. Concerning guidance cues, netrin-1 was added 2-3hrs after plating of the cells 
and kept in the medium until fixation, whereas Sema3A was added only 30min before 
fixation of dissociated cells. For treatment of explants, both guidance cues were added 
with the growth medium and not removed until microscopy. 
 
Table 3: List of inhibitors and chemicals for treatments of primary cells 
Inhibitor Function Concentration Incubation Company 
NPA Inhibition of nNOS 300µM 1-72 h Tocris Biosciences Cat.No:1200 
L-NAME Inhibition of NOSs 300µM 1-72 h Cayman  Cat.No: 80210 
L-NIO Inhibition of eNOS 10µM 1-72 h Calbiochem Cat.No:400600 
LY83583 Inhibition of sGC 1µM 1 h Calbiochem Cat.No:440205 
ODQ Inhibition of sGC 10µM 30min Sigma Cat.No:O3636 
          
Reagent         
SNAP NO-Donor 100µM-1mM 4 h Invitrogen Cat.No:N7927 
Calcimycin Activator of nNOS 1µM 15min Sigma Cat.No:C7522 
DAF-FM-DA Fluorescent indicator for NO 10µM 1 h 
Calbiochem 
Cat.No:D23842 
          
Guidance cue         
Netrin-1 Attraction or repulsion 250ng/ml 21-72 h 
Alexis 
Cat.No:ALX522100 
Semaphorin 3A Repulsion 0.05-1µg/ml 0.5-1h R&D Systems Cat.No:1250-S3 
 
Immunological Assays 
Immunofluorescence of primary neurons and glia cells 
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The cells were fixed by adding gently 8% paraformaldehyde in PBS to the 
medium in order to obtain a final PFA concentration of 4%, washed 3 times with PBS. 
Alternatively, depending on the antibody used, cells were fixed for 5-10min in MetOH 
at -20°C. In case of PFA-fixation, the cell membranes were broken with 0.3% Triton-X-
100 in PBS. Unspecific binding sites were blocked with 5% BSA in PBS for 1h. Then 
the cells were incubated with the first antibodies diluted in 5% BSA (and 0.15% Triton-
X-100 in case of PFA-fixed cells) for 3hrs and, after washing with PBS, incubated with 
labeled secondary antibodies diluted in PBS for 2hrs in the dark. For 
immunofluorescences of cell lines like OLN93, the incubation time of primary and 
secondary antibodies was reduced to 1h each. For the nuclear staining the cells were 
incubated with Hoechst diluted 1:3000 for 10min in the dark. Then cells were washed 
3x with PBS and once with H2O, finally the coverslips were mounted with mowiol. The 
coverslips were analysed by confocal microscopy and LSM software (Zeiss). 
 
Incubation of DRG neurons with the fluorescent NO indicator DAF-FM DA 
 
One hour before fixation, DRG neurons were treated with 5µM DAF-FM DA 
(Calbiochem, 251520). This cell permeable, photo-stable nitric oxide fluorescent 
indicator releases DAF-FM by the action of intracellular esterases. It reacts with NO, in 
the presence of oxygen, resulting in the formation of a triazolo-fluorescein analog DAF-
FM T with an excitation max.: 500nm and emission max.: 515nm. 
 
Immunohistochemistry on cryosections 
 
The cryosections were stored at -80°C. For staining, the slices were dried, and 
the areas with tissue were lined with Daco-pen. In a humidified chamber, the slices 
were first incubated with 0.3% Triton-X-100 in OXPBS; then unspecific binding sites 
were blocked with 10% normal goat serum (NGS) in OXPBS. The primary antibodies 
were diluted in 5% NGS in OXPBS and incubated over night at RT. The next day slices 
were rinsed three times with 5% NGS in OXPBS and the secondary antibodies were 
applied and incubated 1-1.5hrs at RT in the dark. After 10min of DAPI incubation, 
slices were washed intensely and mounted in mowiol. 
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Table 4: List of primary antibodies 
Antigen Name/clone Company IF/IHC  WB 
          
mouse ATP-Synthase   Lilli Winter 1:400   
mouse EF1α   Sigma 1.100   
mouse eNOS hum eNOS   Bioscience 1:50 1:1000(0) 
rabbit iNOS AB5382 p rb IgG Chemicon 1:1000/" 1:5000 
rabbit Laminin L9393 Sigma 1:100  
mouse MAG  513 Chemicon 1:200 1:1000 
rabbit MAP1B LC1a LC1A M. Tögel 1:200 1:1000 
rabbit MAP1B 750 MAP1B-750 F. Nothias 1:3000  
rat MBP bov. MBP Chemicon 1:1000  
rabbit nNOS R-20, sc-648 Santa Cruz 1:500 1:2000 
rabbit Peroxisome pmp70 Kunze 1:1000   
Phalloidin-TR or -488   invitrogen 1:100   
mouse Syntrophin 1351 Sigma 1:100 1:10.000 
rat α1-tubulin YL1/2 Acris 1:300   
mouse α1-tubulin B512 sigma 1:1000 1:5000 
mouse b tub class III tuj MMS435P0250 covance 1:2000 1:10.000 
rabbit b tub class III tuj1 T-2200 sigma 1:100 1:2000 
 
Table 5: List of secondary antibodies 
Antigen Conjugated to Company IF WB 
          
anti Rabbit         
goat α rabbit Alexa 488 Mol. Probes 1:1000   
goat α rabbit Texas Red Mol. Probes 1:1000   
goat α rabbit Amca Jackson Lab 1:50   
goat α rabbit Cy5 Jackson Lab 1:1000   
goat α rabbit HRPO Jackson Lab   1:10000 
goat α rabbit AP Jackson Lab   1:5000 
          
anti Mouse         
goat α mouse Alexa 488 Jackson Lab 1:1000   
donkey α mouse Rhodamine Red Jackson Lab 1:1000   
α mouse-IgM Rhodamine Red Jackson Lab 1:1000   
donkey α mouse Cy 5 Jackson Lab 1:1000   
goat α mouse Amca Jackson Lab 1:50   
goat α mouse HRPO Jackson Lab   1:10000 
goat α mouse AP Jackson Lab   1:5000 
          
anti Rat         
goat α rat FITC Jackson Lab 1:1000   
goat α rat Texas Red Jackson Lab 1:1000   
goat α rat Amca Jackson Lab 1:800   
donkey α rat Cy 5 Jackson Lab 1:500   
          
DAPI   Sigma 1:30000   
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Western blot analysis 
 
The cells were grown until confluence, washed, scraped in Lysis buffer with 
Dnase and Rnase (5mM Hepes/HCl pH 7.0; 0.5mM MgCl2; 0.1mM EGTA; 10mM 
NaCl; 0.5% Triton-X-100; 100nM DTT; 0.5mg Dnase; 0.2ng Rnase; 5% 
Proteaseinhibitormix) and incubated 10minutes at RT. After adding 3x Sample buffer 
they were boiled at 95°C for 10 minutes and stored at -20°C 
Lysates were loaded on a 8-12.5% SDS-PAGE gel, transferred on a Nitrocellulose 
membrane, blocked in 2% BSA in PBST (0.005% Tween in PBS) at RT and incubated 
at RT with the primary antibody, diluted in 2% BSA/PBST and 0.2% Sodium acid; after 
incubation with the secondary antibody conjugated with Horse Reddish Peroxidase, the 
membrane was developed with Pierce Supersignal West Pico Chemiluminescent 
Substrate or using reaction with Alkaline Phosphatase. 
 
Table 6: Components of Acrylamid gel for SDS-PAGE 
Separating gel 8% 10% 12,5% Stacking gel 2 gels 4 gels 
Acrylamide 2,7ml 6ml 7.5ml Acrylamide 1,3ml 2,6ml 
ddH2O 4,7ml 7.5ml 6ml ddH2O 6,1ml 12,2ml
1,5M Tris/Cl pH 8,8 - 
SDS 
2,6ml 4.5ml 4.5ml 
1,5M Tris/Cl pH 
6,8 - SDS 
2,6ml 5,2ml 
APS 100µl 120µl 120µl APS 100µl 200µl 
TEMED 5µl 12µl 12µl TEMED 10µl 20µl 
 
 
Solutions: 
 
Ponceau solution 
0.2% Ponceau-S 
3% Trichloroacetic acid 
 
Amidoblack solution 
0.1% Amidoblack 
45% Ethanol 
10% Acetic acid 
 
Phosphate buffered saline (PBS), pH 
7.4 
137mM NaCl 
2.6mM KCl 
8mM Na2HPO4 
1.5mM KH2PO 
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AP-Buffer 
100mM Tris/HCl pH 9.5 
100mM NaCL 
5mM MgCl2 
 
NBT-solution 
0.5g Nitro blue tetrazolium (NBT) 
10ml 70% DMF, stored at -20°C 
 
BCIP-solution 
0.5g Bromchloroindolyl phosphate 
(BCIP) 
10ml 100% DMF, stored at -20°C 
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